👪

Inheritance

1

Autosomal recessive HP:0000007

Glutaryl-CoA dehydrogenase deficiency is inherited in an autosomal recessive pattern with complete penetrance for biochemical phenotype but variable expressivity for neurological outcome. Carrier frequency varies by population.

Autosomal recessive inheritance

Show evidence (2 references)

PMID:39185018 SUPPORT Human Clinical

"Sequencing results showed each case had compound heterozygous variants in GCDH(NM_000159.4)"

Demonstrates compound heterozygous inheritance pattern consistent with autosomal recessive transmission.

url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable SUPPORT Other

"At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier."

GeneReviews provides the canonical 25/50/25 autosomal recessive recurrence risk framework for GA1 families.

◆

Subtypes

2

High excreter biochemical phenotype

Very low GCDH activity is associated with high GA excretion. Extrastriatal and cognitive abnormalities are enriched in this group; clinical severity is not determined by excretion alone.

Show evidence (1 reference)

PMID:34588557 SUPPORT Human Clinical

"The biochemical high excreter phenotype is the major risk factor for cognitive impairment while cognitive functions do not appear to be impacted by current therapy and striatal damage."

Cognitive phenotype cannot be reduced to a consequence of striatal injury.

Low excreter biochemical phenotype

Residual GCDH activity can produce low or intermittently normal peripheral markers. Newborn screening is less sensitive, but clinically serious striatal injury remains possible.

Show evidence (1 reference)

PMID:29665094 SUPPORT Human Clinical

"Overall, cumulative sensitivity of NBS is 95.6%, but it is lower (84%) for patients with low excreter phenotype."

Prospective German screening follow-up quantifies the low-excreter limitation.

◈

Mechanistic Hypotheses

3

Canonical GCDH Deficiency-Toxic Metabolite Model

canonical_ga1_metabolic_model CANONICAL

Evidence balance 4 support

Biallelic GCDH loss of function causes accumulation of glutaryl-CoA and organic-acid derivatives that contribute to cerebral metabolic injury. Glutarylcarnitine reflects the metabolic block and carnitine conjugation; it is not an established neurotoxin.

The core enzyme-deficiency model is compatible with both local cerebral production and a hepatic contribution. Low-excreter peripheral biomarkers do not exclude brain risk. Treatment outcome depends strongly on early diagnosis and adherence, so residual injury after screening does not itself prove a missing hepatic mechanism. Astrocytic, bioenergetic, excitotoxic and vascular mechanisms have differing experimental support.

Pathograph links

GCDH protein misfolding -> GCDH enzymatic deficiency DIRECT Loss of proper GCDH assembly decreases catalytic function in lysine degradation.

Deep research

Falcon citations 36 citations 2026-05-23T05:45:42.817249

Show evidence (4 references)

PMID:17879145 SUPPORT In Vitro

"catalyses the oxidative decarboxylation of glutaryl-CoA to crotonyl-CoA and CO2."

Defines the actual GCDH substrate and reaction; free glutaric acid is not the substrate.

PMID:36221165 SUPPORT Other

"resulting in deficiency of mitochondrial glutaryl-CoA dehydrogenase (GCDH) and, consequently, accumulation of glutaric acid, 3-hydroxyglutaric acid, glutaconic acid and glutarylcarnitine"

The guideline summarizes the inherited metabolic block and its biochemical consequences.

PMID:25968119 SUPPORT In Vitro

"Antioxidants abrogated the neuronal death induced by astrocytes exposed to Lys or GA."

Antioxidant rescue supports oxidative stress-dependent non-cell-autonomous toxicity in this culture system.

+ 1 more reference

Intracerebral Catabolite Origin Model

intracerebral_catabolite_origin_model ALTERNATIVE

Evidence balance 3 support

Local cerebral synthesis and limited efflux contribute to brain metabolite accumulation. Evidence supports this component without establishing an exclusively intracerebral source or excluding hepatic effects.

OpenScientist review retained local production but rejected absolute barrier impermeability and quantitative tissue-localization from global AASS perturbations. See the report assessment for source and analysis limitations.

Pathograph links

GCDH enzymatic deficiency -> Intracerebral GA1 catabolite production INDIRECT KNOWN INTERMEDIATES Deficient astrocytes can produce catabolites locally when lysine availability increases. Intermediates: intracerebral lysine degradation

Intracerebral GA1 catabolite production -> Brain accumulation of GA1 catabolites INDIRECT KNOWN INTERMEDIATES Local synthesis contributes to cerebral accumulation when clearance is limited. Intermediates: limited cerebral dicarboxylate efflux

Deep research

OpenScientist citations 27 citations 2026-05-23T04:05:10.575708

Show evidence (3 references)

PMID:25968119 SUPPORT In Vitro

"Upon Lys treatment, Gcdh-/- astrocytes synthetized and released GA and 3-hydroxyglutaric acid (3HGA)."

Direct production by isolated mouse astrocytes establishes a local capacity; it does not measure the fraction of human brain metabolites produced locally.

PMID:16573641 SUPPORT Model Organism

"These results suggest limited flux of GA and 3-OH-GA across the BBB"

Experiments support restricted cerebral exchange, not an absolutely impermeable barrier.

PMID:20302929 SUPPORT In Vitro

"low but specific efflux transport for GA, 3-OH-GA, and MMA across pBCEC"

Transport assays demonstrate a limited specific efflux pathway.

Hepatic Catabolite Origin and Transport Model

hepatic_catabolite_origin_model EMERGING

Evidence balance 1 support

Liver-directed mouse interventions support a therapeutically important hepatic contribution to cerebral GA1 metabolite burden. The transported species, relative contribution and human translation remain unresolved.

OpenScientist assessment rejects quantitative predominance, direct enzymatic clearance of free GA by GCDH, and the inference that vascular barrier injury proves increased catabolite influx. Complementary local cerebral synthesis remains supported. Counterbalancing mouse experiments constrain the transport step this model needs: cerebral concentrations stay low in liver-restricted Gcdh-null mice and after intraperitoneal loading, and radiolabelled 3-hydroxyglutaric acid is recovered poorly in brain at baseline and less still during an induced encephalopathic crisis. Whatever carries the hepatic contribution, it is not readily transported free glutaric or 3-hydroxyglutaric acid.

Pathograph links

GCDH enzymatic deficiency -> Hepatic GA1 catabolite production INDIRECT KNOWN INTERMEDIATES The hepatic metabolic block produces a peripheral pool that can influence cerebral metabolites in mice. Intermediates: hepatic lysine degradation

Hepatic GA1 catabolite production -> Brain accumulation of GA1 catabolites INDIRECT UNKNOWN INTERMEDIATES Hepatic perturbation influences brain metabolites, but direct transport of a particular free acid and quantitative predominance are unproven.

Deep research

OpenScientist citations 25 citations 2026-05-23T04:17:54.058409

Show evidence (1 reference)

PMID:37075130 SUPPORT Model Organism

"In a series of experiments using knockout mice of the lysine catabolic pathway and liver cell transplantation, we uncovered that toxic GA-1 catabolites in the brain originated from the liver."

Liver perturbation and transplantation support a hepatic contribution in mice. The experiment does not quantify its fraction in humans or identify the circulating species.

?

Discussions and Knowledge Gaps

4

Which liver-derived molecular species influences the brain, and how do hepatic and intracerebral source fractions change with genotype and catabolic state?

KNOWLEDGE GAP OPEN ga1-compartment-source-partition

Attached to

pathophysiology#Brain accumulation of GA1 catabolites pathophysiology#Hepatic GA1 catabolite production pathophysiology#Intracerebral GA1 catabolite production mechanistic_hypotheses#hepatic_catabolite_origin_model mechanistic_hypotheses#intracerebral_catabolite_origin_model

Liver-directed rescue and local astrocyte production are both supported, while BBB experiments show limited free-acid transport. Global AASS perturbation and IV-versus-ICV precursor delivery alone do not partition source. Tissue-specific perturbation, matched precursor enrichment, time courses and measurements in liver, plasma, CSF and brain are needed; human CSF is not interchangeable with intracellular striatal pools.

Proposed experiments

Stable-isotope lysine tracing of brain versus hepatic catabolite origin

exp_ga1_compartmental_isotope_tracing

Infuse differentially labelled lysine so that the hepatic and cerebral pools carry distinguishable labels, then quantify labelled glutaric acid, 3-hydroxyglutaric acid and glutarylcarnitine in brain, plasma and liver of Gcdh-null mice at baseline and during a high-protein-diet crisis. Reports the fraction of brain catabolite carrying the peripheral label and identifies the transported species.

Would support

mechanistic_hypotheses#hepatic_catabolite_origin_model

Would refute

mechanistic_hypotheses#intracerebral_catabolite_origin_model

Supporting outcome

A substantial and quantifiable share of brain glutaric acid and 3-hydroxyglutaric acid carries the peripherally introduced label, and the labelled species crossing into brain can be named.

Refuting outcome

Brain catabolite label derives almost entirely from lysine taken up and catabolized within brain, with negligible peripheral label recovered even during crisis.

Tissue-specific AASS deletion to localize glutarate production

exp_ga1_tissue_specific_aass_deletion

Compare liver-specific, brain-specific and global conditional Aass deletion on the Gcdh-null background, measuring brain and peripheral catabolite concentrations, striatal pathology and survival under a high-protein diet. Converts the existing global knockout into a compartment-discriminating experiment.

Would support

mechanistic_hypotheses#hepatic_catabolite_origin_model

Would refute

mechanistic_hypotheses#intracerebral_catabolite_origin_model

Supporting outcome

Liver-restricted Aass deletion reproduces most of the brain catabolite reduction and neuroprotection seen with global deletion.

Refuting outcome

Only brain-restricted Aass deletion lowers brain catabolites and protects the striatum, while liver-restricted deletion changes peripheral markers alone.

Show evidence (5 references)

PMID:37075130 SUPPORT Model Organism

"In a series of experiments using knockout mice of the lysine catabolic pathway and liver cell transplantation, we uncovered that toxic GA-1 catabolites in the brain originated from the liver."

Liver perturbation and transplantation support a hepatic contribution in mice. The experiment does not quantify its fraction in humans or identify the circulating species.

PMID:25968119 SUPPORT In Vitro

"Upon Lys treatment, Gcdh-/- astrocytes synthetized and released GA and 3-hydroxyglutaric acid (3HGA)."

Direct production by isolated mouse astrocytes establishes a local capacity; it does not measure the fraction of human brain metabolites produced locally.

PMID:16573641 SUPPORT Model Organism

"These results suggest limited flux of GA and 3-OH-GA across the BBB"

Experiments support restricted cerebral exchange, not an absolutely impermeable barrier.

+ 2 more references

Which cerebral lysine catabolic route actually supplies brain glutaric acid, given that the pipecolate pathway dominates lysine degradation in brain while glutarate production tracks the saccharopine enzyme AASS?

KNOWLEDGE GAP OPEN ga1-brain-lysine-route-to-glutarate

Attached to

pathophysiology#GCDH enzymatic deficiency pathophysiology#Intracerebral GA1 catabolite production mechanistic_hypotheses#intracerebral_catabolite_origin_model

Two well-conducted mouse studies point in different directions. Labelled lysine experiments find pipecolate to be the major cerebral degradation product with little saccharopine formed in brain, whereas deleting the saccharopine enzyme AASS lowers brain glutaric acid several fold. The results are reconcilable if a quantitatively minor cerebral saccharopine flux is nonetheless the main route to glutarate, but that has not been shown directly, and the relative fluxes have never been measured in human brain. The answer decides whether AASS inhibition, currently pursued as substrate reduction therapy, can lower the brain catabolite pool or only the peripheral one.

Show evidence (2 references)

PMID:25214427 SUPPORT Model Organism

"In line with these findings, we observed only little production of saccharopine in the murine brain."

Direct measurement with labelled lysine finds minimal cerebral saccharopine production, which sits in tension with the several-fold drop in brain glutaric acid caused by deleting the saccharopine enzyme, and establishes this as a genuine unresolved flux question rather than a settled pathway assignment.

PMID:32567100 REFUTE Model Organism

"These in vivo data demonstrate that the saccharopine pathway is the main source of glutaric acid production in the brain and periphery of a mouse model for GA1"

The opposite reading of the same question. These authors attribute brain glutarate production to the saccharopine pathway, but the inference rests on a global deletion that also removes peripheral flux, so it does not measure cerebral saccharopine flux directly and does not settle the tension with the pipecolate tracer data.

Does the compartmental origin of brain catabolites established in Gcdh-null mice apply to human GA1, where cerebral lysine influx, barrier maturation and catabolic rates differ?

HUMAN MODEL MISMATCH OPEN ga1-compartmental-evidence-is-mouse-only

Attached to

mechanistic_hypotheses#hepatic_catabolite_origin_model mechanistic_hypotheses#intracerebral_catabolite_origin_model

Every experiment that discriminates hepatic from intracerebral origin has been done in mice: tissue-restricted GCDH loss, peripheral catabolite loading, radiotracer distribution, hepatocyte transplantation and liver-directed gene therapy. No GA1 patient has received a liver transplant or liver-directed gene therapy, and systematic paired CSF and plasma metabolomics in patient cohorts does not exist, so there is no human compartmental measurement to test the mouse result against. The nearest human evidence is dietary: arginine fortification lowers plasma lysine and modelled cerebral lysine influx and improves neurological outcome, but it acts at the gastrointestinal barrier as well as the cerebrovascular one and so cannot isolate a brain-specific route. Until human compartmental data exist, the origin models should be read as established for the mouse and provisional for patients.

Show evidence (1 reference)

PMID:21820344 SUPPORT Human Clinical

"The relationship between arginine fortification and plasma lysine indicates that transport competition exists at both cerebrovascular and gastrointestinal barriers, suggesting their co-administration is key to efficacy."

The authors locate the competition at two barriers at once. That is why the best available human intervention supports reducing lysine substrate flux in general without isolating cerebral lysine import, leaving the compartmental question open on the human side.

Which astrocytic, energy, excitotoxic and inflammatory effects determine human striatal injury under clinically relevant exposure?

HUMAN MODEL MISMATCH OPEN ga1-cellular-neurotoxicity-context

Astrocyte-mediated toxicity is experimentally supported, but direct excitotoxicity differs across neuronal culture systems. The GCDH-knockout iPSC line is an enabling resource rather than an executed compartmental disease study. Human cell differentiation, nutrient-state controls and metabolite-specific dose-response experiments could distinguish mechanisms.

Show evidence (3 references)

PMID:25968119 SUPPORT In Vitro

"Antioxidants abrogated the neuronal death induced by astrocytes exposed to Lys or GA."

Antioxidant rescue supports oxidative stress-dependent non-cell-autonomous toxicity in this culture system.

PMID:12149496 SUPPORT In Vitro

"NMDA receptor activation and subsequent disturbance of Ca(2+) homeostasis contribute to 3-OH-GA-induced cell damage."

Receptor expression and chick-neuron experiments support a possible direct 3-OH-GA excitotoxic mechanism.

PMID:15262270 REFUTE In Vitro

"3OHG is not excitotoxic in this model of neuronal rat cell cultures despite the presence of functional NMDA receptors."

Negative rat-neuron findings limit generalization across culture models and argue against a universal direct-toxin mechanism.

⚙

Pathophysiology

15

GCDH protein misfolding

Several pathogenic GCDH missense variants destabilize the protein or impair tetramerization, reducing enzyme activity. This mechanism is variant-dependent; null and splice variants need not act through protein misfolding.

Canonical GCDH Deficiency-Toxic Metabolite Model

GCDH hgnc:4189 ↓ DECREASED

L-lysine catabolic process GO:0019477 ↓ DECREASED

glutaryl-CoA dehydrogenase activity GO:0004361 ↓ DECREASED

mitochondrial matrix GO:0005759

Downstream

GCDH enzymatic deficiency Loss of proper GCDH assembly decreases catalytic function in lysine degradation.

Show evidence (3 references)

PMID:37685964 SUPPORT In Vitro

"An altered oligomerization, loss of protein stability and solubility, as well as an augmented susceptibility to aggregation were observed."

Comprehensive biochemical characterization of GCDH misfolding across multiple variants.

PMID:37685964 SUPPORT In Vitro

"The reduced cellular activity was associated with loss of tetramerization."

Loss of the native tetrameric assembly directly impairs enzymatic activity.

PMID:37685964 SUPPORT In Vitro

"The broad panel of variant-mediated conformational changes of the GCDH protein supports the classification of GA1 as a protein-misfolding disorder."

Establishes GA1 as a protein misfolding disorder, opening avenues for pharmacological chaperone therapy.

GCDH enzymatic deficiency

Biallelic pathogenic GCDH variants reduce mitochondrial oxidative decarboxylation of glutaryl-CoA to crotonyl-CoA, impairing the shared lysine, hydroxylysine and tryptophan degradation pathway. Glutaryl-CoA and organic-acid derivatives accumulate. Glutarylcarnitine is a carnitine conjugate and diagnostic readout, not an established neurotoxin.

Hepatic Catabolite Origin and Transport Model Intracerebral Catabolite Origin Model

GCDH hgnc:4189 ↓ DECREASED

L-lysine catabolic process GO:0019477 ↓ DECREASED cellular amino acid catabolic process GO:0009063 ↓ DECREASED proteinogenic amino acid catabolic process GO:0170040 ↓ DECREASED

glutaryl-CoA dehydrogenase activity GO:0004361 ↓ DECREASED

mitochondrial matrix GO:0005759 mitochondrion GO:0005739

Liver UBERON:0002107 Striatum UBERON:0002435

Downstream

Intracerebral GA1 catabolite production Deficient astrocytes can produce catabolites locally when lysine availability increases.

Hepatic GA1 catabolite production The hepatic metabolic block produces a peripheral pool that can influence cerebral metabolites in mice.

Renal metabolic injury Renal metabolic dysfunction is a parallel manifestation, not a consequence of striatal injury.

Secondary carnitine depletion Glutaryl-CoA conjugation sequesters carnitine in glutarylcarnitine.

Show evidence (2 references)

PMID:17879145 SUPPORT In Vitro

"catalyses the oxidative decarboxylation of glutaryl-CoA to crotonyl-CoA and CO2."

Defines the actual GCDH substrate and reaction; free glutaric acid is not the substrate.

PMID:36221165 SUPPORT Other

"resulting in deficiency of mitochondrial glutaryl-CoA dehydrogenase (GCDH) and, consequently, accumulation of glutaric acid, 3-hydroxyglutaric acid, glutaconic acid and glutarylcarnitine"

The guideline summarizes the inherited metabolic block and its biochemical consequences.

Intracerebral GA1 catabolite production

Mechanism confidence: Provisional

GCDH-deficient astrocytes produce and release GA and 3-OH-GA under lysine challenge. Restricted barrier exchange favors retention. Older pipecolate flux studies and global AASS knockout studies do not settle the quantitative contribution of each pathway or tissue in humans.

Intracerebral Catabolite Origin Model

astrocyte CL:0000127

brain UBERON:0000955

Experimental models

Gcdh-deficient astrocyte-neuron co-culture CO CULTURE Lysine-challenged Gcdh-deficient astrocytes synthesize and release glutaric and 3-hydroxyglutaric acids.

Downstream

Brain accumulation of GA1 catabolites Local synthesis contributes to cerebral accumulation when clearance is limited.

Show evidence (1 reference)

PMID:25968119 SUPPORT In Vitro

"Upon Lys treatment, Gcdh-/- astrocytes synthetized and released GA and 3-hydroxyglutaric acid (3HGA)."

Direct production by isolated mouse astrocytes establishes a local capacity; it does not measure the fraction of human brain metabolites produced locally.

Hepatic GA1 catabolite production

Mechanism confidence: Provisional

Liver-directed GCDH replacement, AASS editing and hepatocyte transplantation alter brain metabolite burden and disease severity in Gcdh-deficient mice. The identity of the exchanged species and the relative hepatic contribution in humans remain unresolved.

Hepatic Catabolite Origin and Transport Model

liver UBERON:0002107

Downstream

Brain accumulation of GA1 catabolites Hepatic perturbation influences brain metabolites, but direct transport of a particular free acid and quantitative predominance are unproven.

Show evidence (1 reference)

PMID:37075130 SUPPORT Model Organism

"In a series of experiments using knockout mice of the lysine catabolic pathway and liver cell transplantation, we uncovered that toxic GA-1 catabolites in the brain originated from the liver."

Liver perturbation and transplantation support a hepatic contribution in mice. The experiment does not quantify its fraction in humans or identify the circulating species.

Brain accumulation of GA1 catabolites

GA, 3-OH-GA and related glutaryl-CoA-derived compounds accumulate in the brain. Local production and hepatic influences can coexist. Specific low-capacity efflux has been measured, so an absolute blood-brain-barrier blockade is incorrect. Peripheral C5DC and urinary organic acids do not reliably measure the intracerebral pool.

brain UBERON:0000955

Animal models

Gcdh knockout mouse with lysine or protein challenge Mouse recapitulates Liver-directed genetic interventions and transplantation change the brain metabolite burden in Gcdh-deficient mice, testing a peripheral contribution.

Downstream

Astrocyte oxidative stress Lysine/GA-challenged astrocytes develop oxidative stress-dependent neurotoxicity.

Impaired cerebral energy metabolism Accumulating metabolites interfere with energy pathways, including astrocytic glutamate dehydrogenase.

Neuroinflammatory activation The Gcdh-deficient, lysine-challenged brain develops microglial and NF-kB-associated inflammation.

Cerebral microvascular dysfunction Metabolic swelling can compromise cerebral capillary perfusion in the mouse model.

Extrastriatal white matter injury Chronic cerebral accumulation is associated with white-matter injury independently of an acute striatal crisis.

Context-dependent excitotoxicity 3-OH-GA can activate excitotoxic pathways in some experimental systems.

Encephalopathy Cerebral metabolic injury can manifest during an acute encephalopathic crisis; the clinical feature is not assumed to require established striatal necrosis.

Hypotonia Cerebral metabolic injury can manifest during an acute encephalopathic crisis; the clinical feature is not assumed to require established striatal necrosis.

Seizures Cerebral metabolic injury can manifest during an acute encephalopathic crisis; the clinical feature is not assumed to require established striatal necrosis.

Feeding difficulties Cerebral metabolic injury can manifest during an acute encephalopathic crisis; the clinical feature is not assumed to require established striatal necrosis.

Show evidence (3 references)

PMID:16573641 SUPPORT Model Organism

"These results suggest limited flux of GA and 3-OH-GA across the BBB"

Experiments support restricted cerebral exchange, not an absolutely impermeable barrier.

PMID:20302929 SUPPORT In Vitro

"low but specific efflux transport for GA, 3-OH-GA, and MMA across pBCEC"

Transport assays demonstrate a limited specific efflux pathway.

PMID:25860816 SUPPORT Human Clinical

"3-OH-GA was elevated in white matter of older patients with associated signal changes on MRI"

Human MRS links white-matter metabolite accumulation to extrastriatal abnormalities; the study is observational.

Astrocyte oxidative stress

Mechanism confidence: Provisional

Lysine- or GA-exposed Gcdh-deficient astrocytes develop redox stress and become toxic to striatal and cortical neurons. Antioxidants prevent neuronal death in co-culture. Direct GA exposure is not toxic in that particular neuronal culture; this does not exclude toxicity of other metabolites or in other systems.

astrocyte CL:0000127

response to oxidative stress GO:0006979

brain UBERON:0000955

Experimental models

Gcdh-deficient astrocyte-neuron co-culture CO CULTURE Lysine and glutaric-acid exposure increase astrocyte oxidative stress; antioxidants prevent this response and the associated neuronal toxicity.

Downstream

Striatal degeneration Astrocytic oxidative stress can drive striatal neuronal death in co-culture; the secreted toxic effector remains unresolved.

Show evidence (1 reference)

PMID:25968119 SUPPORT In Vitro

"Antioxidants abrogated the neuronal death induced by astrocytes exposed to Lys or GA."

Antioxidant rescue supports oxidative stress-dependent non-cell-autonomous toxicity in this culture system.

Impaired cerebral energy metabolism

Mechanism confidence: Provisional

GA inhibits astrocytic glutamate dehydrogenase under nutrient stress, while Gcdh-deficient animal brains show impaired energy metabolism. Glutaryl-CoA-mediated enzyme inhibition and glial mitochondrial protein glutarylation are additional candidate modifiers; protein glutarylation is not established as uniformly harmful.

brain UBERON:0000955

Animal models

Gcdh R411W knock-in rat Rat recapitulates The challenged knock-in rat develops impaired oxidative-phosphorylation activities and neuronal damage.

Downstream

Striatal degeneration Energy impairment may increase neuronal vulnerability during catabolic stress.

Show evidence (3 references)

PMID:29098534 SUPPORT In Vitro

"GA disturbs glutamine degradation by specifically inhibiting glutamate dehydrogenase."

Cell experiments identify impaired astrocytic glutaminolysis, particularly under nutrient stress.

PMID:33965309 SUPPORT Model Organism

"impaired OXPHOS activities and neuronal damage."

Lysine-challenged knock-in rats show impaired brain oxidative phosphorylation; this does not establish every proposed mitochondrial intermediate in humans.

PMID:30208319 SUPPORT Model Organism

"Glutarylation reduces the catalytic activities of the most abundant glutamate dehydrogenase"

Protein glutarylation changes enzyme function; the net contribution to human neurodegeneration is unresolved.

Neuroinflammatory activation

Mechanism confidence: Provisional

Lysine-challenged Gcdh-null mice show microglial activation and NF-kB-associated inflammatory signaling. The evidence supports an inflammatory response, but does not isolate inflammation as the initiating cause of human striatal injury.

inflammatory response GO:0006954

brain UBERON:0000955

Downstream

Striatal degeneration Inflammation is a proposed amplifier of injury, supported mainly by disease-model changes and biomarker rescue.

Show evidence (1 reference)

PMID:35639256 SUPPORT Model Organism

"the nuclear content of NF-κB was increased, and the cytosolic content of IκBα decreased in the striatum of the mutant animals, indicating a pro-inflammatory response."

A lysine-challenged Gcdh-null mouse model shows inflammatory signaling; its independent contribution to human striatal injury remains uncertain.

Context-dependent excitotoxicity

Mechanism confidence: Hypothetical

3-OH-GA activates recombinant NMDA receptors and can disturb neuronal calcium homeostasis in chick cultures. Rat neuronal cultures show a negative result despite functional NMDA receptors. Excitotoxicity remains a context-dependent candidate contributor; it is not a demonstrated universal initiating mechanism in human GA1.

Downstream

Striatal degeneration Excitotoxic calcium dysregulation is a candidate route to neuronal injury with conflicting in-vitro evidence.

Show evidence (2 references)

PMID:12149496 SUPPORT In Vitro

"NMDA receptor activation and subsequent disturbance of Ca(2+) homeostasis contribute to 3-OH-GA-induced cell damage."

Receptor expression and chick-neuron experiments support a possible direct 3-OH-GA excitotoxic mechanism.

PMID:15262270 REFUTE In Vitro

"3OHG is not excitotoxic in this model of neuronal rat cell cultures despite the presence of functional NMDA receptors."

Negative rat-neuron findings limit generalization across culture models and argue against a universal direct-toxin mechanism.

Cerebral microvascular dysfunction

Mechanism confidence: Provisional

Mouse metabolic injury progresses through neuronal swelling, capillary obstruction and secondary vascular compromise. Human Doppler and perfusion findings suggest reduced reserve and disordered autoregulation. Barrier injury during a crisis does not itself demonstrate increased free-GA transport from blood.

brain UBERON:0000955

Animal models

Gcdh knockout mouse with lysine or protein challenge Mouse recapitulates Dietary challenge produces neuronal swelling and vacuoles that precede cerebral capillary occlusion in the mouse model.

Downstream

Striatal degeneration Microvascular compromise can compound metabolic injury.

Frontotemporal hypoplasia and enlarged CSF spaces Altered cerebral hemodynamics have been proposed to contribute to enlarged CSF spaces; this developmental link remains uncertain.

Show evidence (2 references)

PMID:24468193 SUPPORT Model Organism

"initial neuronal swelling and vacuole formation leading to cerebral capillary occlusion."

Mouse time-course microscopy supports swelling preceding microvascular compromise; this is not evidence for systemic free-glutarate influx.

PMID:20032085 SUPPORT Human Clinical

"Although metabolic toxicity appears central to the pathophysiology of striatal necrosis, cerebrovascular changes probably also contribute to the process."

A small human imaging/perfusion study supports a vascular contribution without establishing a single mechanism for every lesion.

Striatal degeneration

Acute or insidious bilateral striatal injury causes persistent motor dysfunction. Acute episodes cluster in infancy and early childhood, generally before age three and occasionally up to six years, during infection, fever, fasting or surgery. Injury is not inevitable after newborn screening and adherent preventive treatment.

striatum UBERON:0002435

Downstream

Dystonia Striatal injury produces an irreversible predominantly dystonic movement disorder.

Motor delay Loss of motor function after striatal injury impairs motor development.

Developmental regression Acute neurologic injury can cause loss of acquired motor skills.

Show evidence (2 references)

PMID:36221165 SUPPORT Other

"Most untreated individuals present with acute onset of striatal damage before age 3 (to 6) years, precipitated by infectious diseases, fever or surgery, resulting in irreversible, mostly dystonic movement disorder"

Human natural history supports the trigger, vulnerable age range, striatal lesion, and persistent motor consequence.

PMID:36221165 SUPPORT Other

"In some patients, striatal damage develops insidiously."

Striatal injury also occurs without a recognized acute crisis.

Extrastriatal white matter injury

Progressive white-matter abnormalities and cognitive impairment can occur outside the acute striatal-injury pathway, especially in biochemical high excreters. Their causal relationship is incompletely resolved; cognition is not simply inferred from the extent of dystonic disability.

brain UBERON:0000955

Downstream

Cerebral white matter hyperintensity on MRI White-matter signal abnormalities accompany the extrastriatal process.

Cognitive impairment High-excreter status predicts cognitive impairment, but a specific white-matter-to-cognition mechanism is unresolved.

Show evidence (2 references)

PMID:25860816 SUPPORT Human Clinical

"3-OH-GA was elevated in white matter of older patients with associated signal changes on MRI"

Human MRS links white-matter metabolite accumulation to extrastriatal abnormalities; the study is observational.

PMID:34588557 SUPPORT Human Clinical

"The biochemical high excreter phenotype is the major risk factor for cognitive impairment while cognitive functions do not appear to be impacted by current therapy and striatal damage."

Cognitive phenotype cannot be reduced to a consequence of striatal injury.

Frontotemporal hypoplasia and enlarged CSF spaces

Frontotemporal underdevelopment and expanded extra-axial CSF spaces can be present early, including before an encephalopathic crisis. They are distinct from secondary atrophy after striatal injury and predispose to stretching of bridging veins.

brain UBERON:0000955

Downstream

Macrocephaly Expanded intracranial CSF spaces can accompany macrocephaly; the developmental cause is incompletely resolved.

Subdural hemorrhage Expanded CSF spaces predispose to stretching and rupture of bridging veins.

Show evidence (2 references)

url:https://www.ncbi.nlm.nih.gov/books/NBK546575/ SUPPORT Other

"Subdural hemorrhage, typically associated with frontotemporal hypoplasia"

GeneReviews identifies the characteristic developmental imaging abnormality.

PMID:26219480 SUPPORT Human Clinical

"Children with GA1 are reported to be predisposed to subdural hematoma (SDH) development due to stretching of cortical veins secondary to cerebral atrophy and expansion of CSF spaces."

The systematic review supports vein stretching as a proposed link to subdural hemorrhage.

Renal metabolic injury

Mechanism confidence: Provisional

Renal function can decline with age despite neurologic stability. Knock-in rats show proximal tubular abnormalities, altered renal OXPHOS and reduced filtration under lysine stress and with aging; these model findings guide, but do not establish, every human renal mechanism.

kidney UBERON:0002113

Animal models

Gcdh R411W knock-in rat Rat recapitulates High-lysine challenge lowers glomerular filtration and produces biochemical tubulopathy in young knock-in rats.

Downstream

Renal insufficiency Progressive renal injury is associated with declining filtration.

Show evidence (2 references)

PMID:29665094 SUPPORT Human Clinical

"Independent of the neurologic phenotype, kidney function tends to decline with age"

Prospective human follow-up identifies renal involvement independent of the movement disorder.

PMID:34799272 SUPPORT Model Organism

"In young Gcdhki/ki rats exposed to HLD, we observed a GFR decline and biochemical signs of a tubulopathy."

Rat experiments support renal metabolic toxicity; exact human cellular mechanisms remain incompletely resolved.

Secondary carnitine depletion

Formation and loss of glutarylcarnitine deplete free carnitine. Supplementation replenishes carnitine and supports glutaryl-CoA detoxification; it did not independently lower brain GA in the cited mouse study.

Show evidence (1 reference)

PMID:20923787 SUPPORT Model Organism

"L-carnitine supplementation restored the free L-carnitine pool and enhanced the formation of glutarylcarnitine."

Mouse experiments support carnitine depletion and conjugation, rather than direct brain glutaric-acid lowering by carnitine.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

13

Blood 1

Subdural hemorrhage HP:0100309

Show evidence (2 references)

PMID:26219480 SUPPORT Human Clinical

"Children with GA1 are reported to be predisposed to subdural hematoma (SDH) development due to stretching of cortical veins secondary to cerebral atrophy and expansion of CSF spaces."

Systematic review establishing the predisposition to SDH in GA1 and the need to distinguish from abusive head trauma.

PMID:26219480 SUPPORT Human Clinical

"SDHs in 19/20 children with GA1 are accompanied by other brain abnormalities specific for GA1."

SDHs in GA1 almost always co-occur with other GA1-specific brain abnormalities, distinguishing them from abusive head trauma.

Digestive 1

Feeding difficulties Feeding difficulties in infancy HP:0008872

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/books/NBK546575/ SUPPORT Other

"hypotonia, loss of motor skills, feeding difficulty, and sometimes seizures"

Clinical synthesis identifies feeding difficulty during crises.

Genitourinary 1

Renal insufficiency HP:0000083

Show evidence (1 reference)

PMID:29665094 SUPPORT Human Clinical

"Independent of the neurologic phenotype, kidney function tends to decline with age"

Prospective human follow-up identifies renal involvement independent of the movement disorder.

Head and Neck 1

Macrocephaly HP:0000256

Show evidence (1 reference)

PMID:39185018 SUPPORT Human Clinical

"The most common clinical manifestations included increased head circumference (77.19%)"

Literature review of Chinese GA1 patients shows macrocephaly in 77% of cases.

Metabolism 1

Metabolic acidosis HP:0001942

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/books/NBK546575/ SUPPORT Other

"seizure medication as needed, and treatment of metabolic acidosis."

GeneReviews includes acidosis management during acute decompensation without assigning a population frequency.

Musculoskeletal 1

Hypotonia HP:0001252

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/books/NBK546575/ SUPPORT Other

"hypotonia, loss of motor skills, feeding difficulty, and sometimes seizures"

Human clinical synthesis identifies features of acute encephalopathic crises.

Nervous System 7

Dystonia HP:0001332

Show evidence (3 references)

PMID:36221165 SUPPORT Other

"Most untreated individuals present with acute onset of striatal damage before age 3 (to 6) years, precipitated by infectious diseases, fever or surgery, resulting in irreversible, mostly dystonic movement disorder"

Human natural history supports the trigger, vulnerable age range, striatal lesion, and persistent motor consequence.

PMID:36221165 SUPPORT Other

"In some patients, striatal damage develops insidiously."

Striatal injury also occurs without a recognized acute crisis.

PMID:37474264 SUPPORT Human Clinical

"The diffusional kurtosis imaging metrics of the temporal lobe and basal ganglia were significantly correlated with the Barry-Albright dystonia scores."

DKI imaging demonstrates that basal ganglia microstructural changes correlate with dystonia severity scores.

Motor delay HP:0001270

Show evidence (1 reference)

PMID:39185018 SUPPORT Human Clinical

"The most common clinical manifestations included increased head circumference (77.19%) and motor developmental delay (65.15%)."

Literature review shows motor delay in 65% of GA1 patients.

Encephalopathy HP:0001298

Show evidence (2 references)

PMID:36221165 SUPPORT Other

"Most untreated individuals present with acute onset of striatal damage before age 3 (to 6) years, precipitated by infectious diseases, fever or surgery, resulting in irreversible, mostly dystonic movement disorder"

Human natural history supports the trigger, vulnerable age range, striatal lesion, and persistent motor consequence.

PMID:36221165 SUPPORT Other

"In some patients, striatal damage develops insidiously."

Striatal injury also occurs without a recognized acute crisis.

Seizures HP:0001250

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/books/NBK546575/ SUPPORT Other

"hypotonia, loss of motor skills, feeding difficulty, and sometimes seizures"

Human clinical synthesis identifies features of acute encephalopathic crises.

Cognitive impairment HP:0100543

Show evidence (1 reference)

PMID:34588557 SUPPORT Human Clinical

"The biochemical high excreter phenotype is the major risk factor for cognitive impairment while cognitive functions do not appear to be impacted by current therapy and striatal damage."

Cognitive phenotype cannot be reduced to a consequence of striatal injury.

Cerebral white matter hyperintensity on MRI Hyperintensity of cerebral white matter on MRI HP:0030890

Show evidence (1 reference)

PMID:25860816 SUPPORT Human Clinical

"3-OH-GA was elevated in white matter of older patients with associated signal changes on MRI"

Human MRS links white-matter metabolite accumulation to extrastriatal abnormalities; the study is observational.

Developmental regression HP:0002376

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/books/NBK546575/ SUPPORT Other

"hypotonia, loss of motor skills, feeding difficulty, and sometimes seizures"

GeneReviews lists loss of motor skills during encephalopathic crises.

🧬

Genetic Associations

1

GCDH variants causing glutaryl-CoA dehydrogenase deficiency (CAUSATIVE)

Gene: GCDH hgnc:4189

Show evidence (4 references)

PMID:39185018 SUPPORT Human Clinical

"67 distinct GCDH gene variants were identified among 73 patients, with missense variants being the most prevalent type (73.97%). The most frequent variant was c.1244-2 A > C, observed in 17.12% of cases."

Comprehensive literature review of GCDH variant spectrum in Chinese GA1 patients.

PMID:37685964 SUPPORT In Vitro

"The high number of missense variants associated with the disease and their impact on GCDH activity suggest that disturbed protein conformation can affect the biochemical phenotype."

Demonstrates that missense variants cause protein misfolding affecting biochemical phenotype.

PMID:39185018 SUPPORT Human Clinical

"the majority of variant sites were located in exons 11 (25.37%) and 6 (22.39%)."

Exon distribution in the cited Chinese literature-review cohort, not a universal mutational hotspot map.

+ 1 more reference

💊

Medical Actions

10

Lysine-restricted diet

Action: dietary intervention Ontology label: Dietary Intervention NCIT:C15447

Platform: Behavioral / lifestyle

A specialist-supervised low-lysine diet supplies an appropriate amount of natural protein and may use lysine-free, tryptophan-reduced amino-acid formula. Lysine is essential: a completely lysine-free diet is not intended. Adequate energy and nutrition prevent catabolism and growth failure; dietary intensity can be relaxed after age six under specialist guidance.

Mechanism Target:

INHIBITS Brain accumulation of GA1 catabolites — Lysine restriction reduces substrate flux intended to minimize CNS exposure to lysine-derived toxic byproducts.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable SUPPORT Other

"Combined metabolic therapy includes low-lysine diet, carnitine supplementation, and emergency treatment during episodes with the goal of averting catabolism and minimizing CNS exposure to lysine and its toxic metabolic byproducts."

GeneReviews explicitly frames low-lysine diet as part of therapy aimed at minimizing CNS toxic-metabolite exposure.

Show evidence (4 references)

PMID:34588557 SUPPORT Human Clinical

"Long-term neurologic outcome in GA1 involves both motor and cognitive functions. The biochemical high excreter phenotype is the major risk factor for cognitive impairment while cognitive functions do not appear to be impacted by current therapy and striatal damage."

Diet is standard of care but current therapy does not fully prevent cognitive impairment, particularly in high excreters.

url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable SUPPORT Other

"Combined metabolic therapy includes low-lysine diet, carnitine supplementation, and emergency treatment during episodes with the goal of averting catabolism and minimizing CNS exposure to lysine and its toxic metabolic byproducts."

GeneReviews supports low-lysine diet as a core component of combined metabolic therapy aimed at reducing neurotoxic exposure.

PMID:36221165 SUPPORT Other

"Dietary treatment can be relaxed after the vulnerable period for striatal damage, that is, age 6"

The guideline distinguishes the vulnerable age window from later dietary management.

+ 1 more reference

Carnitine supplementation

Action: carnitine supplementation Ontology label: Nutritional Support NCIT:C15433

Agent: carnitine CHEBI:17126

L-carnitine replenishes depleted free carnitine and supports glutaryl-CoA conjugation and detoxification. It is part of combined metabolic treatment; the cited mouse study did not show that carnitine alone lowered brain GA.

Mechanism Target:

INHIBITS Secondary carnitine depletion — Replenishes the depleted free-carnitine pool.

Show evidence (1 reference)

PMID:20923787 SUPPORT Model Organism

"L-carnitine supplementation restored the free L-carnitine pool and enhanced the formation of glutarylcarnitine."

Mouse experiments support carnitine depletion and conjugation, rather than direct brain glutaric-acid lowering by carnitine.

Show evidence (2 references)

url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable SUPPORT Other

"Combined metabolic therapy includes low-lysine diet, carnitine supplementation, and emergency treatment during episodes with the goal of averting catabolism and minimizing CNS exposure to lysine and its toxic metabolic byproducts."

GeneReviews identifies carnitine supplementation as part of standard combined metabolic treatment in GA1.

PMID:20923787 SUPPORT Model Organism

"L-carnitine supplementation restored the free L-carnitine pool and enhanced the formation of glutarylcarnitine."

Mouse experiments support carnitine depletion and conjugation, rather than direct brain glutaric-acid lowering by carnitine.

Emergency management during intercurrent illness

Action: supportive care Ontology label: Supportive Care NCIT:C15747

Prompt specialist-directed sick-day and perioperative treatment supplies energy, limits catabolism and adjusts protein intake during infection, fasting or other stress. The principal window of vulnerability extends through age six; established striatal injury is not reversed by preventive metabolic treatment.

Mechanism Target:

INHIBITS Striatal degeneration — Emergency illness management prevents catabolism during stressors that can precipitate striatal injury and encephalopathic crises.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable SUPPORT Other

"Agents/circumstances to avoid: Excessive dietary protein or protein malnutrition inducing catabolic state, prolonged fasting, catabolic illness (intercurrent infection; brief febrile illness post vaccination), inadequate caloric provision during other stressors (e.g., surgery or procedure..."

GeneReviews lists catabolic illness, fasting, and inadequate calories as circumstances to avoid, supporting emergency management as prevention of the crisis-triggering mechanism.

Show evidence (4 references)

url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable SUPPORT Other

"Combined metabolic therapy includes low-lysine diet, carnitine supplementation, and emergency treatment during episodes with the goal of averting catabolism and minimizing CNS exposure to lysine and its toxic metabolic byproducts."

GeneReviews supports emergency treatment during illness/stress as a core preventive strategy to reduce CNS toxic exposure.

url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable SUPPORT Other

"Agents/circumstances to avoid: Excessive dietary protein or protein malnutrition inducing catabolic state, prolonged fasting, catabolic illness (intercurrent infection; brief febrile illness post vaccination), inadequate caloric provision during other stressors (e.g., surgery or procedure..."

Defines key catabolic triggers that emergency protocols are designed to prevent or mitigate.

PMID:36221165 SUPPORT Other

"Most untreated individuals present with acute onset of striatal damage before age 3 (to 6) years, precipitated by infectious diseases, fever or surgery, resulting in irreversible, mostly dystonic movement disorder"

Human natural history supports the trigger, vulnerable age range, striatal lesion, and persistent motor consequence.

+ 1 more reference

Genetic counseling

Action: Genetic Counseling NCIT:C15240

Genetic counseling is essential for families with GA1 to explain the autosomal recessive inheritance pattern, recurrence risk, and options for prenatal diagnosis.

Show evidence (3 references)

PMID:39185018 SUPPORT Human Clinical

"These findings facilitate the diagnosis and treatment of affected children and provide a basis for genetic counseling and prenatal diagnosis for their families."

Genetic variant identification enables genetic counseling and prenatal diagnosis.

url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable SUPPORT Other

"Evaluation of relatives at risk: Testing of all at-risk sibs of any age to allow for early diagnosis and treatment."

GeneReviews supports proactive testing of at-risk siblings as part of counseling and preventive care.

url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable SUPPORT Other

"Once the GCDH pathogenic variants in an affected family member are known, carrier testing for at-risk relatives, prenatal testing for a pregnancy at increased risk, and preimplantation genetic testing are possible."

Confirms scope of reproductive and familial counseling options once familial variants are identified.

GCDH gene replacement (investigational)

Action: gene therapy Ontology label: Gene Therapy NCIT:C15238

Platform: Gene therapy

Liver-directed and systemic AAV-GCDH rescue biochemical and neurologic abnormalities in mouse models. A separate CNS-administered GCDH gene replacement program, VGM-R02b, is registered in a phase 1 trial. Clinical efficacy is not established by either the mouse experiments or trial registration.

Mechanism Target:

INHIBITS GCDH enzymatic deficiency — Restoring GCDH activity counteracts the pathological enzyme-deficiency node.

Show evidence (1 reference)

PMID:38983872 SUPPORT Model Organism

"Neonatal treatment with AAV-GCDH restores GCDH expression and enzyme activity in liver and striatum."

Supports restoration of the primary deficient enzymatic node by gene replacement therapy.

INHIBITS Brain accumulation of GA1 catabolites — Liver-directed gene therapy approaches reduce pathogenic brain metabolite burden.

Show evidence (1 reference)

PMID:37075130 SUPPORT Model Organism

"the characteristic brain and lethal phenotype of the GA-1 mouse model was rescued by two different liver-directed gene therapy approaches"

Supports inhibition of the downstream toxic-catabolite brain exposure pathway.

Show evidence (4 references)

PMID:37075130 SUPPORT Model Organism

"the characteristic brain and lethal phenotype of the GA-1 mouse model was rescued by two different liver-directed gene therapy approaches: Using an adeno-associated virus, we replaced the defective Gcdh gene or we prevented flux through the lysine degradation pathway by CRISPR deletion of the..."

Preclinical evidence for two liver-directed gene therapy strategies for GA1.

PMID:38983872 SUPPORT Model Organism

"Neonatal treatment with AAV-GCDH restores GCDH expression and enzyme activity in liver and striatum."

Systemic AAV9-GCDH delivery restores enzyme activity in target tissues.

PMID:38983872 SUPPORT Model Organism

"AAV-GCDH significantly ameliorates the striatal neuropathology, minimizing neuronal dysfunction, gliosis, and alterations in myelination."

Gene therapy prevents striatal neuropathology in the GA1 mouse model.

+ 1 more reference

Pharmacological chaperone therapy (investigational)

Action: Pharmacotherapy NCIT:C15986

Structure-targeted allosteric regulators are being explored as pharmacological chaperones for GA1 protein-misfolding variants, aiming to stabilize folded GCDH and increase residual enzyme function without competing with the natural substrate.

Mechanism Target:

MODULATES GCDH protein misfolding — Allosteric pharmacological chaperones are intended to stabilize folded GCDH protein and counter variant-associated misfolding.

Show evidence (1 reference)

PMID:39312412 SUPPORT In Vitro

"Allosteric regulators acting as pharmacological chaperones hold promise for innovative therapeutics since they target noncatalytic sites and stabilize the folded protein without competing with the natural substrate, resulting in a net gain of function."

The abstract describes the intended chaperone mechanism as stabilization of folded protein with gain of function.

Show evidence (1 reference)

PMID:39312412 SUPPORT In Vitro

"Putative allosteric regulators were discovered using structure- and ligand-based virtual screening methods and validated using orthogonal biophysical and biochemical assays."

Preclinical computational discovery followed by biochemical/biophysical validation supports investigational chaperone pharmacotherapy for GA1.

Bezafibrate (investigational)

Action: Pharmacotherapy NCIT:C15986

Agent: bezafibrate CHEBI:47612

Bezafibrate normalized redox and inflammatory markers in lysine-challenged Gcdh-null mice. This is preclinical evidence and does not establish neurologic efficacy or clinical use in GA1.

Mechanism Target:

INHIBITS Astrocyte oxidative stress — Bezafibrate dampens oxidative and pro-inflammatory pathomechanisms in GCDH-deficient brain tissue.

Show evidence (1 reference)

PMID:35639256 SUPPORT Model Organism

"in vivo treatment with the pan-PPAR agonist bezafibrate normalized these alterations."

Supports mechanistic inhibition/modulation of oxidative-inflammatory injury pathways.

INHIBITS Neuroinflammatory activation — Normalizes inflammatory readouts in the mouse study.

Show evidence (1 reference)

PMID:35639256 SUPPORT Model Organism

"in vivo treatment with the pan-PPAR agonist bezafibrate normalized these alterations."

Bezafibrate treatment normalized oxidative stress and inflammatory markers in GCDH-deficient mice.

Show evidence (2 references)

PMID:35639256 SUPPORT Model Organism

"in vivo treatment with the pan-PPAR agonist bezafibrate normalized these alterations."

Bezafibrate treatment normalized oxidative stress and inflammatory markers in GCDH-deficient mice.

PMID:35639256 SUPPORT Model Organism

"bezafibrate should be tested as a potential adjuvant therapy for GA1."

Authors propose bezafibrate as a potential adjuvant therapy based on preclinical evidence.

AASS substrate reduction (investigational)

Action: Gene Therapy NCIT:C15238

Platform: Gene therapy

Upstream AASS inhibition lowers lysine-catabolic flux without replacing GCDH. Liver-directed Aass editing, systemic AAV9-delivered anti-Aass microRNA and global Aass knockout reduce metabolites or rescue disease in mice. Global and systemic interventions do not determine tissue-specific source fractions.

Mechanism Target:

INHIBITS Hepatic GA1 catabolite production — Reduces hepatic upstream lysine catabolism.

Show evidence (2 references)

PMID:37075130 SUPPORT Model Organism

"In a series of experiments using knockout mice of the lysine catabolic pathway and liver cell transplantation, we uncovered that toxic GA-1 catabolites in the brain originated from the liver."

Liver perturbation and transplantation support a hepatic contribution in mice. The experiment does not quantify its fraction in humans or identify the circulating species.

PMID:40682274 SUPPORT Model Organism

"We detected dose-dependent miR-AASS expression and AASS inhibition in liver and striatum"

Systemic AAV9 microRNA affects both compartments, so rescue does not partition hepatic and cerebral sources.

INHIBITS Intracerebral GA1 catabolite production — Systemic microRNA also lowers AASS expression in striatum; the relative contribution of that component remains unresolved.

Show evidence (1 reference)

PMID:40682274 SUPPORT Model Organism

"We detected dose-dependent miR-AASS expression and AASS inhibition in liver and striatum"

Systemic AAV9 microRNA affects both compartments, so rescue does not partition hepatic and cerebral sources.

Show evidence (2 references)

PMID:40682274 SUPPORT Model Organism

"We detected dose-dependent miR-AASS expression and AASS inhibition in liver and striatum"

Systemic AAV9 microRNA affects both compartments, so rescue does not partition hepatic and cerebral sources.

PMID:41917075 SUPPORT Model Organism

"Gcdh/Aass KO mice did not develop a severe phenotype under high-lysine diet."

Additional global Aass knockout protects the challenged mouse phenotype; it is not a human efficacy trial.

Symptomatic neurologic and feeding support

Action: Supportive Care NCIT:C15747

Individualized dystonia treatment can include benzodiazepines, baclofen, trihexyphenidyl or botulinum toxin. Physical and rehabilitation therapy address motor disability; nutritional or enteral support addresses feeding impairment, and seizures receive standard specialist treatment.

Target Phenotypes: Dystonia HP:0001332 Motor delay HP:0001270 Seizure HP:0001250

Show evidence (2 references)

url:https://www.ncbi.nlm.nih.gov/books/NBK546575/ SUPPORT Other

"Standard therapeutic options may incl use of benzodiazepines, baclofen, trihexyphenidyl"

GeneReviews lists symptomatic dystonia options.

url:https://www.ncbi.nlm.nih.gov/books/NBK546575/ SUPPORT Other

"Physical therapy is recommended to maximize mobility and to reduce the risk for later-onset orthopedic complications"

GeneReviews recommends motor rehabilitation.

Metabolic and renal surveillance

Action: Supportive Care NCIT:C15747

Follow growth, nutritional adequacy, development, movement disorders, amino-acid and carnitine status, and kidney function. Renal follow-up remains relevant despite good neurologic control.

Show evidence (2 references)

PMID:29665094 SUPPORT Human Clinical

"Independent of the neurologic phenotype, kidney function tends to decline with age"

Prospective human follow-up identifies renal involvement independent of the movement disorder.

url:https://www.ncbi.nlm.nih.gov/books/NBK546575/ SUPPORT Other

"plasma creatinine and/or cystatin C levels periodically in adolescents and adults"

GeneReviews recommends renal surveillance.

🌍

Environmental Factors

1

Catabolic illness and fasting

Infection, fever, surgery and inadequate caloric intake increase catabolism during the vulnerable early-childhood period.

Show evidence (1 reference)

PMID:36221165 SUPPORT Other

"Most untreated individuals present with acute onset of striatal damage before age 3 (to 6) years, precipitated by infectious diseases, fever or surgery, resulting in irreversible, mostly dystonic movement disorder"

Human natural history supports the trigger, vulnerable age range, striatal lesion, and persistent motor consequence.

Mechanism Target:

TRIGGERS Brain accumulation of GA1 catabolites — Increased endogenous substrate delivery stresses the blocked pathway.

Show evidence (1 reference)

PMID:36221165 SUPPORT Other

"Most untreated individuals present with acute onset of striatal damage before age 3 (to 6) years, precipitated by infectious diseases, fever or surgery, resulting in irreversible, mostly dystonic movement disorder"

Human natural history supports the trigger, vulnerable age range, striatal lesion, and persistent motor consequence.

🔬

Biochemical Markers

3

Elevated glutarylcarnitine (C5DC) (INCREASED)

Pathograph Readouts

Readout Of GCDH enzymatic deficiency Positive Diagnostic

Elevated C5DC in blood reports the disrupted GCDH-dependent lysine-catabolism pathway. Peripheral concentrations do not quantify brain burden.

Show evidence (1 reference)

PMID:39185018 SUPPORT Human Clinical

"patients exhibited significant elevations in C5DC (98.51%) and C5DC/C8 (94.87%) in blood"

Observed in the cited Chinese case-series/literature-review cohort; this is not a universal diagnostic sensitivity estimate.

Elevated glutaric acid in urine (INCREASED)

Pathograph Readouts

Readout Of GCDH enzymatic deficiency Positive Diagnostic

Urinary glutaric acid elevation reports accumulation of GA1 catabolites downstream of GCDH deficiency. Peripheral concentrations do not quantify brain burden.

Show evidence (2 references)

PMID:39185018 SUPPORT Human Clinical

"GA (94.37%) and 3OHGA (69.39%) in urine"

Observed in the cited Chinese case-series/literature-review cohort; this is not a universal diagnostic sensitivity estimate.

PMID:34588557 SUPPORT Human Clinical

"The biochemical high excreter phenotype is the major risk factor for cognitive impairment"

The high/low excreter distinction based on urinary GA levels is clinically significant for cognitive prognosis.

Elevated 3-hydroxyglutaric acid in urine (INCREASED)

Pathograph Readouts

Readout Of GCDH enzymatic deficiency Positive Diagnostic

Urinary 3-OH-GA elevation reports accumulation of neurotoxic GA1 metabolites downstream of GCDH deficiency. Peripheral concentrations do not quantify brain burden.

Show evidence (1 reference)

PMID:39185018 SUPPORT Human Clinical

"GA (94.37%) and 3OHGA (69.39%) in urine"

Observed in the cited Chinese case-series/literature-review cohort; this is not a universal diagnostic sensitivity estimate.

🔬

Diagnosis

2

Newborn screening

Tandem mass spectrometry measures C5DC. Low-excreter false negatives occur; normal screening does not exclude GA1 in a symptomatic child. Digital-tier classifiers remain dependent on the population and validation set.

Show evidence (2 references)

PMID:29665094 SUPPORT Human Clinical

"Overall, cumulative sensitivity of NBS is 95.6%, but it is lower (84%) for patients with low excreter phenotype."

Prospective German screening follow-up quantifies the low-excreter limitation.

PMID:39728403 SUPPORT Computational

"the proposed digital-tier strategy based on logistic regression analysis, ridge regression, and support vector machine reduced the false-positive rate by over 90% compared to regular NBS while identifying all confirmed individuals with GA1 correctly."

Machine learning approaches can dramatically improve NBS specificity for GA1.

Biochemical and molecular confirmation

Quantitative organic acids and acylcarnitines support suspicion; biallelic pathogenic GCDH variants establish the diagnosis. When molecular testing is uncertain, GCDH activity in fibroblasts or leukocytes can resolve it. Metabolic treatment begins promptly when GA1 is suspected while confirmation proceeds.

Show evidence (2 references)

PMID:31536184 SUPPORT Other

"identification of biallelic pathogenic variants in GCDH"

GeneReviews specifies molecular confirmation.

PMID:31536184 SUPPORT Other

"detection of significantly reduced activity of the enzyme glutaryl-CoA dehydrogenase (GCDH) in cultured fibroblasts or leukocytes."

Enzyme assay is useful when molecular results are uncertain.

📊

Prevalence

1

Black South African newborns

Birth Prevalence 19.290123 per 100,000 1–9 per 10,000 (births)

This founder population estimate is substantially higher than the low prevalence usually described for GA1 in Europe and other outbred populations.

Show evidence (1 reference)

PMID:20732827 SUPPORT Human Clinical

"Heterozygosity for the A293T mutation was found 1 in 36 (95% CI; 1/54 - 1/24) unrelated black South African newborns (n=750) giving a predicted prevalence rate for GA 1 of 1 in 5184 (95% CI; 1/11664 - 1/2304) in this population."

Newborn carrier screening and founder-mutation analysis provide a quantitative prevalence estimate for this high-risk population.

🔬

Clinical Trials

2

NCT06217861 PHASE_I RECRUITING

Open-label dose-escalation and dose-expansion study of VGM-R02b gene replacement in genetically confirmed GA1, using CNS administration. The registry estimates 12 participants aged six years or younger.

Show evidence (1 reference)

clinicaltrials:NCT06217861 SUPPORT Human Clinical

"Phase I, open-label, single-arm, single-dose, trial of VGM-R02b (gene replacement therapy)"

Registration documents an early clinical program, not clinical efficacy.

NCT04602325 NOT_APPLICABLE RECRUITING

Observational biomarker study that includes a separate GA1/MSUD aim measuring S100B, NSE and UCHL1. Its inclusion of GA1 does not establish hyperammonemia as the usual GA1 mechanism.

Show evidence (1 reference)

clinicaltrials:NCT04602325 SUPPORT Human Clinical

"Aim 2 will be to determine if S100B, NSE, and UCHL1 are altered in patients with two other inborn errors of metabolism, Maple Syrup Urine Disease (MSUD) and Glutaric Acidemia (GA1)."

The trial distinguishes the GA1/MSUD study aim from inherited hyperammonemia.

🧫

Experimental Models

1

Gcdh-deficient astrocyte-neuron co-culture CO_CULTURE

Primary mouse astrocytes challenged with lysine or GA produce organic acids and become toxic to co-cultured striatal or cortical neurons. Antioxidants prevent the neurotoxicity.

Pathograph links

Intracerebral GA1 catabolite production recapitulates Lysine-challenged Gcdh-deficient astrocytes synthesize and release glutaric and 3-hydroxyglutaric acids.

Limitations: Mouse culture demonstrates local production capacity, not quantitative human tissue fractions.

Show evidence (1 reference)

PMID:25968119 SUPPORT In Vitro

"Upon Lys treatment, Gcdh-/- astrocytes synthetized and released GA and 3-hydroxyglutaric acid (3HGA)."

Direct production by isolated mouse astrocytes establishes a local capacity; it does not measure the fraction of human brain metabolites produced locally.

Astrocyte oxidative stress recapitulates Lysine and glutaric-acid exposure increase astrocyte oxidative stress; antioxidants prevent this response and the associated neuronal toxicity.

Limitations: Culture conditions and metabolite concentrations constrain transfer to human disease.

Show evidence (2 references)

PMID:25968119 SUPPORT In Vitro

"Lys and GA treatments also increased oxidative stress and proliferation in Gcdh-/- astrocytes, both prevented by antioxidants."

The study directly measures increased astrocyte oxidative stress and its antioxidant sensitivity, in addition to the separate coculture neuronal-survival outcome.

+ 1 more reference

Show evidence (2 references)

PMID:25968119 SUPPORT In Vitro

"Upon Lys treatment, Gcdh-/- astrocytes synthetized and released GA and 3-hydroxyglutaric acid (3HGA)."

Direct production by isolated mouse astrocytes establishes a local capacity; it does not measure the fraction of human brain metabolites produced locally.

PMID:25968119 SUPPORT In Vitro

"Antioxidants abrogated the neuronal death induced by astrocytes exposed to Lys or GA."

Antioxidant rescue supports oxidative stress-dependent non-cell-autonomous toxicity in this culture system.

🐁

Animal Models

2

Gcdh knockout mouse with lysine or protein challenge

Disease models show metabolite accumulation and stress-sensitive neuropathology. Liver transplantation and targeted interventions test a peripheral contribution; effects depend on background, age and diet.

Species

Mouse

Genotype

Gcdh-/-

Pathograph links

Brain accumulation of GA1 catabolites recapitulates Liver-directed genetic interventions and transplantation change the brain metabolite burden in Gcdh-deficient mice, testing a peripheral contribution.

Limitations: Transplantation results do not determine human source fractions or identify the exchanged molecule.

Show evidence (1 reference)

PMID:37075130 SUPPORT Model Organism

"In a series of experiments using knockout mice of the lysine catabolic pathway and liver cell transplantation, we uncovered that toxic GA-1 catabolites in the brain originated from the liver."

Liver perturbation and transplantation support a hepatic contribution in mice. The experiment does not quantify its fraction in humans or identify the circulating species.

Cerebral microvascular dysfunction recapitulates Dietary challenge produces neuronal swelling and vacuoles that precede cerebral capillary occlusion in the mouse model.

Limitations: Acute experimental dietary challenge and murine microvasculature limit direct extrapolation to human development.

Show evidence (1 reference)

PMID:24468193 SUPPORT Model Organism

"initial neuronal swelling and vacuole formation leading to cerebral capillary occlusion."

Mouse time-course microscopy supports swelling preceding microvascular compromise; this is not evidence for systemic free-glutarate influx.

Show evidence (1 reference)

PMID:37075130 SUPPORT Model Organism

"In a series of experiments using knockout mice of the lysine catabolic pathway and liver cell transplantation, we uncovered that toxic GA-1 catabolites in the brain originated from the liver."

Liver perturbation and transplantation support a hepatic contribution in mice. The experiment does not quantify its fraction in humans or identify the circulating species.

Gcdh R411W knock-in rat

The rat homolog of the human p.R402W variant produces high excretion and lysine-challenge-dependent cerebral injury; longitudinal studies demonstrate renal decline.

Species

Rat

Genotype

Gcdh p.R411W homozygous knock-in

Pathograph links

Renal metabolic injury recapitulates High-lysine challenge lowers glomerular filtration and produces biochemical tubulopathy in young knock-in rats.

Limitations: Rat tubular pathology supports renal mechanisms but is not direct human histologic evidence.

Show evidence (1 reference)

PMID:34799272 SUPPORT Model Organism

"In young Gcdhki/ki rats exposed to HLD, we observed a GFR decline and biochemical signs of a tubulopathy."

Rat experiments support renal metabolic toxicity; exact human cellular mechanisms remain incompletely resolved.

Impaired cerebral energy metabolism recapitulates The challenged knock-in rat develops impaired oxidative-phosphorylation activities and neuronal damage.

Limitations: Nutritional challenge and species influence phenotype.

Show evidence (1 reference)

PMID:33965309 SUPPORT Model Organism

"impaired OXPHOS activities and neuronal damage."

Lysine-challenged knock-in rats show impaired brain oxidative phosphorylation; this does not establish every proposed mitochondrial intermediate in humans.

Show evidence (2 references)

PMID:33965309 SUPPORT Model Organism

"We generated the first knock-in rat model for GA-I by introduction of the mutation p.R411W"

CRISPR/Cas9 generated the disease-relevant knock-in model.

PMID:34799272 SUPPORT Model Organism

"In young Gcdhki/ki rats exposed to HLD, we observed a GFR decline and biochemical signs of a tubulopathy."

Rat experiments support renal metabolic toxicity; exact human cellular mechanisms remain incompletely resolved.

{ }

Source YAML

click to show

name: Glutaryl-CoA Dehydrogenase Deficiency
creation_date: '2025-12-15T00:00:00Z'
category: Mendelian
description: 'Glutaric aciduria type 1 (GA1) is an autosomal recessive disorder caused by deficient mitochondrial glutaryl-CoA dehydrogenase. Accumulating glutaryl-CoA-derived metabolites disturb cerebral metabolism and can cause acute or insidious striatal injury with dystonia, particularly during catabolic stress in early childhood. Extrastriatal and renal complications are also recognized. Glutarylcarnitine is an important diagnostic marker. Presymptomatic diagnosis and coordinated low-lysine nutrition, carnitine and emergency treatment substantially improve neurologic outcomes.'
disease_term:
  preferred_term: glutaryl-CoA dehydrogenase deficiency
  term:
    id: MONDO:0009281
    label: glutaryl-CoA dehydrogenase deficiency
synonyms:
- glutaric aciduria type 1
- glutaric acidemia type 1
- GA1
parents:
- Organic Acidemia
- Inborn Error of Metabolism
references:
- reference: 'url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable'
  title: Glutaric Acidemia Type 1 - GeneReviews® - NCBI Bookshelf
  tags:
  - GeneReviews
  findings:
  - statement: NBS-identified and promptly treated individuals often avoid classic early striatal injury but still need long-term follow-up.
    supporting_text: In the era of newborn screening (NBS), the prompt initiation of treatment of asymptomatic infants detected by NBS means that most individuals who would have developed manifestations of either infantile-onset or later-onset GA-1 remain asymptomatic; however, they may be at increased risk for other manifestations (e.g., renal disease) that are becoming apparent as the understanding of the natural history of treated GA-1 continues to evolve.
    evidence:
    - reference: 'url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable'
      reference_title: "Glutaric Acidemia Type 1 - GeneReviews® - NCBI Bookshelf"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: In the era of newborn screening (NBS), the prompt initiation of treatment of asymptomatic infants detected by NBS means that most individuals who would have developed manifestations of either infantile-onset or later-onset GA-1 remain asymptomatic; however, they may be at increased risk for other manifestations (e.g., renal disease) that are becoming apparent as the understanding of the natural history of treated GA-1 continues to evolve.
      explanation: Supports continued surveillance, including renal monitoring, despite prevention of classic early neurologic crises.
  - statement: Standard care is combined metabolic therapy centered on lysine restriction, carnitine supplementation, and emergency illness management.
    supporting_text: Combined metabolic therapy includes low-lysine diet, carnitine supplementation, and emergency treatment during episodes with the goal of averting catabolism and minimizing CNS exposure to lysine and its toxic metabolic byproducts.
    evidence:
    - reference: 'url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable'
      reference_title: "Glutaric Acidemia Type 1 - GeneReviews® - NCBI Bookshelf"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Combined metabolic therapy includes low-lysine diet, carnitine supplementation, and emergency treatment during episodes with the goal of averting catabolism and minimizing CNS exposure to lysine and its toxic metabolic byproducts.
      explanation: Captures core treatment principles that structure current management recommendations.
  - statement: Catabolic triggers should be proactively avoided in GA1 management plans.
    supporting_text: "Agents/circumstances to avoid: Excessive dietary protein or protein malnutrition inducing catabolic state, prolonged fasting, catabolic illness (intercurrent infection; brief febrile illness post vaccination), inadequate caloric provision during other stressors (e.g., surgery or procedure requiring fasting/anesthesia)."
    evidence:
    - reference: 'url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable'
      reference_title: "Glutaric Acidemia Type 1 - GeneReviews® - NCBI Bookshelf"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "<i>Agents/circumstances to avoid:</i> Excessive dietary protein or protein malnutrition inducing catabolic state, prolonged fasting, catabolic illness (intercurrent infection; brief febrile illness post vaccination), inadequate caloric provision during other stressors (e.g., surgery or procedure requiring fasting/anesthesia)."
      explanation: Provides explicit avoidant-trigger guidance for sick-day and peri-procedural planning.
- reference: DOI:10.1002/jimd.12608
  title: Exploring genotype–phenotype correlations in glutaric aciduria type 1
  found_in:
  - Glutaryl-CoA_Dehydrogenase_Deficiency-deep-research-falcon.md
  findings:
  - statement: Glutaric aciduria type 1 (GA1) is a rare neurometabolic disease caused by pathogenic variants in the gene encoding the enzyme glutaryl‐CoA dehydrogenase (GCDH).
    supporting_text: Glutaric aciduria type 1 (GA1) is a rare neurometabolic disease caused by pathogenic variants in the gene encoding the enzyme glutaryl‐CoA dehydrogenase (GCDH).
    evidence:
    - reference: DOI:10.1002/jimd.12608
      reference_title: Exploring genotype–phenotype correlations in glutaric aciduria type 1
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Glutaric aciduria type 1 (GA1) is a rare neurometabolic disease caused by pathogenic variants in the gene encoding the enzyme glutaryl‐CoA dehydrogenase (GCDH).
      explanation: Deep research cited this publication as relevant literature for Glutaryl-CoA Dehydrogenase Deficiency.
- reference: DOI:10.1007/s10545-011-9289-5
  title: Diagnosis and management of glutaric aciduria type I – revised recommendations
  found_in:
  - Glutaryl-CoA_Dehydrogenase_Deficiency-deep-research-falcon.md
  findings:
  - statement: Glutaric aciduria type I (synonym, glutaric acidemia type I) is a rare organic aciduria.
    supporting_text: Glutaric aciduria type I (synonym, glutaric acidemia type I) is a rare organic aciduria.
    evidence:
    - reference: DOI:10.1007/s10545-011-9289-5
      reference_title: Diagnosis and management of glutaric aciduria type I – revised recommendations
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Glutaric aciduria type I (synonym, glutaric acidemia type I) is a rare organic aciduria.
      explanation: Deep research cited this publication as relevant literature for Glutaryl-CoA Dehydrogenase Deficiency.
- reference: DOI:10.1021/acs.jmedchem.4c00292
  title: Use of the Novel Site-Directed Enzyme Enhancement Therapy (SEE-Tx) Drug Discovery Platform to Identify Pharmacological Chaperones for Glutaric Acidemia Type 1
  found_in:
  - Glutaryl-CoA_Dehydrogenase_Deficiency-deep-research-falcon.md
  findings:
  - statement: Use of the Novel Site-Directed Enzyme Enhancement Therapy (SEE-Tx) Drug Discovery Platform to Identify Pharmacological Chaperones for Glutaric Acidemia Type 1
    supporting_text: Use of the Novel Site-Directed Enzyme Enhancement Therapy (SEE-Tx) Drug Discovery Platform to Identify Pharmacological Chaperones for Glutaric Acidemia Type 1
- reference: DOI:10.11588/heidok.00035789
  title: New approaches in mathematical and data-based modeling for newborn screening
  found_in:
  - Glutaryl-CoA_Dehydrogenase_Deficiency-deep-research-falcon.md
  findings:
  - statement: New approaches in mathematical and data-based modeling for newborn screening
    supporting_text: New approaches in mathematical and data-based modeling for newborn screening
- reference: DOI:10.1186/s13023-023-02833-z
  title: Biochemical and molecular features of chinese patients with glutaric acidemia type 1 from Fujian Province, southeastern China
  found_in:
  - Glutaryl-CoA_Dehydrogenase_Deficiency-deep-research-falcon.md
  findings:
  - statement: Glutaric acidemia type 1 (GA1) is a rare autosomal recessive inherited metabolic disorder caused by variants in the gene encoding the enzyme glutaryl-CoA dehydrogenase (GCDH).
    supporting_text: Glutaric acidemia type 1 (GA1) is a rare autosomal recessive inherited metabolic disorder caused by variants in the gene encoding the enzyme glutaryl-CoA dehydrogenase (GCDH).
    evidence:
    - reference: DOI:10.1186/s13023-023-02833-z
      reference_title: Biochemical and molecular features of chinese patients with glutaric acidemia type 1 from Fujian Province, southeastern China
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Glutaric acidemia type 1 (GA1) is a rare autosomal recessive inherited metabolic disorder caused by variants in the gene encoding the enzyme glutaryl-CoA dehydrogenase (GCDH).
      explanation: Deep research cited this publication as relevant literature for Glutaryl-CoA Dehydrogenase Deficiency.
- reference: DOI:10.1186/s13052-025-01975-z
  title: 'Diagnosis of glutaric aciduria type I based on neuroradiological findings: when neonatal screening fails'
  found_in:
  - Glutaryl-CoA_Dehydrogenase_Deficiency-deep-research-falcon.md
  findings:
  - statement: Glutaric aciduria type I (GA-I) is an autosomal recessive disorder affecting the metabolism of lysine, hydroxylysine, and tryptophan.
    supporting_text: Glutaric aciduria type I (GA-I) is an autosomal recessive disorder affecting the metabolism of lysine, hydroxylysine, and tryptophan.
    evidence:
    - reference: DOI:10.1186/s13052-025-01975-z
      reference_title: 'Diagnosis of glutaric aciduria type I based on neuroradiological findings: when neonatal screening fails'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Glutaric aciduria type I (GA-I) is an autosomal recessive disorder affecting the metabolism of lysine, hydroxylysine, and tryptophan.
      explanation: Deep research cited this publication as relevant literature for Glutaryl-CoA Dehydrogenase Deficiency.
- reference: DOI:10.7759/cureus.65722
  title: 'Glutaric Aciduria Presenting With an Acute Encephalitic Crisis: A Case Report'
  found_in:
  - Glutaryl-CoA_Dehydrogenase_Deficiency-deep-research-falcon.md
  findings:
  - statement: 'Glutaric Aciduria Presenting With an Acute Encephalitic Crisis: A Case Report'
    supporting_text: 'Glutaric Aciduria Presenting With an Acute Encephalitic Crisis: A Case Report'
- reference: DOI:10.7759/cureus.86380
  title: 'Delayed Diagnosis of Glutaric Aciduria Type 1: A Case Report'
  found_in:
  - Glutaryl-CoA_Dehydrogenase_Deficiency-deep-research-falcon.md
  findings:
  - statement: 'Delayed Diagnosis of Glutaric Aciduria Type 1: A Case Report'
    supporting_text: 'Delayed Diagnosis of Glutaric Aciduria Type 1: A Case Report'
- reference: DOI:10.1016/j.omtm.2024.101276
  title: Systemic delivery of AAV-GCDH ameliorates HLD-induced phenotype in a glutaric aciduria type I mouse model
  found_in:
  - Glutaryl-CoA_Dehydrogenase_Deficiency-deep-research-falcon.md
  findings: []
- reference: DOI:10.3390/ijms241713158
  title: Glutaryl-CoA Dehydrogenase Misfolding in Glutaric Acidemia Type 1
  found_in:
  - Glutaryl-CoA_Dehydrogenase_Deficiency-deep-research-falcon.md
  findings: []
- reference: DOI:10.3390/ijns10040083
  title: Digital-Tier Strategy Improves Newborn Screening for Glutaric Aciduria Type 1
  found_in:
  - Glutaryl-CoA_Dehydrogenase_Deficiency-deep-research-falcon.md
  findings: []
- reference: url:https://www.ncbi.nlm.nih.gov/books/NBK546575/
  title: Glutaric Acidemia Type 1 - GeneReviews® - NCBI Bookshelf
  tags:
  - GeneReviews
inheritance:
- name: Autosomal recessive
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  description: 'Glutaryl-CoA dehydrogenase deficiency is inherited in an autosomal recessive pattern with complete penetrance for biochemical phenotype but variable expressivity for neurological outcome. Carrier frequency varies by population.

    '
  evidence:
  - reference: PMID:39185018
    reference_title: "Clinical features and GCDH gene variants in three Chinese families with glutaric aciduria type 1: A case series and literature review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Sequencing results showed each case had compound heterozygous variants in GCDH(NM_000159.4)
    explanation: Demonstrates compound heterozygous inheritance pattern consistent with autosomal recessive transmission.
  - reference: 'url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable'
    reference_title: "Glutaric Acidemia Type 1 - GeneReviews® - NCBI Bookshelf"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier.
    explanation: GeneReviews provides the canonical 25/50/25 autosomal recessive recurrence risk framework for GA1 families.
prevalence:
- population: Black South African newborns
  measure_type: BIRTH_PREVALENCE
  prevalence_class: BAND_1_5_PER_10000
  rate_per_100000: 19.290123
  percentage: 1 in 5,184
  notes: >-
    This founder population estimate is substantially higher than the low
    prevalence usually described for GA1 in Europe and other outbred
    populations.
  evidence:
  - reference: PMID:20732827
    reference_title: "Glutaric aciduria type 1 in South Africa-high incidence of glutaryl-CoA dehydrogenase deficiency in black South Africans."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Heterozygosity for the A293T mutation was found 1 in 36 (95% CI; 1/54 - 1/24) unrelated black South African newborns (n=750) giving a predicted prevalence rate for GA 1 of 1 in 5184 (95% CI; 1/11664 - 1/2304) in this population."
    explanation: Newborn carrier screening and founder-mutation analysis provide a quantitative prevalence estimate for this high-risk population.
mechanistic_hypotheses:
- hypothesis_group_id: canonical_ga1_metabolic_model
  hypothesis_label: Canonical GCDH Deficiency-Toxic Metabolite Model
  status: CANONICAL
  description: >-
    Biallelic GCDH loss of function causes accumulation of glutaryl-CoA and organic-acid derivatives
    that contribute to cerebral metabolic injury. Glutarylcarnitine reflects the metabolic
    block and carnitine conjugation; it is not an established neurotoxin.
  notes: >-
    The core enzyme-deficiency model is compatible with both local cerebral production and
    a hepatic contribution. Low-excreter peripheral biomarkers do not exclude brain risk.
    Treatment outcome depends strongly on early diagnosis and adherence, so residual injury
    after screening does not itself prove a missing hepatic mechanism. Astrocytic, bioenergetic,
    excitotoxic and vascular mechanisms have differing experimental support.
  evidence:
  - &id001
    reference: PMID:17879145
    reference_title: Biochemistry and bioenergetics of glutaryl-CoA dehydrogenase deficiency.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: catalyses the oxidative decarboxylation of glutaryl-CoA to crotonyl-CoA and CO2.
    explanation: Defines the actual GCDH substrate and reaction; free glutaric acid is not the substrate.
  - &id002
    reference: PMID:36221165
    reference_title: 'Recommendations for diagnosing and managing individuals with glutaric aciduria type 1: Third revision.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: resulting in deficiency of mitochondrial glutaryl-CoA dehydrogenase (GCDH) and, consequently, accumulation of glutaric acid, 3-hydroxyglutaric acid, glutaconic acid and glutarylcarnitine
    explanation: The guideline summarizes the inherited metabolic block and its biochemical consequences.
  - &id008
    reference: PMID:25968119
    reference_title: Striatal neuronal death mediated by astrocytes from the Gcdh-/- mouse model of glutaric acidemia type I.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Antioxidants abrogated the neuronal death induced by astrocytes exposed to Lys or GA.
    explanation: Antioxidant rescue supports oxidative stress-dependent non-cell-autonomous toxicity in this culture system.
  - reference: PMID:29665094
    reference_title: 'Newborn screening: A disease-changing intervention for glutaric aciduria type 1.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'Presymptomatic start of treatment according to current guideline recommendations clearly improves the neurologic outcome (MD: 7% of patients)'
    explanation: The outcome of guideline-adherent treatment qualifies unstratified failure-rate claims.
- hypothesis_group_id: intracerebral_catabolite_origin_model
  hypothesis_label: Intracerebral Catabolite Origin Model
  status: ALTERNATIVE
  description: >-
    Local cerebral synthesis and limited efflux contribute to brain metabolite accumulation.
    Evidence supports this component without establishing an exclusively intracerebral source
    or excluding hepatic effects.
  evidence:
  - &id003
    reference: PMID:25968119
    reference_title: Striatal neuronal death mediated by astrocytes from the Gcdh-/- mouse model of glutaric acidemia type I.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Upon Lys treatment, Gcdh-/- astrocytes synthetized and released GA and 3-hydroxyglutaric acid (3HGA).
    explanation: Direct production by isolated mouse astrocytes establishes a local capacity; it does not measure the fraction of human brain metabolites produced locally.
  - &id005
    reference: PMID:16573641
    reference_title: Intracerebral accumulation of glutaric and 3-hydroxyglutaric acids secondary to limited flux across the blood-brain barrier constitute a biochemical risk factor for neurodegeneration in glutaryl-CoA dehydrogenase deficiency.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: These results suggest limited flux of GA and 3-OH-GA across the BBB
    explanation: Experiments support restricted cerebral exchange, not an absolutely impermeable barrier.
  - &id006
    reference: PMID:20302929
    reference_title: 'Glutaric aciduria type I and methylmalonic aciduria: simulation of cerebral import and export of accumulating neurotoxic dicarboxylic acids in in vitro models of the blood-brain barrier and the choroid plexus.'
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: low but specific efflux transport for GA, 3-OH-GA, and MMA across pBCEC
    explanation: Transport assays demonstrate a limited specific efflux pathway.
  notes: OpenScientist review retained local production but rejected absolute barrier impermeability and quantitative tissue-localization from global AASS perturbations. See the report assessment for source and analysis limitations.
- hypothesis_group_id: hepatic_catabolite_origin_model
  hypothesis_label: Hepatic Catabolite Origin and Transport Model
  status: EMERGING
  description: >-
    Liver-directed mouse interventions support a therapeutically important hepatic contribution
    to cerebral GA1 metabolite burden. The transported species, relative contribution and
    human translation remain unresolved.
  evidence: &id004
  - &id017
    reference: PMID:37075130
    reference_title: Rescue of glutaric aciduria type I in mice by liver-directed therapies.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: In a series of experiments using knockout mice of the lysine catabolic pathway and liver cell transplantation, we uncovered that toxic GA-1 catabolites in the brain originated from the liver.
    explanation: Liver perturbation and transplantation support a hepatic contribution in mice. The experiment does not quantify its fraction in humans or identify the circulating species.
  notes: >-
    OpenScientist assessment rejects quantitative predominance, direct enzymatic clearance of
    free GA by GCDH, and the inference that vascular barrier injury proves increased catabolite
    influx. Complementary local cerebral synthesis remains supported. Counterbalancing mouse
    experiments constrain the transport step this model needs: cerebral concentrations stay low
    in liver-restricted Gcdh-null mice and after intraperitoneal loading, and radiolabelled
    3-hydroxyglutaric acid is recovered poorly in brain at baseline and less still during an
    induced encephalopathic crisis. Whatever carries the hepatic contribution, it is not
    readily transported free glutaric or 3-hydroxyglutaric acid.
pathophysiology:
- name: GCDH protein misfolding
  description: 'Several pathogenic GCDH missense variants destabilize the protein or impair tetramerization, reducing enzyme activity. This mechanism is variant-dependent; null and splice variants need not act through protein misfolding.'
  gene:
    preferred_term: GCDH
    description: Glutaryl-CoA dehydrogenase, whose missense variants lead to protein misfolding and loss of enzymatic activity.
    modifier: DECREASED
    term:
      id: hgnc:4189
      label: GCDH
  molecular_functions:
  - preferred_term: glutaryl-CoA dehydrogenase activity
    term:
      id: GO:0004361
      label: glutaryl-CoA dehydrogenase activity
    modifier: DECREASED
  biological_processes:
  - preferred_term: L-lysine catabolic process
    term:
      id: GO:0019477
      label: L-lysine catabolic process
    modifier: DECREASED
  cellular_components:
  - preferred_term: mitochondrial matrix
    term:
      id: GO:0005759
      label: mitochondrial matrix
  evidence:
  - reference: PMID:37685964
    reference_title: "Glutaryl-CoA Dehydrogenase Misfolding in Glutaric Acidemia Type 1."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: An altered oligomerization, loss of protein stability and solubility, as well as an augmented susceptibility to aggregation were observed.
    explanation: Comprehensive biochemical characterization of GCDH misfolding across multiple variants.
  - reference: PMID:37685964
    reference_title: "Glutaryl-CoA Dehydrogenase Misfolding in Glutaric Acidemia Type 1."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: The reduced cellular activity was associated with loss of tetramerization.
    explanation: Loss of the native tetrameric assembly directly impairs enzymatic activity.
  - reference: PMID:37685964
    reference_title: "Glutaryl-CoA Dehydrogenase Misfolding in Glutaric Acidemia Type 1."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: The broad panel of variant-mediated conformational changes of the GCDH protein supports the classification of GA1 as a protein-misfolding disorder.
    explanation: Establishes GA1 as a protein misfolding disorder, opening avenues for pharmacological chaperone therapy.
  downstream:
  - target: GCDH enzymatic deficiency
    description: Loss of proper GCDH assembly decreases catalytic function in lysine degradation.
    hypothesis_groups:
    - canonical_ga1_metabolic_model
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:37685964
      reference_title: "Glutaryl-CoA Dehydrogenase Misfolding in Glutaric Acidemia Type 1."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: The reduced cellular activity was associated with loss of tetramerization.
      explanation: Links variant-driven misfolding directly to reduced enzymatic function.
- name: GCDH enzymatic deficiency
  description: >-
    Biallelic pathogenic GCDH variants reduce mitochondrial oxidative decarboxylation of glutaryl-CoA
    to crotonyl-CoA, impairing the shared lysine, hydroxylysine and tryptophan degradation
    pathway. Glutaryl-CoA and organic-acid derivatives accumulate. Glutarylcarnitine is a
    carnitine conjugate and diagnostic readout, not an established neurotoxin.
  gene:
    preferred_term: GCDH
    description: Glutaryl-CoA dehydrogenase, a mitochondrial matrix enzyme catalyzing oxidative decarboxylation of glutaryl-CoA.
    modifier: DECREASED
    term:
      id: hgnc:4189
      label: GCDH
  molecular_functions:
  - preferred_term: glutaryl-CoA dehydrogenase activity
    term:
      id: GO:0004361
      label: glutaryl-CoA dehydrogenase activity
    modifier: DECREASED
  biological_processes:
  - preferred_term: L-lysine catabolic process
    term:
      id: GO:0019477
      label: L-lysine catabolic process
    modifier: DECREASED
  - preferred_term: cellular amino acid catabolic process
    term:
      id: GO:0009063
      label: amino acid catabolic process
    modifier: DECREASED
  - preferred_term: proteinogenic amino acid catabolic process
    term:
      id: GO:0170040
      label: proteinogenic amino acid catabolic process
    modifier: DECREASED
  chemical_entities:
  - preferred_term: glutaric acid
    term:
      id: CHEBI:17859
      label: glutaric acid
    modifier: INCREASED
  - preferred_term: 3-hydroxyglutaric acid
    term:
      id: CHEBI:39980
      label: 3-hydroxyglutaric acid
    modifier: INCREASED
  - preferred_term: glutarylcarnitine
    term:
      id: CHEBI:82952
      label: O-glutaroyl-L-carnitine
    modifier: INCREASED
  cellular_components:
  - preferred_term: mitochondrial matrix
    term:
      id: GO:0005759
      label: mitochondrial matrix
  - preferred_term: mitochondrion
    term:
      id: GO:0005739
      label: mitochondrion
  locations:
  - preferred_term: Liver
    term:
      id: UBERON:0002107
      label: liver
  - preferred_term: Striatum
    term:
      id: UBERON:0002435
      label: striatum
  evidence:
  - *id001
  - *id002
  downstream:
  - target: Intracerebral GA1 catabolite production
    description: Deficient astrocytes can produce catabolites locally when lysine availability increases.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:25968119
      reference_title: Striatal neuronal death mediated by astrocytes from the Gcdh-/- mouse model of glutaric acidemia type I.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: Upon Lys treatment, Gcdh-/- astrocytes synthetized and released GA and 3-hydroxyglutaric acid (3HGA).
      explanation: Direct production by isolated mouse astrocytes establishes a local capacity; it does not measure the fraction of human brain metabolites produced locally.
    hypothesis_groups:
    - intracerebral_catabolite_origin_model
    intermediate_mechanisms:
    - intracerebral lysine degradation
  - target: Hepatic GA1 catabolite production
    description: The hepatic metabolic block produces a peripheral pool that can influence cerebral metabolites in mice.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:37075130
      reference_title: Rescue of glutaric aciduria type I in mice by liver-directed therapies.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: In a series of experiments using knockout mice of the lysine catabolic pathway and liver cell transplantation, we uncovered that toxic GA-1 catabolites in the brain originated from the liver.
      explanation: Liver perturbation and transplantation support a hepatic contribution in mice. The experiment does not quantify its fraction in humans or identify the circulating species.
    hypothesis_groups:
    - hepatic_catabolite_origin_model
    intermediate_mechanisms:
    - hepatic lysine degradation
  - target: Renal metabolic injury
    description: Renal metabolic dysfunction is a parallel manifestation, not a consequence of striatal injury.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:29665094
      reference_title: 'Newborn screening: A disease-changing intervention for glutaric aciduria type 1.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Independent of the neurologic phenotype, kidney function tends to decline with age
      explanation: Prospective human follow-up identifies renal involvement independent of the movement disorder.
    - reference: PMID:34799272
      reference_title: A knock-in rat model unravels acute and chronic renal toxicity in glutaric aciduria type I.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: In young Gcdhki/ki rats exposed to HLD, we observed a GFR decline and biochemical signs of a tubulopathy.
      explanation: Rat experiments support renal metabolic toxicity; exact human cellular mechanisms remain incompletely resolved.
  - target: Secondary carnitine depletion
    description: Glutaryl-CoA conjugation sequesters carnitine in glutarylcarnitine.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:20923787
      reference_title: Therapeutic modulation of cerebral L-lysine metabolism in a mouse model for glutaric aciduria type I.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: L-carnitine supplementation restored the free L-carnitine pool and enhanced the formation of glutarylcarnitine.
      explanation: Mouse experiments support carnitine depletion and conjugation, rather than direct brain glutaric-acid lowering by carnitine.
    intermediate_mechanisms:
    - glutarylcarnitine formation
- name: Intracerebral GA1 catabolite production
  mechanism_confidence: PROVISIONAL
  description: GCDH-deficient astrocytes produce and release GA and 3-OH-GA under lysine challenge. Restricted barrier exchange favors retention. Older pipecolate flux studies and global AASS knockout studies do not settle the quantitative contribution of each pathway or tissue in humans.
  evidence:
  - *id003
  locations: &id007
  - preferred_term: brain
    term:
      id: UBERON:0000955
      label: brain
  cell_types:
  - preferred_term: astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  downstream:
  - target: Brain accumulation of GA1 catabolites
    description: Local synthesis contributes to cerebral accumulation when clearance is limited.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:25968119
      reference_title: Striatal neuronal death mediated by astrocytes from the Gcdh-/- mouse model of glutaric acidemia type I.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: Upon Lys treatment, Gcdh-/- astrocytes synthetized and released GA and 3-hydroxyglutaric acid (3HGA).
      explanation: Direct production by isolated mouse astrocytes establishes a local capacity; it does not measure the fraction of human brain metabolites produced locally.
    - reference: PMID:16573641
      reference_title: Intracerebral accumulation of glutaric and 3-hydroxyglutaric acids secondary to limited flux across the blood-brain barrier constitute a biochemical risk factor for neurodegeneration in glutaryl-CoA dehydrogenase deficiency.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: These results suggest limited flux of GA and 3-OH-GA across the BBB
      explanation: Experiments support restricted cerebral exchange, not an absolutely impermeable barrier.
    - reference: PMID:20302929
      reference_title: 'Glutaric aciduria type I and methylmalonic aciduria: simulation of cerebral import and export of accumulating neurotoxic dicarboxylic acids in in vitro models of the blood-brain barrier and the choroid plexus.'
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: low but specific efflux transport for GA, 3-OH-GA, and MMA across pBCEC
      explanation: Transport assays demonstrate a limited specific efflux pathway.
    hypothesis_groups:
    - intracerebral_catabolite_origin_model
    intermediate_mechanisms:
    - limited cerebral dicarboxylate efflux
- name: Hepatic GA1 catabolite production
  description: Liver-directed GCDH replacement, AASS editing and hepatocyte transplantation alter brain metabolite burden and disease severity in Gcdh-deficient mice. The identity of the exchanged species and the relative hepatic contribution in humans remain unresolved.
  evidence: *id004
  locations:
  - preferred_term: liver
    term:
      id: UBERON:0002107
      label: liver
  downstream:
  - target: Brain accumulation of GA1 catabolites
    description: Hepatic perturbation influences brain metabolites, but direct transport of a particular free acid and quantitative predominance are unproven.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:37075130
      reference_title: Rescue of glutaric aciduria type I in mice by liver-directed therapies.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: In a series of experiments using knockout mice of the lysine catabolic pathway and liver cell transplantation, we uncovered that toxic GA-1 catabolites in the brain originated from the liver.
      explanation: Liver perturbation and transplantation support a hepatic contribution in mice. The experiment does not quantify its fraction in humans or identify the circulating species.
    - reference: PMID:18348873
      reference_title: Transport and distribution of 3-hydroxyglutaric acid before and during induced encephalopathic crises in a mouse model of glutaric aciduria type 1.
      supports: REFUTE
      evidence_source: MODEL_ORGANISM
      snippet: Under these conditions, high amounts of injected 3H-3OHGA were found in kidneys of Gcdh(-/-) mice, whereas the radioactivity recovered in brain and blood was reduced.
      explanation: >-
        Radiolabelled 3-hydroxyglutaric acid injected into Gcdh-null mice was recovered poorly
        in brain at baseline and less still during a high-protein-diet encephalopathic crisis,
        with the authors concluding the barrier appears to remain intact. Circulating catabolite
        therefore does not readily reach brain even under the catabolic stress that precipitates
        striatal injury, which argues against this edge operating by transport of the free acid.
    hypothesis_groups:
    - hepatic_catabolite_origin_model
  mechanism_confidence: PROVISIONAL
- name: Brain accumulation of GA1 catabolites
  description: GA, 3-OH-GA and related glutaryl-CoA-derived compounds accumulate in the brain. Local production and hepatic influences can coexist. Specific low-capacity efflux has been measured, so an absolute blood-brain-barrier blockade is incorrect. Peripheral C5DC and urinary organic acids do not reliably measure the intracerebral pool.
  evidence:
  - *id005
  - *id006
  - &id009
    reference: PMID:25860816
    reference_title: '(1)H-MRS in glutaric aciduria type 1: impact of biochemical phenotype and age on the cerebral accumulation of neurotoxic metabolites.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 3-OH-GA was elevated in white matter of older patients with associated signal changes on MRI
    explanation: Human MRS links white-matter metabolite accumulation to extrastriatal abnormalities; the study is observational.
  locations: *id007
  downstream:
  - target: Astrocyte oxidative stress
    description: Lysine/GA-challenged astrocytes develop oxidative stress-dependent neurotoxicity.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:25968119
      reference_title: Striatal neuronal death mediated by astrocytes from the Gcdh-/- mouse model of glutaric acidemia type I.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: Antioxidants abrogated the neuronal death induced by astrocytes exposed to Lys or GA.
      explanation: Antioxidant rescue supports oxidative stress-dependent non-cell-autonomous toxicity in this culture system.
  - target: Impaired cerebral energy metabolism
    description: Accumulating metabolites interfere with energy pathways, including astrocytic glutamate dehydrogenase.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:29098534
      reference_title: Impairment of astrocytic glutaminolysis in glutaric aciduria type I.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: GA disturbs glutamine degradation by specifically inhibiting glutamate dehydrogenase.
      explanation: Cell experiments identify impaired astrocytic glutaminolysis, particularly under nutrient stress.
    - reference: PMID:33965309
      reference_title: The first knock-in rat model for glutaric aciduria type I allows further insights into pathophysiology in brain and periphery.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: impaired OXPHOS activities and neuronal damage.
      explanation: Lysine-challenged knock-in rats show impaired brain oxidative phosphorylation; this does not establish every proposed mitochondrial intermediate in humans.
  - target: Neuroinflammatory activation
    description: The Gcdh-deficient, lysine-challenged brain develops microglial and NF-kB-associated inflammation.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:35639256
      reference_title: 'Disturbance of Mitochondrial Dynamics, Endoplasmic Reticulum-Mitochondria Crosstalk, Redox Homeostasis, and Inflammatory Response in the Brain of Glutaryl-CoA Dehydrogenase-Deficient Mice: Neuroprotective Effects of Bezafibrate.'
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: the nuclear content of NF-κB was increased, and the cytosolic content of IκBα decreased in the striatum of the mutant animals, indicating a pro-inflammatory response.
      explanation: A lysine-challenged Gcdh-null mouse model shows inflammatory signaling; its independent contribution to human striatal injury remains uncertain.
  - target: Cerebral microvascular dysfunction
    description: Metabolic swelling can compromise cerebral capillary perfusion in the mouse model.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:24468193
      reference_title: Mechanism of metabolic stroke and spontaneous cerebral hemorrhage in glutaric aciduria type I.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: initial neuronal swelling and vacuole formation leading to cerebral capillary occlusion.
      explanation: Mouse time-course microscopy supports swelling preceding microvascular compromise; this is not evidence for systemic free-glutarate influx.
    - reference: PMID:20032085
      reference_title: Cerebral haemodynamics in patients with glutaryl-coenzyme A dehydrogenase deficiency.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Although metabolic toxicity appears central to the pathophysiology of striatal necrosis, cerebrovascular changes probably also contribute to the process.
      explanation: A small human imaging/perfusion study supports a vascular contribution without establishing a single mechanism for every lesion.
  - target: Extrastriatal white matter injury
    description: Chronic cerebral accumulation is associated with white-matter injury independently of an acute striatal crisis.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:25860816
      reference_title: '(1)H-MRS in glutaric aciduria type 1: impact of biochemical phenotype and age on the cerebral accumulation of neurotoxic metabolites.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: 3-OH-GA was elevated in white matter of older patients with associated signal changes on MRI
      explanation: Human MRS links white-matter metabolite accumulation to extrastriatal abnormalities; the study is observational.
    - reference: PMID:34588557
      reference_title: 'The biochemical subtype is a predictor for cognitive function in glutaric aciduria type 1: a national prospective follow-up study.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: The biochemical high excreter phenotype is the major risk factor for cognitive impairment while cognitive functions do not appear to be impacted by current therapy and striatal damage.
      explanation: Cognitive phenotype cannot be reduced to a consequence of striatal injury.
  - target: Context-dependent excitotoxicity
    description: 3-OH-GA can activate excitotoxic pathways in some experimental systems.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:12149496
      reference_title: Ca(2+) and Na(+) dependence of 3-hydroxyglutarate-induced excitotoxicity in primary neuronal cultures from chick embryo telencephalons.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: NMDA receptor activation and subsequent disturbance of Ca(2+) homeostasis contribute to 3-OH-GA-induced cell damage.
      explanation: Receptor expression and chick-neuron experiments support a possible direct 3-OH-GA excitotoxic mechanism.
    - reference: PMID:15262270
      reference_title: 3-Hydroxyglutaric acid fails to affect the viability of primary neuronal rat cells.
      supports: REFUTE
      evidence_source: IN_VITRO
      snippet: 3OHG is not excitotoxic in this model of neuronal rat cell cultures despite the presence of functional NMDA receptors.
      explanation: Negative rat-neuron findings limit generalization across culture models and argue against a universal direct-toxin mechanism.
  - target: Encephalopathy
    description: Cerebral metabolic injury can manifest during an acute encephalopathic crisis; the clinical feature is not assumed to require established striatal necrosis.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK546575/
      reference_title: Glutaric Acidemia Type 1 - GeneReviews® - NCBI Bookshelf
      supports: SUPPORT
      evidence_source: OTHER
      snippet: hypotonia, loss of motor skills, feeding difficulty, and sometimes seizures
      explanation: Clinical features accompany the acute encephalopathic process; individual downstream intermediates are not established.
  - target: Hypotonia
    description: Cerebral metabolic injury can manifest during an acute encephalopathic crisis; the clinical feature is not assumed to require established striatal necrosis.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK546575/
      reference_title: Glutaric Acidemia Type 1 - GeneReviews® - NCBI Bookshelf
      supports: SUPPORT
      evidence_source: OTHER
      snippet: hypotonia, loss of motor skills, feeding difficulty, and sometimes seizures
      explanation: Clinical features accompany the acute encephalopathic process; individual downstream intermediates are not established.
  - target: Seizures
    description: Cerebral metabolic injury can manifest during an acute encephalopathic crisis; the clinical feature is not assumed to require established striatal necrosis.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK546575/
      reference_title: Glutaric Acidemia Type 1 - GeneReviews® - NCBI Bookshelf
      supports: SUPPORT
      evidence_source: OTHER
      snippet: hypotonia, loss of motor skills, feeding difficulty, and sometimes seizures
      explanation: Clinical features accompany the acute encephalopathic process; individual downstream intermediates are not established.
  - target: Feeding difficulties
    description: Cerebral metabolic injury can manifest during an acute encephalopathic crisis; the clinical feature is not assumed to require established striatal necrosis.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK546575/
      reference_title: Glutaric Acidemia Type 1 - GeneReviews® - NCBI Bookshelf
      supports: SUPPORT
      evidence_source: OTHER
      snippet: hypotonia, loss of motor skills, feeding difficulty, and sometimes seizures
      explanation: Clinical features accompany the acute encephalopathic process; individual downstream intermediates are not established.
- name: Astrocyte oxidative stress
  description: Lysine- or GA-exposed Gcdh-deficient astrocytes develop redox stress and become toxic to striatal and cortical neurons. Antioxidants prevent neuronal death in co-culture. Direct GA exposure is not toxic in that particular neuronal culture; this does not exclude toxicity of other metabolites or in other systems.
  evidence:
  - *id008
  locations: *id007
  biological_processes:
  - preferred_term: response to oxidative stress
    term:
      id: GO:0006979
      label: response to oxidative stress
  cell_types:
  - preferred_term: astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  downstream:
  - target: Striatal degeneration
    description: Astrocytic oxidative stress can drive striatal neuronal death in co-culture; the secreted toxic effector remains unresolved.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:25968119
      reference_title: Striatal neuronal death mediated by astrocytes from the Gcdh-/- mouse model of glutaric acidemia type I.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: Antioxidants abrogated the neuronal death induced by astrocytes exposed to Lys or GA.
      explanation: Antioxidant rescue supports oxidative stress-dependent non-cell-autonomous toxicity in this culture system.
  mechanism_confidence: PROVISIONAL
- name: Impaired cerebral energy metabolism
  description: GA inhibits astrocytic glutamate dehydrogenase under nutrient stress, while Gcdh-deficient animal brains show impaired energy metabolism. Glutaryl-CoA-mediated enzyme inhibition and glial mitochondrial protein glutarylation are additional candidate modifiers; protein glutarylation is not established as uniformly harmful.
  evidence:
  - reference: PMID:29098534
    reference_title: Impairment of astrocytic glutaminolysis in glutaric aciduria type I.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: GA disturbs glutamine degradation by specifically inhibiting glutamate dehydrogenase.
    explanation: Cell experiments identify impaired astrocytic glutaminolysis, particularly under nutrient stress.
  - reference: PMID:33965309
    reference_title: The first knock-in rat model for glutaric aciduria type I allows further insights into pathophysiology in brain and periphery.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: impaired OXPHOS activities and neuronal damage.
    explanation: Lysine-challenged knock-in rats show impaired brain oxidative phosphorylation; this does not establish every proposed mitochondrial intermediate in humans.
  - reference: PMID:30208319
    reference_title: Disease-Linked Glutarylation Impairs Function and Interactions of Mitochondrial Proteins and Contributes to Mitochondrial Heterogeneity.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Glutarylation reduces the catalytic activities of the most abundant glutamate dehydrogenase
    explanation: Protein glutarylation changes enzyme function; the net contribution to human neurodegeneration is unresolved.
  locations: *id007
  downstream:
  - target: Striatal degeneration
    description: Energy impairment may increase neuronal vulnerability during catabolic stress.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:29098534
      reference_title: Impairment of astrocytic glutaminolysis in glutaric aciduria type I.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: GA disturbs glutamine degradation by specifically inhibiting glutamate dehydrogenase.
      explanation: Cell experiments identify impaired astrocytic glutaminolysis, particularly under nutrient stress.
    - reference: PMID:33965309
      reference_title: The first knock-in rat model for glutaric aciduria type I allows further insights into pathophysiology in brain and periphery.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: impaired OXPHOS activities and neuronal damage.
      explanation: Lysine-challenged knock-in rats show impaired brain oxidative phosphorylation; this does not establish every proposed mitochondrial intermediate in humans.
  mechanism_confidence: PROVISIONAL
- name: Neuroinflammatory activation
  description: Lysine-challenged Gcdh-null mice show microglial activation and NF-kB-associated inflammatory signaling. The evidence supports an inflammatory response, but does not isolate inflammation as the initiating cause of human striatal injury.
  evidence:
  - reference: PMID:35639256
    reference_title: 'Disturbance of Mitochondrial Dynamics, Endoplasmic Reticulum-Mitochondria Crosstalk, Redox Homeostasis, and Inflammatory Response in the Brain of Glutaryl-CoA Dehydrogenase-Deficient Mice: Neuroprotective Effects of Bezafibrate.'
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: the nuclear content of NF-κB was increased, and the cytosolic content of IκBα decreased in the striatum of the mutant animals, indicating a pro-inflammatory response.
    explanation: A lysine-challenged Gcdh-null mouse model shows inflammatory signaling; its independent contribution to human striatal injury remains uncertain.
  locations: *id007
  biological_processes:
  - preferred_term: inflammatory response
    term:
      id: GO:0006954
      label: inflammatory response
  downstream:
  - target: Striatal degeneration
    description: Inflammation is a proposed amplifier of injury, supported mainly by disease-model changes and biomarker rescue.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:35639256
      reference_title: 'Disturbance of Mitochondrial Dynamics, Endoplasmic Reticulum-Mitochondria Crosstalk, Redox Homeostasis, and Inflammatory Response in the Brain of Glutaryl-CoA Dehydrogenase-Deficient Mice: Neuroprotective Effects of Bezafibrate.'
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: the nuclear content of NF-κB was increased, and the cytosolic content of IκBα decreased in the striatum of the mutant animals, indicating a pro-inflammatory response.
      explanation: A lysine-challenged Gcdh-null mouse model shows inflammatory signaling; its independent contribution to human striatal injury remains uncertain.
  mechanism_confidence: PROVISIONAL
- name: Context-dependent excitotoxicity
  description: 3-OH-GA activates recombinant NMDA receptors and can disturb neuronal calcium homeostasis in chick cultures. Rat neuronal cultures show a negative result despite functional NMDA receptors. Excitotoxicity remains a context-dependent candidate contributor; it is not a demonstrated universal initiating mechanism in human GA1.
  evidence:
  - reference: PMID:12149496
    reference_title: Ca(2+) and Na(+) dependence of 3-hydroxyglutarate-induced excitotoxicity in primary neuronal cultures from chick embryo telencephalons.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: NMDA receptor activation and subsequent disturbance of Ca(2+) homeostasis contribute to 3-OH-GA-induced cell damage.
    explanation: Receptor expression and chick-neuron experiments support a possible direct 3-OH-GA excitotoxic mechanism.
  - reference: PMID:15262270
    reference_title: 3-Hydroxyglutaric acid fails to affect the viability of primary neuronal rat cells.
    supports: REFUTE
    evidence_source: IN_VITRO
    snippet: 3OHG is not excitotoxic in this model of neuronal rat cell cultures despite the presence of functional NMDA receptors.
    explanation: Negative rat-neuron findings limit generalization across culture models and argue against a universal direct-toxin mechanism.
  downstream:
  - target: Striatal degeneration
    description: Excitotoxic calcium dysregulation is a candidate route to neuronal injury with conflicting in-vitro evidence.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:12149496
      reference_title: Ca(2+) and Na(+) dependence of 3-hydroxyglutarate-induced excitotoxicity in primary neuronal cultures from chick embryo telencephalons.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: NMDA receptor activation and subsequent disturbance of Ca(2+) homeostasis contribute to 3-OH-GA-induced cell damage.
      explanation: Receptor expression and chick-neuron experiments support a possible direct 3-OH-GA excitotoxic mechanism.
    - reference: PMID:15262270
      reference_title: 3-Hydroxyglutaric acid fails to affect the viability of primary neuronal rat cells.
      supports: REFUTE
      evidence_source: IN_VITRO
      snippet: 3OHG is not excitotoxic in this model of neuronal rat cell cultures despite the presence of functional NMDA receptors.
      explanation: Negative rat-neuron findings limit generalization across culture models and argue against a universal direct-toxin mechanism.
  mechanism_confidence: HYPOTHETICAL
- name: Cerebral microvascular dysfunction
  description: Mouse metabolic injury progresses through neuronal swelling, capillary obstruction and secondary vascular compromise. Human Doppler and perfusion findings suggest reduced reserve and disordered autoregulation. Barrier injury during a crisis does not itself demonstrate increased free-GA transport from blood.
  evidence:
  - reference: PMID:24468193
    reference_title: Mechanism of metabolic stroke and spontaneous cerebral hemorrhage in glutaric aciduria type I.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: initial neuronal swelling and vacuole formation leading to cerebral capillary occlusion.
    explanation: Mouse time-course microscopy supports swelling preceding microvascular compromise; this is not evidence for systemic free-glutarate influx.
  - reference: PMID:20032085
    reference_title: Cerebral haemodynamics in patients with glutaryl-coenzyme A dehydrogenase deficiency.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Although metabolic toxicity appears central to the pathophysiology of striatal necrosis, cerebrovascular changes probably also contribute to the process.
    explanation: A small human imaging/perfusion study supports a vascular contribution without establishing a single mechanism for every lesion.
  locations: *id007
  downstream:
  - target: Striatal degeneration
    description: Microvascular compromise can compound metabolic injury.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:24468193
      reference_title: Mechanism of metabolic stroke and spontaneous cerebral hemorrhage in glutaric aciduria type I.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: initial neuronal swelling and vacuole formation leading to cerebral capillary occlusion.
      explanation: Mouse time-course microscopy supports swelling preceding microvascular compromise; this is not evidence for systemic free-glutarate influx.
    - reference: PMID:20032085
      reference_title: Cerebral haemodynamics in patients with glutaryl-coenzyme A dehydrogenase deficiency.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Although metabolic toxicity appears central to the pathophysiology of striatal necrosis, cerebrovascular changes probably also contribute to the process.
      explanation: A small human imaging/perfusion study supports a vascular contribution without establishing a single mechanism for every lesion.
  - target: Frontotemporal hypoplasia and enlarged CSF spaces
    description: Altered cerebral hemodynamics have been proposed to contribute to enlarged CSF spaces; this developmental link remains uncertain.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:20032085
      reference_title: Cerebral haemodynamics in patients with glutaryl-coenzyme A dehydrogenase deficiency.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Although metabolic toxicity appears central to the pathophysiology of striatal necrosis, cerebrovascular changes probably also contribute to the process.
      explanation: A small human imaging/perfusion study supports a vascular contribution without establishing a single mechanism for every lesion.
  mechanism_confidence: PROVISIONAL
- name: Striatal degeneration
  description: Acute or insidious bilateral striatal injury causes persistent motor dysfunction. Acute episodes cluster in infancy and early childhood, generally before age three and occasionally up to six years, during infection, fever, fasting or surgery. Injury is not inevitable after newborn screening and adherent preventive treatment.
  evidence: &id012
  - &id010
    reference: PMID:36221165
    reference_title: 'Recommendations for diagnosing and managing individuals with glutaric aciduria type 1: Third revision.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Most untreated individuals present with acute onset of striatal damage before age 3 (to 6) years, precipitated by infectious diseases, fever or surgery, resulting in irreversible, mostly dystonic movement disorder
    explanation: Human natural history supports the trigger, vulnerable age range, striatal lesion, and persistent motor consequence.
  - &id011
    reference: PMID:36221165
    reference_title: 'Recommendations for diagnosing and managing individuals with glutaric aciduria type 1: Third revision.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: In some patients, striatal damage develops insidiously.
    explanation: Striatal injury also occurs without a recognized acute crisis.
  locations:
  - preferred_term: striatum
    term:
      id: UBERON:0002435
      label: striatum
  downstream:
  - target: Dystonia
    description: Striatal injury produces an irreversible predominantly dystonic movement disorder.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:36221165
      reference_title: 'Recommendations for diagnosing and managing individuals with glutaric aciduria type 1: Third revision.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Most untreated individuals present with acute onset of striatal damage before age 3 (to 6) years, precipitated by infectious diseases, fever or surgery, resulting in irreversible, mostly dystonic movement disorder
      explanation: Human natural history supports the trigger, vulnerable age range, striatal lesion, and persistent motor consequence.
    - reference: PMID:36221165
      reference_title: 'Recommendations for diagnosing and managing individuals with glutaric aciduria type 1: Third revision.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: In some patients, striatal damage develops insidiously.
      explanation: Striatal injury also occurs without a recognized acute crisis.
  - target: Motor delay
    description: Loss of motor function after striatal injury impairs motor development.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:36221165
      reference_title: 'Recommendations for diagnosing and managing individuals with glutaric aciduria type 1: Third revision.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Most untreated individuals present with acute onset of striatal damage before age 3 (to 6) years, precipitated by infectious diseases, fever or surgery, resulting in irreversible, mostly dystonic movement disorder
      explanation: Human natural history supports the trigger, vulnerable age range, striatal lesion, and persistent motor consequence.
    - reference: PMID:36221165
      reference_title: 'Recommendations for diagnosing and managing individuals with glutaric aciduria type 1: Third revision.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: In some patients, striatal damage develops insidiously.
      explanation: Striatal injury also occurs without a recognized acute crisis.
  - target: Developmental regression
    description: Acute neurologic injury can cause loss of acquired motor skills.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK546575/
      reference_title: Glutaric Acidemia Type 1 - GeneReviews® - NCBI Bookshelf
      supports: SUPPORT
      evidence_source: OTHER
      snippet: hypotonia, loss of motor skills, feeding difficulty, and sometimes seizures
      explanation: GeneReviews lists loss of motor skills during encephalopathic crises.
- name: Extrastriatal white matter injury
  description: Progressive white-matter abnormalities and cognitive impairment can occur outside the acute striatal-injury pathway, especially in biochemical high excreters. Their causal relationship is incompletely resolved; cognition is not simply inferred from the extent of dystonic disability.
  evidence:
  - *id009
  - &id013
    reference: PMID:34588557
    reference_title: 'The biochemical subtype is a predictor for cognitive function in glutaric aciduria type 1: a national prospective follow-up study.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The biochemical high excreter phenotype is the major risk factor for cognitive impairment while cognitive functions do not appear to be impacted by current therapy and striatal damage.
    explanation: Cognitive phenotype cannot be reduced to a consequence of striatal injury.
  locations: *id007
  downstream:
  - target: Cerebral white matter hyperintensity on MRI
    description: White-matter signal abnormalities accompany the extrastriatal process.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:25860816
      reference_title: '(1)H-MRS in glutaric aciduria type 1: impact of biochemical phenotype and age on the cerebral accumulation of neurotoxic metabolites.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: 3-OH-GA was elevated in white matter of older patients with associated signal changes on MRI
      explanation: Human MRS links white-matter metabolite accumulation to extrastriatal abnormalities; the study is observational.
  - target: Cognitive impairment
    description: High-excreter status predicts cognitive impairment, but a specific white-matter-to-cognition mechanism is unresolved.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:34588557
      reference_title: 'The biochemical subtype is a predictor for cognitive function in glutaric aciduria type 1: a national prospective follow-up study.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: The biochemical high excreter phenotype is the major risk factor for cognitive impairment while cognitive functions do not appear to be impacted by current therapy and striatal damage.
      explanation: Cognitive phenotype cannot be reduced to a consequence of striatal injury.
- name: Frontotemporal hypoplasia and enlarged CSF spaces
  description: Frontotemporal underdevelopment and expanded extra-axial CSF spaces can be present early, including before an encephalopathic crisis. They are distinct from secondary atrophy after striatal injury and predispose to stretching of bridging veins.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK546575/
    reference_title: Glutaric Acidemia Type 1 - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Subdural hemorrhage, typically associated with frontotemporal hypoplasia
    explanation: GeneReviews identifies the characteristic developmental imaging abnormality.
  - reference: PMID:26219480
    reference_title: 'Subdural hematomas: glutaric aciduria type 1 or abusive head trauma? A systematic review.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Children with GA1 are reported to be predisposed to subdural hematoma (SDH) development due to stretching of cortical veins secondary to cerebral atrophy and expansion of CSF spaces.
    explanation: The systematic review supports vein stretching as a proposed link to subdural hemorrhage.
  locations: *id007
  downstream:
  - target: Macrocephaly
    description: Expanded intracranial CSF spaces can accompany macrocephaly; the developmental cause is incompletely resolved.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:20032085
      reference_title: Cerebral haemodynamics in patients with glutaryl-coenzyme A dehydrogenase deficiency.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Although metabolic toxicity appears central to the pathophysiology of striatal necrosis, cerebrovascular changes probably also contribute to the process.
      explanation: A small human imaging/perfusion study supports a vascular contribution without establishing a single mechanism for every lesion.
  - target: Subdural hemorrhage
    description: Expanded CSF spaces predispose to stretching and rupture of bridging veins.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:26219480
      reference_title: 'Subdural hematomas: glutaric aciduria type 1 or abusive head trauma? A systematic review.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Children with GA1 are reported to be predisposed to subdural hematoma (SDH) development due to stretching of cortical veins secondary to cerebral atrophy and expansion of CSF spaces.
      explanation: The systematic review supports vein stretching as a proposed link to subdural hemorrhage.
    intermediate_mechanisms:
    - stretching of cortical bridging veins
- name: Renal metabolic injury
  description: Renal function can decline with age despite neurologic stability. Knock-in rats show proximal tubular abnormalities, altered renal OXPHOS and reduced filtration under lysine stress and with aging; these model findings guide, but do not establish, every human renal mechanism.
  evidence:
  - &id014
    reference: PMID:29665094
    reference_title: 'Newborn screening: A disease-changing intervention for glutaric aciduria type 1.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Independent of the neurologic phenotype, kidney function tends to decline with age
    explanation: Prospective human follow-up identifies renal involvement independent of the movement disorder.
  - &id020
    reference: PMID:34799272
    reference_title: A knock-in rat model unravels acute and chronic renal toxicity in glutaric aciduria type I.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: In young Gcdhki/ki rats exposed to HLD, we observed a GFR decline and biochemical signs of a tubulopathy.
    explanation: Rat experiments support renal metabolic toxicity; exact human cellular mechanisms remain incompletely resolved.
  locations:
  - preferred_term: kidney
    term:
      id: UBERON:0002113
      label: kidney
  downstream:
  - target: Renal insufficiency
    description: Progressive renal injury is associated with declining filtration.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:29665094
      reference_title: 'Newborn screening: A disease-changing intervention for glutaric aciduria type 1.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Independent of the neurologic phenotype, kidney function tends to decline with age
      explanation: Prospective human follow-up identifies renal involvement independent of the movement disorder.
    - reference: PMID:34799272
      reference_title: A knock-in rat model unravels acute and chronic renal toxicity in glutaric aciduria type I.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: In young Gcdhki/ki rats exposed to HLD, we observed a GFR decline and biochemical signs of a tubulopathy.
      explanation: Rat experiments support renal metabolic toxicity; exact human cellular mechanisms remain incompletely resolved.
  mechanism_confidence: PROVISIONAL
- name: Secondary carnitine depletion
  description: Formation and loss of glutarylcarnitine deplete free carnitine. Supplementation replenishes carnitine and supports glutaryl-CoA detoxification; it did not independently lower brain GA in the cited mouse study.
  evidence: &id015
  - &id016
    reference: PMID:20923787
    reference_title: Therapeutic modulation of cerebral L-lysine metabolism in a mouse model for glutaric aciduria type I.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: L-carnitine supplementation restored the free L-carnitine pool and enhanced the formation of glutarylcarnitine.
    explanation: Mouse experiments support carnitine depletion and conjugation, rather than direct brain glutaric-acid lowering by carnitine.
phenotypes:
- name: Macrocephaly
  description: 'Macrocephaly may precede neurologic injury. A review of Chinese patients reported increased head circumference in 77.19%; this cohort proportion is not a universal frequency.'
  phenotype_term:
    preferred_term: Macrocephaly
    term:
      id: HP:0000256
      label: Macrocephaly
  evidence:
  - reference: PMID:39185018
    reference_title: "Clinical features and GCDH gene variants in three Chinese families with glutaric aciduria type 1: A case series and literature review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The most common clinical manifestations included increased head circumference (77.19%)
    explanation: Literature review of Chinese GA1 patients shows macrocephaly in 77% of cases.
- name: Dystonia
  description: 'Persistent, often complex dystonic movement disorder follows acute or insidious striatal damage. Risk is much lower with presymptomatic guideline-adherent treatment.'
  phenotype_term:
    preferred_term: Dystonia
    term:
      id: HP:0001332
      label: Dystonia
  evidence:
  - *id010
  - *id011
  - reference: PMID:37474264
    reference_title: "Glutaric Aciduria Type 1: Comparison between Diffusional Kurtosis Imaging and Conventional MR Imaging."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The diffusional kurtosis imaging metrics of the temporal lobe and basal ganglia were significantly correlated with the Barry-Albright dystonia scores.
    explanation: DKI imaging demonstrates that basal ganglia microstructural changes correlate with dystonia severity scores.
- name: Motor delay
  description: 'Motor development may be delayed or disrupted by striatal injury. A review of Chinese patients reported motor delay in 65.15%.'
  phenotype_term:
    preferred_term: Motor delay
    term:
      id: HP:0001270
      label: Motor delay
  evidence:
  - reference: PMID:39185018
    reference_title: "Clinical features and GCDH gene variants in three Chinese families with glutaric aciduria type 1: A case series and literature review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The most common clinical manifestations included increased head circumference (77.19%) and motor developmental delay (65.15%).
    explanation: Literature review shows motor delay in 65% of GA1 patients.
- name: Encephalopathy
  description: 'Acute encephalopathic crises occur mainly before age three and occasionally up to six years, often during catabolic illness. Insidious striatal injury can also occur without a recognized crisis.'
  phenotype_term:
    preferred_term: Encephalopathy
    term:
      id: HP:0001298
      label: Encephalopathy
  evidence: *id012
- name: Subdural hemorrhage
  description: 'Children with GA1 are predisposed to subdural hematoma development due to stretching of cortical veins secondary to cerebral atrophy and expansion of CSF spaces. SDH in GA1 must be distinguished from abusive head trauma.

    '
  phenotype_term:
    preferred_term: Subdural hemorrhage
    term:
      id: HP:0100309
      label: Subdural hemorrhage
  evidence:
  - reference: PMID:26219480
    reference_title: "Subdural hematomas: glutaric aciduria type 1 or abusive head trauma? A systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Children with GA1 are reported to be predisposed to subdural hematoma (SDH) development due to stretching of cortical veins secondary to cerebral atrophy and expansion of CSF spaces.
    explanation: Systematic review establishing the predisposition to SDH in GA1 and the need to distinguish from abusive head trauma.
  - reference: PMID:26219480
    reference_title: "Subdural hematomas: glutaric aciduria type 1 or abusive head trauma? A systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: SDHs in 19/20 children with GA1 are accompanied by other brain abnormalities specific for GA1.
    explanation: SDHs in GA1 almost always co-occur with other GA1-specific brain abnormalities, distinguishing them from abusive head trauma.
- name: Metabolic acidosis
  description: >-
    Metabolic acidosis can require treatment during acute illness, but is not required to
    recognize a GA1 encephalopathic crisis.
  phenotype_term:
    preferred_term: Metabolic acidosis
    term:
      id: HP:0001942
      label: Metabolic acidosis
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK546575/
    reference_title: Glutaric Acidemia Type 1 - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    snippet: seizure medication as needed, and treatment of metabolic acidosis.
    explanation: GeneReviews includes acidosis management during acute decompensation without assigning a population frequency.
- name: Seizures
  description: Seizures may occur during or after encephalopathic crises.
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK546575/
    reference_title: Glutaric Acidemia Type 1 - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    snippet: hypotonia, loss of motor skills, feeding difficulty, and sometimes seizures
    explanation: Human clinical synthesis identifies features of acute encephalopathic crises.
- name: Cognitive impairment
  description: >-
    Cognitive performance can be reduced, particularly in high excreters, without necessarily
    meeting criteria for intellectual disability. Cognitive outcome is not explained solely
    by striatal damage or movement-disorder severity.
  phenotype_term:
    preferred_term: Cognitive impairment
    term:
      id: HP:0100543
      label: Cognitive impairment
  evidence:
  - *id013
- name: Hypotonia
  description: 'Muscular hypotonia may be present in infancy, particularly before the onset of dystonia.

    '
  phenotype_term:
    preferred_term: Hypotonia
    term:
      id: HP:0001252
      label: Hypotonia
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK546575/
    reference_title: Glutaric Acidemia Type 1 - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    snippet: hypotonia, loss of motor skills, feeding difficulty, and sometimes seizures
    explanation: Human clinical synthesis identifies features of acute encephalopathic crises.
- name: Cerebral white matter hyperintensity on MRI
  description: 'White-matter MRI signal abnormalities may progress with age and accompany cerebral metabolite accumulation, including outside the acute striatal-injury pathway.'
  phenotype_term:
    preferred_term: Hyperintensity of cerebral white matter on MRI
    term:
      id: HP:0030890
      label: Hyperintensity of cerebral white matter on MRI
  evidence:
  - *id009
- name: Developmental regression
  description: Loss of acquired motor skills can accompany an acute encephalopathic crisis.
  phenotype_term:
    preferred_term: Developmental regression
    term:
      id: HP:0002376
      label: Developmental regression
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK546575/
    reference_title: Glutaric Acidemia Type 1 - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    snippet: hypotonia, loss of motor skills, feeding difficulty, and sometimes seizures
    explanation: GeneReviews lists loss of motor skills during encephalopathic crises.
- name: Renal insufficiency
  description: Kidney function can decline with age independently of neurologic phenotype, including in patients identified through newborn screening.
  phenotype_term:
    preferred_term: Renal insufficiency
    term:
      id: HP:0000083
      label: Renal insufficiency
  evidence:
  - *id014
- name: Feeding difficulties
  description: Feeding difficulty can accompany an acute crisis or persistent neurologic disability and may require enteral support.
  phenotype_term:
    preferred_term: Feeding difficulties in infancy
    term:
      id: HP:0008872
      label: Feeding difficulties in infancy
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK546575/
    reference_title: Glutaric Acidemia Type 1 - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    snippet: hypotonia, loss of motor skills, feeding difficulty, and sometimes seizures
    explanation: Clinical synthesis identifies feeding difficulty during crises.
biochemical:
- name: Elevated glutarylcarnitine (C5DC)
  presence: INCREASED
  readouts:
  - target: GCDH enzymatic deficiency
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: Elevated C5DC in blood reports the disrupted GCDH-dependent lysine-catabolism pathway. Peripheral concentrations do not quantify brain burden.
  notes: 'Blood C5DC is the principal newborn-screening marker. Low excreters may be missed; renal dysfunction and other causes can also elevate C5DC. Screening is not a direct measure of brain toxicity.'
  evidence:
  - reference: PMID:39185018
    reference_title: "Clinical features and GCDH gene variants in three Chinese families with glutaric aciduria type 1: A case series and literature review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: patients exhibited significant elevations in C5DC (98.51%) and C5DC/C8 (94.87%) in blood
    explanation: Observed in the cited Chinese case-series/literature-review cohort; this is not a universal diagnostic sensitivity estimate.
- name: Elevated glutaric acid in urine
  presence: INCREASED
  readouts:
  - target: GCDH enzymatic deficiency
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: Urinary glutaric acid elevation reports accumulation of GA1 catabolites downstream of GCDH deficiency. Peripheral concentrations do not quantify brain burden.
  notes: 'Urinary GA helps distinguish high and low excreters. Low or intermittently normal excretion does not exclude GA1 or indicate low neurologic risk.'
  evidence:
  - reference: PMID:39185018
    reference_title: "Clinical features and GCDH gene variants in three Chinese families with glutaric aciduria type 1: A case series and literature review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: GA (94.37%) and 3OHGA (69.39%) in urine
    explanation: Observed in the cited Chinese case-series/literature-review cohort; this is not a universal diagnostic sensitivity estimate.
  - reference: PMID:34588557
    reference_title: "The biochemical subtype is a predictor for cognitive function in glutaric aciduria type 1: a national prospective follow-up study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The biochemical high excreter phenotype is the major risk factor for cognitive impairment
    explanation: The high/low excreter distinction based on urinary GA levels is clinically significant for cognitive prognosis.
- name: Elevated 3-hydroxyglutaric acid in urine
  presence: INCREASED
  readouts:
  - target: GCDH enzymatic deficiency
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: Urinary 3-OH-GA elevation reports accumulation of neurotoxic GA1 metabolites downstream of GCDH deficiency. Peripheral concentrations do not quantify brain burden.
  notes: 'Quantitative urine or plasma 3-OH-GA contributes to diagnostic evaluation. The dominant toxic molecular species and a reliable peripheral proxy for cerebral burden remain unresolved.'
  evidence:
  - reference: PMID:39185018
    reference_title: "Clinical features and GCDH gene variants in three Chinese families with glutaric aciduria type 1: A case series and literature review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: GA (94.37%) and 3OHGA (69.39%) in urine
    explanation: Observed in the cited Chinese case-series/literature-review cohort; this is not a universal diagnostic sensitivity estimate.
genetic:
- name: GCDH variants causing glutaryl-CoA dehydrogenase deficiency
  gene_term:
    preferred_term: GCDH
    term:
      id: hgnc:4189
      label: GCDH
  association: CAUSATIVE
  features: 'Biallelic pathogenic GCDH variants cause GA1. Missense, splice and other loss-of-function variants occur. In the cited 73-patient Chinese review, 73.97% of reported variants were missense and c.1244-2A>C was the most frequent variant; these proportions are population-specific. Residual activity influences biochemical excretion but does not reliably predict freedom from striatal injury.'
  evidence:
  - reference: PMID:39185018
    reference_title: "Clinical features and GCDH gene variants in three Chinese families with glutaric aciduria type 1: A case series and literature review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 67 distinct GCDH gene variants were identified among 73 patients, with missense variants being the most prevalent type (73.97%). The most frequent variant was c.1244-2 A > C, observed in 17.12% of cases.
    explanation: Comprehensive literature review of GCDH variant spectrum in Chinese GA1 patients.
  - reference: PMID:37685964
    reference_title: "Glutaryl-CoA Dehydrogenase Misfolding in Glutaric Acidemia Type 1."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: The high number of missense variants associated with the disease and their impact on GCDH activity suggest that disturbed protein conformation can affect the biochemical phenotype.
    explanation: Demonstrates that missense variants cause protein misfolding affecting biochemical phenotype.
  - reference: PMID:39185018
    reference_title: "Clinical features and GCDH gene variants in three Chinese families with glutaric aciduria type 1: A case series and literature review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: the majority of variant sites were located in exons 11 (25.37%) and 6 (22.39%).
    explanation: Exon distribution in the cited Chinese literature-review cohort, not a universal mutational hotspot map.
  - reference: CGGV:assertion_33a2c95e-a057-4b93-b97e-27b6597516e5-2019-11-08T170000.000Z
    reference_title: "GCDH / glutaryl-CoA dehydrogenase deficiency (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "GCDH | HGNC:4189 | glutaryl-CoA dehydrogenase deficiency | MONDO:0009281 | AR | Definitive"
    explanation: ClinGen classifies the GCDH-glutaryl-CoA dehydrogenase deficiency gene-disease relationship as definitive with autosomal recessive inheritance.
treatments:
- name: Lysine-restricted diet
  description: 'A specialist-supervised low-lysine diet supplies an appropriate amount of natural protein and may use lysine-free, tryptophan-reduced amino-acid formula. Lysine is essential: a completely lysine-free diet is not intended. Adequate energy and nutrition prevent catabolism and growth failure; dietary intensity can be relaxed after age six under specialist guidance.'
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: dietary intervention
    term:
      id: NCIT:C15447
      label: Dietary Intervention
  target_mechanisms:
  - target: Brain accumulation of GA1 catabolites
    treatment_effect: INHIBITS
    description: Lysine restriction reduces substrate flux intended to minimize CNS exposure to lysine-derived toxic byproducts.
    evidence:
    - reference: 'url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable'
      reference_title: "Glutaric Acidemia Type 1 - GeneReviews® - NCBI Bookshelf"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Combined metabolic therapy includes low-lysine diet, carnitine supplementation, and emergency treatment during episodes with the goal of averting catabolism and minimizing CNS exposure to lysine and its toxic metabolic byproducts.
      explanation: GeneReviews explicitly frames low-lysine diet as part of therapy aimed at minimizing CNS toxic-metabolite exposure.
  evidence:
  - reference: PMID:34588557
    reference_title: "The biochemical subtype is a predictor for cognitive function in glutaric aciduria type 1: a national prospective follow-up study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Long-term neurologic outcome in GA1 involves both motor and cognitive functions. The biochemical high excreter phenotype is the major risk factor for cognitive impairment while cognitive functions do not appear to be impacted by current therapy and striatal damage.
    explanation: Diet is standard of care but current therapy does not fully prevent cognitive impairment, particularly in high excreters.
  - reference: 'url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable'
    reference_title: "Glutaric Acidemia Type 1 - GeneReviews® - NCBI Bookshelf"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Combined metabolic therapy includes low-lysine diet, carnitine supplementation, and emergency treatment during episodes with the goal of averting catabolism and minimizing CNS exposure to lysine and its toxic metabolic byproducts.
    explanation: GeneReviews supports low-lysine diet as a core component of combined metabolic therapy aimed at reducing neurotoxic exposure.
  - reference: PMID:36221165
    reference_title: 'Recommendations for diagnosing and managing individuals with glutaric aciduria type 1: Third revision.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Dietary treatment can be relaxed after the vulnerable period for striatal damage, that is, age 6
    explanation: The guideline distinguishes the vulnerable age window from later dietary management.
  - reference: PMID:21820344
    reference_title: 'Safety, efficacy and physiological actions of a lysine-free, arginine-rich formula to treat glutaryl-CoA dehydrogenase deficiency: focus on cerebral amino acid influx.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: This represents a 36% reduction of neurological risk (95% confidence interval 14-52%, p=0.018) that we can directly attribute to altered amino acid intake.
    explanation: >-
      Twelve consecutively treated children given a lysine-free, arginine-rich formula were
      compared with 25 historical controls on natural protein restriction. The quantified
      reduction in neurological risk is the strongest human outcome evidence that lowering
      lysine substrate flux is neuroprotective, supporting dietary lysine restriction as
      disease-modifying rather than only supportive. It is a non-randomized comparison against
      a historical cohort, so the effect size is not trial-grade.
- name: Carnitine supplementation
  description: 'L-carnitine replenishes depleted free carnitine and supports glutaryl-CoA conjugation and detoxification. It is part of combined metabolic treatment; the cited mouse study did not show that carnitine alone lowered brain GA.'
  treatment_term:
    preferred_term: carnitine supplementation
    term:
      id: NCIT:C15433
      label: Nutritional Support
    therapeutic_agent:
    - preferred_term: carnitine
      term:
        id: CHEBI:17126
        label: carnitine
  target_mechanisms:
  - target: Secondary carnitine depletion
    treatment_effect: INHIBITS
    description: Replenishes the depleted free-carnitine pool.
    evidence: *id015
  notes: >-
    L-carnitine supplementation is recommended in international GA1 guidelines to
    replenish secondary
    carnitine deficiency caused by urinary losses of glutarylcarnitine (C5DC). Nearly
    all GA1 patients
    (98.51%) show elevated C5DC (PMID:39185018), reflecting ongoing carnitine conjugation
    and loss.
  evidence:
  - reference: 'url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable'
    reference_title: "Glutaric Acidemia Type 1 - GeneReviews® - NCBI Bookshelf"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Combined metabolic therapy includes low-lysine diet, carnitine supplementation, and emergency treatment during episodes with the goal of averting catabolism and minimizing CNS exposure to lysine and its toxic metabolic byproducts.
    explanation: GeneReviews identifies carnitine supplementation as part of standard combined metabolic treatment in GA1.
  - *id016
- name: Emergency management during intercurrent illness
  description: 'Prompt specialist-directed sick-day and perioperative treatment supplies energy, limits catabolism and adjusts protein intake during infection, fasting or other stress. The principal window of vulnerability extends through age six; established striatal injury is not reversed by preventive metabolic treatment.'
  treatment_term:
    preferred_term: supportive care
    term:
      id: NCIT:C15747
      label: Supportive Care
  target_mechanisms:
  - target: Striatal degeneration
    treatment_effect: INHIBITS
    description: Emergency illness management prevents catabolism during stressors that can precipitate striatal injury and encephalopathic crises.
    evidence:
    - reference: 'url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable'
      reference_title: "Glutaric Acidemia Type 1 - GeneReviews® - NCBI Bookshelf"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "<i>Agents/circumstances to avoid:</i> Excessive dietary protein or protein malnutrition inducing catabolic state, prolonged fasting, catabolic illness (intercurrent infection; brief febrile illness post vaccination), inadequate caloric provision during other stressors (e.g., surgery or procedure requiring fasting/anesthesia)."
      explanation: GeneReviews lists catabolic illness, fasting, and inadequate calories as circumstances to avoid, supporting emergency management as prevention of the crisis-triggering mechanism.
  evidence:
  - reference: 'url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable'
    reference_title: "Glutaric Acidemia Type 1 - GeneReviews® - NCBI Bookshelf"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Combined metabolic therapy includes low-lysine diet, carnitine supplementation, and emergency treatment during episodes with the goal of averting catabolism and minimizing CNS exposure to lysine and its toxic metabolic byproducts.
    explanation: GeneReviews supports emergency treatment during illness/stress as a core preventive strategy to reduce CNS toxic exposure.
  - reference: 'url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable'
    reference_title: "Glutaric Acidemia Type 1 - GeneReviews® - NCBI Bookshelf"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "<i>Agents/circumstances to avoid:</i> Excessive dietary protein or protein malnutrition inducing catabolic state, prolonged fasting, catabolic illness (intercurrent infection; brief febrile illness post vaccination), inadequate caloric provision during other stressors (e.g., surgery or procedure requiring fasting/anesthesia)."
    explanation: Defines key catabolic triggers that emergency protocols are designed to prevent or mitigate.
  - *id010
  - *id011
- name: Genetic counseling
  description: 'Genetic counseling is essential for families with GA1 to explain the autosomal recessive inheritance pattern, recurrence risk, and options for prenatal diagnosis.

    '
  treatment_term:
    preferred_term: Genetic Counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  evidence:
  - reference: PMID:39185018
    reference_title: "Clinical features and GCDH gene variants in three Chinese families with glutaric aciduria type 1: A case series and literature review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: These findings facilitate the diagnosis and treatment of affected children and provide a basis for genetic counseling and prenatal diagnosis for their families.
    explanation: Genetic variant identification enables genetic counseling and prenatal diagnosis.
  - reference: 'url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable'
    reference_title: "Glutaric Acidemia Type 1 - GeneReviews® - NCBI Bookshelf"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "<i>Evaluation of relatives at risk:</i> Testing of all at-risk sibs of any age to allow for early diagnosis and treatment."
    explanation: GeneReviews supports proactive testing of at-risk siblings as part of counseling and preventive care.
  - reference: 'url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable'
    reference_title: "Glutaric Acidemia Type 1 - GeneReviews® - NCBI Bookshelf"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Once the <i>GCDH</i> pathogenic variants in an affected family member are known, carrier testing for at-risk relatives, prenatal testing for a pregnancy at increased risk, and preimplantation genetic testing are possible.
    explanation: Confirms scope of reproductive and familial counseling options once familial variants are identified.
- name: GCDH gene replacement (investigational)
  description: 'Liver-directed and systemic AAV-GCDH rescue biochemical and neurologic abnormalities in mouse models. A separate CNS-administered GCDH gene replacement program, VGM-R02b, is registered in a phase 1 trial. Clinical efficacy is not established by either the mouse experiments or trial registration.'
  therapeutic_modality: GENE_THERAPY
  treatment_term:
    preferred_term: gene therapy
    term:
      id: NCIT:C15238
      label: Gene Therapy
  target_mechanisms:
  - target: GCDH enzymatic deficiency
    treatment_effect: INHIBITS
    description: Restoring GCDH activity counteracts the pathological enzyme-deficiency node.
    evidence:
    - reference: PMID:38983872
      reference_title: "Systemic delivery of AAV-GCDH ameliorates HLD-induced phenotype in a glutaric aciduria type I mouse model."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: Neonatal treatment with AAV-GCDH restores GCDH expression and enzyme activity in liver and striatum.
      explanation: Supports restoration of the primary deficient enzymatic node by gene replacement therapy.
  - target: Brain accumulation of GA1 catabolites
    treatment_effect: INHIBITS
    description: Liver-directed gene therapy approaches reduce pathogenic brain metabolite burden.
    evidence:
    - reference: PMID:37075130
      reference_title: "Rescue of glutaric aciduria type I in mice by liver-directed therapies."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: the characteristic brain and lethal phenotype of the GA-1 mouse model was rescued by two different liver-directed gene therapy approaches
      explanation: Supports inhibition of the downstream toxic-catabolite brain exposure pathway.
  evidence:
  - reference: PMID:37075130
    reference_title: "Rescue of glutaric aciduria type I in mice by liver-directed therapies."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: 'the characteristic brain and lethal phenotype of the GA-1 mouse model was rescued by two different liver-directed gene therapy approaches: Using an adeno-associated virus, we replaced the defective Gcdh gene or we prevented flux through the lysine degradation pathway by CRISPR deletion of the aminoadipate-semialdehyde synthase (Aass) gene.'
    explanation: Preclinical evidence for two liver-directed gene therapy strategies for GA1.
  - reference: PMID:38983872
    reference_title: "Systemic delivery of AAV-GCDH ameliorates HLD-induced phenotype in a glutaric aciduria type I mouse model."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Neonatal treatment with AAV-GCDH restores GCDH expression and enzyme activity in liver and striatum.
    explanation: Systemic AAV9-GCDH delivery restores enzyme activity in target tissues.
  - reference: PMID:38983872
    reference_title: "Systemic delivery of AAV-GCDH ameliorates HLD-induced phenotype in a glutaric aciduria type I mouse model."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: AAV-GCDH significantly ameliorates the striatal neuropathology, minimizing neuronal dysfunction, gliosis, and alterations in myelination.
    explanation: Gene therapy prevents striatal neuropathology in the GA1 mouse model.
  - &id019
    reference: clinicaltrials:NCT06217861
    reference_title: An Open-Label, Dose-Escalation and Dose-Expansion Phase I Clinical Study to Evaluate the Tolerability, Safety and Efficacy of VGM-R02b in Patients With Glutaric Acidemia Type I
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Phase I, open-label, single-arm, single-dose, trial of VGM-R02b (gene replacement therapy)
    explanation: Registration documents an early clinical program, not clinical efficacy.
- name: Pharmacological chaperone therapy (investigational)
  description: 'Structure-targeted allosteric regulators are being explored as pharmacological chaperones for GA1 protein-misfolding variants, aiming to stabilize folded GCDH and increase residual enzyme function without competing with the natural substrate.

    '
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  target_mechanisms:
  - target: GCDH protein misfolding
    treatment_effect: MODULATES
    description: Allosteric pharmacological chaperones are intended to stabilize folded GCDH protein and counter variant-associated misfolding.
    evidence:
    - reference: PMID:39312412
      reference_title: "Use of the Novel Site-Directed Enzyme Enhancement Therapy (SEE-Tx) Drug Discovery Platform to Identify Pharmacological Chaperones for Glutaric Acidemia Type 1."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: Allosteric regulators acting as pharmacological chaperones hold promise for innovative therapeutics since they target noncatalytic sites and stabilize the folded protein without competing with the natural substrate, resulting in a net gain of function.
      explanation: The abstract describes the intended chaperone mechanism as stabilization of folded protein with gain of function.
  evidence:
  - reference: PMID:39312412
    reference_title: "Use of the Novel Site-Directed Enzyme Enhancement Therapy (SEE-Tx) Drug Discovery Platform to Identify Pharmacological Chaperones for Glutaric Acidemia Type 1."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Putative allosteric regulators were discovered using structure- and ligand-based virtual screening methods and validated using orthogonal biophysical and biochemical assays.
    explanation: Preclinical computational discovery followed by biochemical/biophysical validation supports investigational chaperone pharmacotherapy for GA1.
- name: Bezafibrate (investigational)
  description: 'Bezafibrate normalized redox and inflammatory markers in lysine-challenged Gcdh-null mice. This is preclinical evidence and does not establish neurologic efficacy or clinical use in GA1.'
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: bezafibrate
      term:
        id: CHEBI:47612
        label: bezafibrate
  target_mechanisms:
  - target: Astrocyte oxidative stress
    treatment_effect: INHIBITS
    description: Bezafibrate dampens oxidative and pro-inflammatory pathomechanisms in GCDH-deficient brain tissue.
    evidence:
    - reference: PMID:35639256
      reference_title: "Disturbance of Mitochondrial Dynamics, Endoplasmic Reticulum-Mitochondria Crosstalk, Redox Homeostasis, and Inflammatory Response in the Brain of Glutaryl-CoA Dehydrogenase-Deficient Mice: Neuroprotective Effects of Bezafibrate."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: in vivo treatment with the pan-PPAR agonist bezafibrate normalized these alterations.
      explanation: Supports mechanistic inhibition/modulation of oxidative-inflammatory injury pathways.
  - target: Neuroinflammatory activation
    treatment_effect: INHIBITS
    description: Normalizes inflammatory readouts in the mouse study.
    evidence:
    - reference: PMID:35639256
      reference_title: "Disturbance of Mitochondrial Dynamics, Endoplasmic Reticulum-Mitochondria Crosstalk, Redox Homeostasis, and Inflammatory Response in the Brain of Glutaryl-CoA Dehydrogenase-Deficient Mice: Neuroprotective Effects of Bezafibrate."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: in vivo treatment with the pan-PPAR agonist bezafibrate normalized these alterations.
      explanation: Bezafibrate treatment normalized oxidative stress and inflammatory markers in GCDH-deficient mice.
  evidence:
  - reference: PMID:35639256
    reference_title: "Disturbance of Mitochondrial Dynamics, Endoplasmic Reticulum-Mitochondria Crosstalk, Redox Homeostasis, and Inflammatory Response in the Brain of Glutaryl-CoA Dehydrogenase-Deficient Mice: Neuroprotective Effects of Bezafibrate."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: in vivo treatment with the pan-PPAR agonist bezafibrate normalized these alterations.
    explanation: Bezafibrate treatment normalized oxidative stress and inflammatory markers in GCDH-deficient mice.
  - reference: PMID:35639256
    reference_title: "Disturbance of Mitochondrial Dynamics, Endoplasmic Reticulum-Mitochondria Crosstalk, Redox Homeostasis, and Inflammatory Response in the Brain of Glutaryl-CoA Dehydrogenase-Deficient Mice: Neuroprotective Effects of Bezafibrate."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: bezafibrate should be tested as a potential adjuvant therapy for GA1.
    explanation: Authors propose bezafibrate as a potential adjuvant therapy based on preclinical evidence.
- name: AASS substrate reduction (investigational)
  description: Upstream AASS inhibition lowers lysine-catabolic flux without replacing GCDH. Liver-directed Aass editing, systemic AAV9-delivered anti-Aass microRNA and global Aass knockout reduce metabolites or rescue disease in mice. Global and systemic interventions do not determine tissue-specific source fractions.
  therapeutic_modality: GENE_THERAPY
  treatment_term:
    preferred_term: Gene Therapy
    term:
      id: NCIT:C15238
      label: Gene Therapy
  target_mechanisms:
  - target: Hepatic GA1 catabolite production
    treatment_effect: INHIBITS
    description: Reduces hepatic upstream lysine catabolism.
    evidence:
    - *id017
    - &id018
      reference: PMID:40682274
      reference_title: Therapeutic AASS inhibition by AAV-miRNA rescues glutaric aciduria type I severe phenotype in mice.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: We detected dose-dependent miR-AASS expression and AASS inhibition in liver and striatum
      explanation: Systemic AAV9 microRNA affects both compartments, so rescue does not partition hepatic and cerebral sources.
  - target: Intracerebral GA1 catabolite production
    treatment_effect: INHIBITS
    description: Systemic microRNA also lowers AASS expression in striatum; the relative contribution of that component remains unresolved.
    evidence:
    - *id018
  evidence:
  - *id018
  - reference: PMID:41917075
    reference_title: Aminoadipate-semialdehyde synthase, a potential target for substrate reduction therapy in glutaric aciduria type 1.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Gcdh/Aass KO mice did not develop a severe phenotype under high-lysine diet.
    explanation: Additional global Aass knockout protects the challenged mouse phenotype; it is not a human efficacy trial.
- name: Symptomatic neurologic and feeding support
  description: Individualized dystonia treatment can include benzodiazepines, baclofen, trihexyphenidyl or botulinum toxin. Physical and rehabilitation therapy address motor disability; nutritional or enteral support addresses feeding impairment, and seizures receive standard specialist treatment.
  treatment_term:
    preferred_term: Supportive Care
    term:
      id: NCIT:C15747
      label: Supportive Care
  target_phenotypes:
  - preferred_term: Dystonia
    term:
      id: HP:0001332
      label: Dystonia
  - preferred_term: Motor delay
    term:
      id: HP:0001270
      label: Motor delay
  - preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK546575/
    reference_title: Glutaric Acidemia Type 1 - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Standard therapeutic options may incl use of benzodiazepines, baclofen, trihexyphenidyl
    explanation: GeneReviews lists symptomatic dystonia options.
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK546575/
    reference_title: Glutaric Acidemia Type 1 - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Physical therapy is recommended to maximize mobility and to reduce the risk for later-onset orthopedic complications
    explanation: GeneReviews recommends motor rehabilitation.
- name: Metabolic and renal surveillance
  description: Follow growth, nutritional adequacy, development, movement disorders, amino-acid and carnitine status, and kidney function. Renal follow-up remains relevant despite good neurologic control.
  treatment_term:
    preferred_term: Supportive Care
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - *id014
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK546575/
    reference_title: Glutaric Acidemia Type 1 - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    snippet: plasma creatinine and/or cystatin C levels periodically in adolescents and adults
    explanation: GeneReviews recommends renal surveillance.
diagnosis:
- name: Newborn screening
  description: Tandem mass spectrometry measures C5DC. Low-excreter false negatives occur; normal screening does not exclude GA1 in a symptomatic child. Digital-tier classifiers remain dependent on the population and validation set.
  evidence:
  - reference: PMID:29665094
    reference_title: 'Newborn screening: A disease-changing intervention for glutaric aciduria type 1.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Overall, cumulative sensitivity of NBS is 95.6%, but it is lower (84%) for patients with low excreter phenotype.
    explanation: Prospective German screening follow-up quantifies the low-excreter limitation.
  - reference: PMID:39728403
    reference_title: "Digital-Tier Strategy Improves Newborn Screening for Glutaric Aciduria Type 1."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: the proposed digital-tier strategy based on logistic regression analysis, ridge regression, and support vector machine reduced the false-positive rate by over 90% compared to regular NBS while identifying all confirmed individuals with GA1 correctly.
    explanation: Machine learning approaches can dramatically improve NBS specificity for GA1.
- name: Biochemical and molecular confirmation
  description: Quantitative organic acids and acylcarnitines support suspicion; biallelic pathogenic GCDH variants establish the diagnosis. When molecular testing is uncertain, GCDH activity in fibroblasts or leukocytes can resolve it. Metabolic treatment begins promptly when GA1 is suspected while confirmation proceeds.
  evidence:
  - reference: PMID:31536184
    reference_title: Glutaric Acidemia Type 1.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: identification of biallelic pathogenic variants in GCDH
    explanation: GeneReviews specifies molecular confirmation.
  - reference: PMID:31536184
    reference_title: Glutaric Acidemia Type 1.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: detection of significantly reduced activity of the enzyme glutaryl-CoA dehydrogenase (GCDH) in cultured fibroblasts or leukocytes.
    explanation: Enzyme assay is useful when molecular results are uncertain.
has_subtypes:
- name: High excreter biochemical phenotype
  description: Very low GCDH activity is associated with high GA excretion. Extrastriatal and cognitive abnormalities are enriched in this group; clinical severity is not determined by excretion alone.
  evidence:
  - *id013
- name: Low excreter biochemical phenotype
  description: Residual GCDH activity can produce low or intermittently normal peripheral markers. Newborn screening is less sensitive, but clinically serious striatal injury remains possible.
  evidence:
  - reference: PMID:29665094
    reference_title: 'Newborn screening: A disease-changing intervention for glutaric aciduria type 1.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Overall, cumulative sensitivity of NBS is 95.6%, but it is lower (84%) for patients with low excreter phenotype.
    explanation: Prospective German screening follow-up quantifies the low-excreter limitation.
environmental:
- name: Catabolic illness and fasting
  description: Infection, fever, surgery and inadequate caloric intake increase catabolism during the vulnerable early-childhood period.
  effect: TRIGGERS
  influences_mechanisms:
  - target: Brain accumulation of GA1 catabolites
    environmental_effect: TRIGGERS
    description: Increased endogenous substrate delivery stresses the blocked pathway.
    evidence:
    - reference: PMID:36221165
      reference_title: 'Recommendations for diagnosing and managing individuals with glutaric aciduria type 1: Third revision.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Most untreated individuals present with acute onset of striatal damage before age 3 (to 6) years, precipitated by infectious diseases, fever or surgery, resulting in irreversible, mostly dystonic movement disorder
      explanation: Human natural history supports the trigger, vulnerable age range, striatal lesion, and persistent motor consequence.
  evidence:
  - reference: PMID:36221165
    reference_title: 'Recommendations for diagnosing and managing individuals with glutaric aciduria type 1: Third revision.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Most untreated individuals present with acute onset of striatal damage before age 3 (to 6) years, precipitated by infectious diseases, fever or surgery, resulting in irreversible, mostly dystonic movement disorder
    explanation: Human natural history supports the trigger, vulnerable age range, striatal lesion, and persistent motor consequence.
clinical_trials:
- name: NCT06217861
  phase: PHASE_I
  status: RECRUITING
  description: Open-label dose-escalation and dose-expansion study of VGM-R02b gene replacement in genetically confirmed GA1, using CNS administration. The registry estimates 12 participants aged six years or younger.
  notes: ClinicalTrials.gov checked 2026-09-04; last update posted 2026-05-13. No results posted. This trial must not be confused with preclinical liver-directed AAV or AASS substrate reduction.
  evidence:
  - *id019
- name: NCT04602325
  phase: NOT_APPLICABLE
  status: RECRUITING
  description: Observational biomarker study that includes a separate GA1/MSUD aim measuring S100B, NSE and UCHL1. Its inclusion of GA1 does not establish hyperammonemia as the usual GA1 mechanism.
  notes: ClinicalTrials.gov API checked 2026-09-04; latest posted record dated 2024-02-07 still lists RECRUITING, with no results posted. Candidate injury markers have not thereby become validated GA1 monitoring biomarkers.
  evidence:
  - reference: clinicaltrials:NCT04602325
    reference_title: Systemic Biomarkers of Brain Injury From Hyperammonemia
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Aim 2 will be to determine if S100B, NSE, and UCHL1 are altered in patients with two other inborn errors of metabolism, Maple Syrup Urine Disease (MSUD) and Glutaric Acidemia (GA1).
    explanation: The trial distinguishes the GA1/MSUD study aim from inherited hyperammonemia.
animal_models:
- name: Gcdh knockout mouse with lysine or protein challenge
  species: Mouse
  genotype: Gcdh-/-
  description: Disease models show metabolite accumulation and stress-sensitive neuropathology. Liver transplantation and targeted interventions test a peripheral contribution; effects depend on background, age and diet.
  modeled_mechanisms:
  - target: Brain accumulation of GA1 catabolites
    relationship: RECAPITULATES
    description: Liver-directed genetic interventions and transplantation change the brain metabolite burden in Gcdh-deficient mice, testing a peripheral contribution.
    limitations: Transplantation results do not determine human source fractions or identify the exchanged molecule.
    evidence:
    - reference: PMID:37075130
      reference_title: Rescue of glutaric aciduria type I in mice by liver-directed therapies.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: In a series of experiments using knockout mice of the lysine catabolic pathway and liver cell transplantation, we uncovered that toxic GA-1 catabolites in the brain originated from the liver.
      explanation: Liver perturbation and transplantation support a hepatic contribution in mice. The experiment does not quantify its fraction in humans or identify the circulating species.
  - target: Cerebral microvascular dysfunction
    relationship: RECAPITULATES
    description: Dietary challenge produces neuronal swelling and vacuoles that precede cerebral capillary occlusion in the mouse model.
    limitations: Acute experimental dietary challenge and murine microvasculature limit direct extrapolation to human development.
    evidence:
    - reference: PMID:24468193
      reference_title: Mechanism of metabolic stroke and spontaneous cerebral hemorrhage in glutaric aciduria type I.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: initial neuronal swelling and vacuole formation leading to cerebral capillary occlusion.
      explanation: Mouse time-course microscopy supports swelling preceding microvascular compromise; this is not evidence for systemic free-glutarate influx.
  evidence:
  - reference: PMID:37075130
    reference_title: Rescue of glutaric aciduria type I in mice by liver-directed therapies.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: In a series of experiments using knockout mice of the lysine catabolic pathway and liver cell transplantation, we uncovered that toxic GA-1 catabolites in the brain originated from the liver.
    explanation: Liver perturbation and transplantation support a hepatic contribution in mice. The experiment does not quantify its fraction in humans or identify the circulating species.
- name: Gcdh R411W knock-in rat
  species: Rat
  genotype: Gcdh p.R411W homozygous knock-in
  description: The rat homolog of the human p.R402W variant produces high excretion and lysine-challenge-dependent cerebral injury; longitudinal studies demonstrate renal decline.
  modeled_mechanisms:
  - target: Renal metabolic injury
    relationship: RECAPITULATES
    description: High-lysine challenge lowers glomerular filtration and produces biochemical tubulopathy in young knock-in rats.
    limitations: Rat tubular pathology supports renal mechanisms but is not direct human histologic evidence.
    evidence:
    - reference: PMID:34799272
      reference_title: A knock-in rat model unravels acute and chronic renal toxicity in glutaric aciduria type I.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: In young Gcdhki/ki rats exposed to HLD, we observed a GFR decline and biochemical signs of a tubulopathy.
      explanation: Rat experiments support renal metabolic toxicity; exact human cellular mechanisms remain incompletely resolved.
  - target: Impaired cerebral energy metabolism
    relationship: RECAPITULATES
    description: The challenged knock-in rat develops impaired oxidative-phosphorylation activities and neuronal damage.
    limitations: Nutritional challenge and species influence phenotype.
    evidence:
    - reference: PMID:33965309
      reference_title: The first knock-in rat model for glutaric aciduria type I allows further insights into pathophysiology in brain and periphery.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: impaired OXPHOS activities and neuronal damage.
      explanation: Lysine-challenged knock-in rats show impaired brain oxidative phosphorylation; this does not establish every proposed mitochondrial intermediate in humans.
  evidence:
  - reference: PMID:33965309
    reference_title: The first knock-in rat model for glutaric aciduria type I allows further insights into pathophysiology in brain and periphery.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: We generated the first knock-in rat model for GA-I by introduction of the mutation p.R411W
    explanation: CRISPR/Cas9 generated the disease-relevant knock-in model.
  - *id020
experimental_models:
- name: Gcdh-deficient astrocyte-neuron co-culture
  experimental_model_type: CO_CULTURE
  description: Primary mouse astrocytes challenged with lysine or GA produce organic acids and become toxic to co-cultured striatal or cortical neurons. Antioxidants prevent the neurotoxicity.
  cell_types:
  - preferred_term: astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  modeled_mechanisms:
  - target: Intracerebral GA1 catabolite production
    relationship: RECAPITULATES
    description: Lysine-challenged Gcdh-deficient astrocytes synthesize and release glutaric and 3-hydroxyglutaric acids.
    limitations: Mouse culture demonstrates local production capacity, not quantitative human tissue fractions.
    evidence:
    - reference: PMID:25968119
      reference_title: Striatal neuronal death mediated by astrocytes from the Gcdh-/- mouse model of glutaric acidemia type I.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: Upon Lys treatment, Gcdh-/- astrocytes synthetized and released GA and 3-hydroxyglutaric acid (3HGA).
      explanation: Direct production by isolated mouse astrocytes establishes a local capacity; it does not measure the fraction of human brain metabolites produced locally.
  - target: Astrocyte oxidative stress
    relationship: RECAPITULATES
    description: Lysine and glutaric-acid exposure increase astrocyte oxidative stress; antioxidants prevent this response and the associated neuronal toxicity.
    limitations: Culture conditions and metabolite concentrations constrain transfer to human disease.
    evidence:
    - reference: PMID:25968119
      reference_title: Striatal neuronal death mediated by astrocytes from the Gcdh-/- mouse model of glutaric acidemia type I.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: Lys and GA treatments also increased oxidative stress and proliferation in Gcdh-/- astrocytes, both prevented by antioxidants.
      explanation: The study directly measures increased astrocyte oxidative stress and its antioxidant sensitivity, in addition to the separate coculture neuronal-survival outcome.
    - reference: PMID:25968119
      reference_title: Striatal neuronal death mediated by astrocytes from the Gcdh-/- mouse model of glutaric acidemia type I.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: Antioxidants abrogated the neuronal death induced by astrocytes exposed to Lys or GA.
      explanation: Antioxidant rescue supports oxidative stress-dependent non-cell-autonomous toxicity in this culture system.
  evidence:
  - reference: PMID:25968119
    reference_title: Striatal neuronal death mediated by astrocytes from the Gcdh-/- mouse model of glutaric acidemia type I.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Upon Lys treatment, Gcdh-/- astrocytes synthetized and released GA and 3-hydroxyglutaric acid (3HGA).
    explanation: Direct production by isolated mouse astrocytes establishes a local capacity; it does not measure the fraction of human brain metabolites produced locally.
  - reference: PMID:25968119
    reference_title: Striatal neuronal death mediated by astrocytes from the Gcdh-/- mouse model of glutaric acidemia type I.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Antioxidants abrogated the neuronal death induced by astrocytes exposed to Lys or GA.
    explanation: Antioxidant rescue supports oxidative stress-dependent non-cell-autonomous toxicity in this culture system.
updated_date: '2026-09-04T22:30:00Z'
discussions:
- discussion_id: ga1-compartment-source-partition
  kind: KNOWLEDGE_GAP
  status: OPEN
  prompt: Which liver-derived molecular species influences the brain, and how do hepatic and intracerebral source fractions change with genotype and catabolic state?
  rationale: Liver-directed rescue and local astrocyte production are both supported, while BBB experiments show limited free-acid transport. Global AASS perturbation and IV-versus-ICV precursor delivery alone do not partition source. Tissue-specific perturbation, matched precursor enrichment, time courses and measurements in liver, plasma, CSF and brain are needed; human CSF is not interchangeable with intracellular striatal pools.
  attaches_to:
  - pathophysiology#Brain accumulation of GA1 catabolites
  - pathophysiology#Hepatic GA1 catabolite production
  - pathophysiology#Intracerebral GA1 catabolite production
  - mechanistic_hypotheses#hepatic_catabolite_origin_model
  - mechanistic_hypotheses#intracerebral_catabolite_origin_model
  evidence:
  - reference: PMID:37075130
    reference_title: Rescue of glutaric aciduria type I in mice by liver-directed therapies.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: In a series of experiments using knockout mice of the lysine catabolic pathway and liver cell transplantation, we uncovered that toxic GA-1 catabolites in the brain originated from the liver.
    explanation: Liver perturbation and transplantation support a hepatic contribution in mice. The experiment does not quantify its fraction in humans or identify the circulating species.
  - reference: PMID:25968119
    reference_title: Striatal neuronal death mediated by astrocytes from the Gcdh-/- mouse model of glutaric acidemia type I.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Upon Lys treatment, Gcdh-/- astrocytes synthetized and released GA and 3-hydroxyglutaric acid (3HGA).
    explanation: Direct production by isolated mouse astrocytes establishes a local capacity; it does not measure the fraction of human brain metabolites produced locally.
  - reference: PMID:16573641
    reference_title: Intracerebral accumulation of glutaric and 3-hydroxyglutaric acids secondary to limited flux across the blood-brain barrier constitute a biochemical risk factor for neurodegeneration in glutaryl-CoA dehydrogenase deficiency.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: These results suggest limited flux of GA and 3-OH-GA across the BBB
    explanation: Experiments support restricted cerebral exchange, not an absolutely impermeable barrier.
  - reference: PMID:20302929
    reference_title: 'Glutaric aciduria type I and methylmalonic aciduria: simulation of cerebral import and export of accumulating neurotoxic dicarboxylic acids in in vitro models of the blood-brain barrier and the choroid plexus.'
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: low but specific efflux transport for GA, 3-OH-GA, and MMA across pBCEC
    explanation: Transport assays demonstrate a limited specific efflux pathway.
  - reference: PMID:32567100
    reference_title: Deletion of 2-aminoadipic semialdehyde synthase limits metabolite accumulation in cell and mouse models for glutaric aciduria type 1.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: In the GA1 mouse model, deletion of Aass leads to a 4.3-, 3.8-, and 3.2-fold decrease in the glutaric acid levels in urine, brain, and liver, respectively.
    explanation: >-
      Substrate reduction upstream of GCDH lowers glutaric acid in all three compartments at
      once. Because the deletion is global, the fall in brain glutaric acid is equally
      consistent with reduced local synthesis, reduced hepatic supply, or both, which is why
      this experiment cannot close the partitioning question it is often cited to answer.
  proposed_experiments:
  - experiment_id: exp_ga1_compartmental_isotope_tracing
    name: Stable-isotope lysine tracing of brain versus hepatic catabolite origin
    description: >-
      Infuse differentially labelled lysine so that the hepatic and cerebral pools carry
      distinguishable labels, then quantify labelled glutaric acid, 3-hydroxyglutaric acid and
      glutarylcarnitine in brain, plasma and liver of Gcdh-null mice at baseline and during a
      high-protein-diet crisis. Reports the fraction of brain catabolite carrying the
      peripheral label and identifies the transported species.
    would_support:
    - mechanistic_hypotheses#hepatic_catabolite_origin_model
    would_refute:
    - mechanistic_hypotheses#intracerebral_catabolite_origin_model
    supporting_outcome:
    - >-
      A substantial and quantifiable share of brain glutaric acid and 3-hydroxyglutaric acid
      carries the peripherally introduced label, and the labelled species crossing into brain
      can be named.
    refuting_outcome:
    - >-
      Brain catabolite label derives almost entirely from lysine taken up and catabolized
      within brain, with negligible peripheral label recovered even during crisis.
  - experiment_id: exp_ga1_tissue_specific_aass_deletion
    name: Tissue-specific AASS deletion to localize glutarate production
    description: >-
      Compare liver-specific, brain-specific and global conditional Aass deletion on the
      Gcdh-null background, measuring brain and peripheral catabolite concentrations, striatal
      pathology and survival under a high-protein diet. Converts the existing global knockout
      into a compartment-discriminating experiment.
    would_support:
    - mechanistic_hypotheses#hepatic_catabolite_origin_model
    would_refute:
    - mechanistic_hypotheses#intracerebral_catabolite_origin_model
    supporting_outcome:
    - >-
      Liver-restricted Aass deletion reproduces most of the brain catabolite reduction and
      neuroprotection seen with global deletion.
    refuting_outcome:
    - >-
      Only brain-restricted Aass deletion lowers brain catabolites and protects the striatum,
      while liver-restricted deletion changes peripheral markers alone.
- discussion_id: ga1-brain-lysine-route-to-glutarate
  kind: KNOWLEDGE_GAP
  status: OPEN
  prompt: >-
    Which cerebral lysine catabolic route actually supplies brain glutaric acid, given that
    the pipecolate pathway dominates lysine degradation in brain while glutarate production
    tracks the saccharopine enzyme AASS?
  rationale: >-
    Two well-conducted mouse studies point in different directions. Labelled lysine
    experiments find pipecolate to be the major cerebral degradation product with little
    saccharopine formed in brain, whereas deleting the saccharopine enzyme AASS lowers brain
    glutaric acid several fold. The results are reconcilable if a quantitatively minor
    cerebral saccharopine flux is nonetheless the main route to glutarate, but that has not
    been shown directly, and the relative fluxes have never been measured in human brain. The
    answer decides whether AASS inhibition, currently pursued as substrate reduction therapy,
    can lower the brain catabolite pool or only the peripheral one.
  attaches_to:
  - pathophysiology#GCDH enzymatic deficiency
  - pathophysiology#Intracerebral GA1 catabolite production
  - mechanistic_hypotheses#intracerebral_catabolite_origin_model
  evidence:
  - reference: PMID:25214427
    reference_title: 'Understanding cerebral L-lysine metabolism: the role of L-pipecolate metabolism in Gcdh-deficient mice as a model for glutaric aciduria type I.'
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: In line with these findings, we observed only little production of saccharopine in the murine brain.
    explanation: >-
      Direct measurement with labelled lysine finds minimal cerebral saccharopine production,
      which sits in tension with the several-fold drop in brain glutaric acid caused by
      deleting the saccharopine enzyme, and establishes this as a genuine unresolved flux
      question rather than a settled pathway assignment.
  - reference: PMID:32567100
    reference_title: Deletion of 2-aminoadipic semialdehyde synthase limits metabolite accumulation in cell and mouse models for glutaric aciduria type 1.
    supports: REFUTE
    evidence_source: MODEL_ORGANISM
    snippet: These in vivo data demonstrate that the saccharopine pathway is the main source of glutaric acid production in the brain and periphery of a mouse model for GA1
    explanation: >-
      The opposite reading of the same question. These authors attribute brain glutarate
      production to the saccharopine pathway, but the inference rests on a global deletion
      that also removes peripheral flux, so it does not measure cerebral saccharopine flux
      directly and does not settle the tension with the pipecolate tracer data.
- discussion_id: ga1-compartmental-evidence-is-mouse-only
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  prompt: >-
    Does the compartmental origin of brain catabolites established in Gcdh-null mice apply to
    human GA1, where cerebral lysine influx, barrier maturation and catabolic rates differ?
  rationale: >-
    Every experiment that discriminates hepatic from intracerebral origin has been done in
    mice: tissue-restricted GCDH loss, peripheral catabolite loading, radiotracer
    distribution, hepatocyte transplantation and liver-directed gene therapy. No GA1 patient
    has received a liver transplant or liver-directed gene therapy, and systematic paired CSF
    and plasma metabolomics in patient cohorts does not exist, so there is no human
    compartmental measurement to test the mouse result against. The nearest human evidence is
    dietary: arginine fortification lowers plasma lysine and modelled cerebral lysine influx
    and improves neurological outcome, but it acts at the gastrointestinal barrier as well as
    the cerebrovascular one and so cannot isolate a brain-specific route. Until human
    compartmental data exist, the origin models should be read as established for the mouse
    and provisional for patients.
  attaches_to:
  - mechanistic_hypotheses#hepatic_catabolite_origin_model
  - mechanistic_hypotheses#intracerebral_catabolite_origin_model
  evidence:
  - reference: PMID:21820344
    reference_title: 'Safety, efficacy and physiological actions of a lysine-free, arginine-rich formula to treat glutaryl-CoA dehydrogenase deficiency: focus on cerebral amino acid influx.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The relationship between arginine fortification and plasma lysine indicates that transport competition exists at both cerebrovascular and gastrointestinal barriers, suggesting their co-administration is key to efficacy.
    explanation: >-
      The authors locate the competition at two barriers at once. That is why the best
      available human intervention supports reducing lysine substrate flux in general without
      isolating cerebral lysine import, leaving the compartmental question open on the human
      side.
- discussion_id: ga1-cellular-neurotoxicity-context
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  prompt: Which astrocytic, energy, excitotoxic and inflammatory effects determine human striatal injury under clinically relevant exposure?
  rationale: Astrocyte-mediated toxicity is experimentally supported, but direct excitotoxicity differs across neuronal culture systems. The GCDH-knockout iPSC line is an enabling resource rather than an executed compartmental disease study. Human cell differentiation, nutrient-state controls and metabolite-specific dose-response experiments could distinguish mechanisms.
  evidence:
  - reference: PMID:25968119
    reference_title: Striatal neuronal death mediated by astrocytes from the Gcdh-/- mouse model of glutaric acidemia type I.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Antioxidants abrogated the neuronal death induced by astrocytes exposed to Lys or GA.
    explanation: Antioxidant rescue supports oxidative stress-dependent non-cell-autonomous toxicity in this culture system.
  - reference: PMID:12149496
    reference_title: Ca(2+) and Na(+) dependence of 3-hydroxyglutarate-induced excitotoxicity in primary neuronal cultures from chick embryo telencephalons.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: NMDA receptor activation and subsequent disturbance of Ca(2+) homeostasis contribute to 3-OH-GA-induced cell damage.
    explanation: Receptor expression and chick-neuron experiments support a possible direct 3-OH-GA excitotoxic mechanism.
  - reference: PMID:15262270
    reference_title: 3-Hydroxyglutaric acid fails to affect the viability of primary neuronal rat cells.
    supports: REFUTE
    evidence_source: IN_VITRO
    snippet: 3OHG is not excitotoxic in this model of neuronal rat cell cultures despite the presence of functional NMDA receptors.
    explanation: Negative rat-neuron findings limit generalization across culture models and argue against a universal direct-toxin mechanism.

📚

References & Deep Research

References

13

url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable

Glutaric Acidemia Type 1 - GeneReviews® - NCBI Bookshelf

3 findings

NBS-identified and promptly treated individuals often avoid classic early striatal injury but still need long-term follow-up.

"In the era of newborn screening (NBS), the prompt initiation of treatment of asymptomatic infants detected by NBS means that most individuals who would have developed manifestations of either infantile-onset or later-onset GA-1 remain asymptomatic; however, they may be at increased risk for..."

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable SUPPORT Other

"In the era of newborn screening (NBS), the prompt initiation of treatment of asymptomatic infants detected by NBS means that most individuals who would have developed manifestations of either infantile-onset or later-onset GA-1 remain asymptomatic; however, they may be at increased risk for..."

Supports continued surveillance, including renal monitoring, despite prevention of classic early neurologic crises.

Standard care is combined metabolic therapy centered on lysine restriction, carnitine supplementation, and emergency illness management.

"Combined metabolic therapy includes low-lysine diet, carnitine supplementation, and emergency treatment during episodes with the goal of averting catabolism and minimizing CNS exposure to lysine and its toxic metabolic byproducts."

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable SUPPORT Other

"Combined metabolic therapy includes low-lysine diet, carnitine supplementation, and emergency treatment during episodes with the goal of averting catabolism and minimizing CNS exposure to lysine and its toxic metabolic byproducts."

Captures core treatment principles that structure current management recommendations.

Catabolic triggers should be proactively avoided in GA1 management plans.

"Agents/circumstances to avoid: Excessive dietary protein or protein malnutrition inducing catabolic state, prolonged fasting, catabolic illness (intercurrent infection; brief febrile illness post vaccination), inadequate caloric provision during other stressors (e.g., surgery or procedure..."

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/books/NBK546575/?report=printable SUPPORT Other

"Agents/circumstances to avoid: Excessive dietary protein or protein malnutrition inducing catabolic state, prolonged fasting, catabolic illness (intercurrent infection; brief febrile illness post vaccination), inadequate caloric provision during other stressors (e.g., surgery or procedure..."

Provides explicit avoidant-trigger guidance for sick-day and peri-procedural planning.

DOI:10.1002/jimd.12608

Exploring genotype–phenotype correlations in glutaric aciduria type 1

1 finding

Glutaric aciduria type 1 (GA1) is a rare neurometabolic disease caused by pathogenic variants in the gene encoding the enzyme glutaryl‐CoA dehydrogenase (GCDH).

"Glutaric aciduria type 1 (GA1) is a rare neurometabolic disease caused by pathogenic variants in the gene encoding the enzyme glutaryl‐CoA dehydrogenase (GCDH)."

Show evidence (1 reference)

DOI:10.1002/jimd.12608 SUPPORT Human Clinical

"Glutaric aciduria type 1 (GA1) is a rare neurometabolic disease caused by pathogenic variants in the gene encoding the enzyme glutaryl‐CoA dehydrogenase (GCDH)."

Deep research cited this publication as relevant literature for Glutaryl-CoA Dehydrogenase Deficiency.

DOI:10.1007/s10545-011-9289-5

Diagnosis and management of glutaric aciduria type I – revised recommendations

1 finding

Glutaric aciduria type I (synonym, glutaric acidemia type I) is a rare organic aciduria.

"Glutaric aciduria type I (synonym, glutaric acidemia type I) is a rare organic aciduria."

Show evidence (1 reference)

DOI:10.1007/s10545-011-9289-5 SUPPORT Other

"Glutaric aciduria type I (synonym, glutaric acidemia type I) is a rare organic aciduria."

Deep research cited this publication as relevant literature for Glutaryl-CoA Dehydrogenase Deficiency.

DOI:10.1021/acs.jmedchem.4c00292

Use of the Novel Site-Directed Enzyme Enhancement Therapy (SEE-Tx) Drug Discovery Platform to Identify Pharmacological Chaperones for Glutaric Acidemia Type 1

1 finding

Use of the Novel Site-Directed Enzyme Enhancement Therapy (SEE-Tx) Drug Discovery Platform to Identify Pharmacological Chaperones for Glutaric Acidemia Type 1

"Use of the Novel Site-Directed Enzyme Enhancement Therapy (SEE-Tx) Drug Discovery Platform to Identify Pharmacological Chaperones for Glutaric Acidemia Type 1"

DOI:10.11588/heidok.00035789

New approaches in mathematical and data-based modeling for newborn screening

1 finding

New approaches in mathematical and data-based modeling for newborn screening

"New approaches in mathematical and data-based modeling for newborn screening"

DOI:10.1186/s13023-023-02833-z

Biochemical and molecular features of chinese patients with glutaric acidemia type 1 from Fujian Province, southeastern China

1 finding

Glutaric acidemia type 1 (GA1) is a rare autosomal recessive inherited metabolic disorder caused by variants in the gene encoding the enzyme glutaryl-CoA dehydrogenase (GCDH).

"Glutaric acidemia type 1 (GA1) is a rare autosomal recessive inherited metabolic disorder caused by variants in the gene encoding the enzyme glutaryl-CoA dehydrogenase (GCDH)."

Show evidence (1 reference)

DOI:10.1186/s13023-023-02833-z SUPPORT Human Clinical

"Glutaric acidemia type 1 (GA1) is a rare autosomal recessive inherited metabolic disorder caused by variants in the gene encoding the enzyme glutaryl-CoA dehydrogenase (GCDH)."

Deep research cited this publication as relevant literature for Glutaryl-CoA Dehydrogenase Deficiency.

DOI:10.1186/s13052-025-01975-z

Diagnosis of glutaric aciduria type I based on neuroradiological findings: when neonatal screening fails

1 finding

Glutaric aciduria type I (GA-I) is an autosomal recessive disorder affecting the metabolism of lysine, hydroxylysine, and tryptophan.

"Glutaric aciduria type I (GA-I) is an autosomal recessive disorder affecting the metabolism of lysine, hydroxylysine, and tryptophan."

Show evidence (1 reference)

DOI:10.1186/s13052-025-01975-z SUPPORT Human Clinical

"Glutaric aciduria type I (GA-I) is an autosomal recessive disorder affecting the metabolism of lysine, hydroxylysine, and tryptophan."

Deep research cited this publication as relevant literature for Glutaryl-CoA Dehydrogenase Deficiency.

DOI:10.7759/cureus.65722

Glutaric Aciduria Presenting With an Acute Encephalitic Crisis: A Case Report

1 finding

Glutaric Aciduria Presenting With an Acute Encephalitic Crisis: A Case Report

"Glutaric Aciduria Presenting With an Acute Encephalitic Crisis: A Case Report"

DOI:10.7759/cureus.86380

Delayed Diagnosis of Glutaric Aciduria Type 1: A Case Report

1 finding

Delayed Diagnosis of Glutaric Aciduria Type 1: A Case Report

"Delayed Diagnosis of Glutaric Aciduria Type 1: A Case Report"

DOI:10.1016/j.omtm.2024.101276

Systemic delivery of AAV-GCDH ameliorates HLD-induced phenotype in a glutaric aciduria type I mouse model

No top-level findings curated for this source.

DOI:10.3390/ijms241713158

Glutaryl-CoA Dehydrogenase Misfolding in Glutaric Acidemia Type 1

No top-level findings curated for this source.

DOI:10.3390/ijns10040083

Digital-Tier Strategy Improves Newborn Screening for Glutaric Aciduria Type 1

No top-level findings curated for this source.

url:https://www.ncbi.nlm.nih.gov/books/NBK546575/

Glutaric Acidemia Type 1 - GeneReviews® - NCBI Bookshelf

No top-level findings curated for this source.

Deep Research

1

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Falcon ▸

Disease Characteristics Research Template

Edison Scientific Literature 48 citations 2026-05-08T19:29:56.789508

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

Disease Name: Glutaryl-CoA Dehydrogenase Deficiency
MONDO ID: (if available)
Category: Mendelian

Research Objectives

Please provide a comprehensive research report on Glutaryl-CoA Dehydrogenase Deficiency covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

What is the disease? Provide a concise overview.
What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
What are the common synonyms and alternative names?
Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
Risk Factors:

Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
Genetic risk factors (causal variants, susceptibility loci, modifier genes)
Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
Protective Factors:

Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
Genetic protective factors (protective variants, modifier alleles)
Environmental protective factors (diet, lifestyle, exposures that reduce risk)
Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
Pathogenic Variants:
Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
Variant type/class (missense, frameshift, nonsense, splice-site, structural)
Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
Functional consequences (loss of function, gain of function, dominant negative)
Modifier Genes: Genes that modify disease severity or expression
Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

Search first: CDC databases, WHO, PubMed, NHANES
Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc
Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

Search first: Gene Ontology (GO), Reactome, KEGG, PubMed
Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

Search first: ImmPort, Immunome Database, IEDB, Gene Ontology
Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

Search first: PubMed, Gene Ontology, Reactome
Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

Search first: BRENDA, UniProt, KEGG, OMIM, PubMed
Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Molecular Profiling (if available):
Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
Advanced Technologies (if applicable):
Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

Organ Level:
Primary organs directly affected
Secondary organ involvement (complications, secondary effects)
Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
Tissue and Cell Level:
Specific tissue types affected (epithelial, connective, muscle, nervous)
Specific cell populations targeted (with Cell Ontology terms)

Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
Subcellular Level:
Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
Localization:
Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

Onset:
Typical age of onset (congenital, pediatric, adult, geriatric)
Onset pattern (acute, subacute, chronic, insidious)

Search first: OMIM, Orphanet, HPO, PubMed
Progression:
Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
Progression rate (rapid, slow, variable)
Disease course pattern (episodic, relapsing-remitting, progressive, stable)
Disease duration (self-limited, chronic lifelong)

Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
Patterns:
Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

Epidemiology:
Prevalence (cases per 100,000 at given time)
Incidence (new cases per 100,000 per year)

Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
For Genetic Etiology:
Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
Population Demographics:
Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
Geographic distribution of specific variants
Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

Clinical Tests:
Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
Genetic Testing:

Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen
Overview of recommended genetic testing approach
Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
FISH > Search first: ClinVar, cytogenetics databases, PubMed
Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
Omics-Based Diagnostics (if applicable):
RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
Clinical Criteria:
Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
Screening:
Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

Survival and Mortality:
Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
Morbidity and Function:
Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
Disease Course:
Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
Prediction:
Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

Pharmacotherapy:
Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
Advanced Therapeutics:
Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
Surgical and Interventional:
Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
Supportive and Rehabilitative:
Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
Experimental:
Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
Treatment Outcomes:
Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
Treatment Strategy:
Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.

13. Prevention

Prevention Levels:
Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
Immunization: Vaccine strategies (if applicable)

Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database
Screening and Early Detection:
Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
Behavioral Interventions: Lifestyle modifications to reduce risk

Search first: CDC, WHO, behavioral intervention databases, Cochrane Library
Counseling: Genetic counseling (risk assessment, family planning guidance)

Search first: NSGC resources, ACMG guidelines, GeneReviews
Public Health:
Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
Prophylaxis: Preventive medications or procedures

Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

Taxonomy: Species affected (with NCBI Taxon identifiers)

Search first: NCBI Taxonomy
Breed: Specific breeds affected (with VBO identifiers if applicable)

Search first: VBO (Vertebrate Breed Ontology)
Gene: Orthologous genes in other species (with NCBI Gene IDs)

Search first: NCBI Gene
Natural Disease:
Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
Comparative Biology:
Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
Transmission (if applicable):
Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

Model Types:
Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
Genetic Models:
Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
Model Characteristics:
Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
Applications:
Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
Resources:
Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

Cite primary literature (PMID preferred) for all mechanistic and clinical claims
Prioritize recent reviews and landmark papers
Include direct quotes from abstracts where possible to support key statements
Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Comprehensive Disease Characteristics Report: Glutaryl‑CoA Dehydrogenase Deficiency (Glutaric Aciduria Type 1, GA1)

Executive summary

Glutaryl‑CoA dehydrogenase deficiency—commonly called glutaric aciduria type 1 (GA1)—is an autosomal recessive neurometabolic disorder of lysine, hydroxylysine, and tryptophan catabolism due to pathogenic variants in GCDH, leading to accumulation of glutaric acid (GA), 3‑hydroxyglutaric acid (3‑OH‑GA), and glutarylcarnitine (C5DC). The classic catastrophic outcome is acute or insidious striatal injury in early childhood with a severe dystonic movement disorder; critically, outcomes improve markedly with newborn screening (NBS) plus early dietary and emergency management, but false positives and false negatives (especially “low excretors”) remain important challenges. (kolker2011diagnosisandmanagement pages 1-2, kolker2011diagnosisandmanagement pages 2-4, zhou2023biochemicalandmolecular pages 1-2)

Abbreviations

GA1: glutaric aciduria type 1; GCDH: glutaryl‑CoA dehydrogenase; DBS: dried blood spot; MS/MS: tandem mass spectrometry; GC/MS: gas chromatography mass spectrometry; NBS: newborn screening; HE/LE: high/low excretor biochemical phenotypes; C5DC: glutarylcarnitine.

1. Disease information

1.1 What is the disease?

GA1 is a rare organic aciduria/neurometabolic disease caused by deficiency of mitochondrial glutaryl‑CoA dehydrogenase (GCDH), which is required for the catabolism of lysine, hydroxylysine, and tryptophan; deficiency leads to accumulation of GA, 3‑OH‑GA, glutaconic acid, and C5DC (detectable by GC/MS and MS/MS). (kolker2011diagnosisandmanagement pages 1-2, schuurmans2023exploringgenotype–phenotypecorrelations pages 2-2)

Authoritative guideline definition (abstract quote): - “Glutaric aciduria type I (synonym, glutaric acidemia type I) is a rare organic aciduria.” (Kölker et al., 2011, J Inherit Metab Dis, published 2011‑03; DOI:10.1007/s10545-011-9289-5; https://doi.org/10.1007/s10545-011-9289-5) (kolker2011diagnosisandmanagement pages 1-2) - “This defect gives rise to elevated glutaric acid, 3-hydroxyglutaric acid, glutaconic acid, and glutarylcarnitine which can be detected by gas chromatography/mass spectrometry (organic acids) or tandem mass spectrometry (acylcarnitines).” (same abstract) (kolker2011diagnosisandmanagement pages 1-2)

1.2 Key identifiers (retrieved from current evidence)

Disease OMIM: 231670 (GA1) (schuurmans2023exploringgenotype–phenotypecorrelations pages 2-2, kolker2011diagnosisandmanagement pages 1-2)
Causal gene: GCDH (gene OMIM 608801) (kolker2011diagnosisandmanagement pages 2-4)

Not retrieved in the current tool evidence set (will require external database lookup): MONDO ID, Orphanet ID, MeSH ID, ICD‑10/ICD‑11 codes.

1.3 Synonyms and alternative names

Glutaric aciduria type I / type 1 (GA‑I/GA1) (kolker2011diagnosisandmanagement pages 1-2)
Glutaric acidemia type I / type 1 (GA‑I/GA1) (kolker2011diagnosisandmanagement pages 1-2)
Glutaryl‑CoA dehydrogenase deficiency (schuurmans2023exploringgenotype–phenotypecorrelations pages 2-2)

1.4 Evidence provenance (patient vs aggregated)

The current evidence includes: - Aggregated resources/guidelines & literature syntheses: major clinical guideline (2011) and variant landscape/genotype–phenotype synthesis (2023). (kolker2011diagnosisandmanagement pages 1-2, schuurmans2023exploringgenotype–phenotypecorrelations pages 1-2) - Population screening cohorts: large NBS program data (Germany; 2024) and provincial NBS cohort (China; 2023). (zaunseder2024digitaltierstrategyimproves pages 2-4, zhou2023biochemicalandmolecular pages 1-2) - Mechanistic/therapeutics research: protein misfolding characterization (2023) and emerging therapy preclinical studies (AAV; chaperones; 2024). (barroso2023glutarylcoadehydrogenasemisfolding pages 1-2, mateubosch2024systemicdeliveryof pages 1-2, barroso2024useofthe pages 2-3) - Case reports to illustrate diagnostic pitfalls (2025). (gragnaniello2025diagnosisofglutaric pages 1-2, larancuent2025delayeddiagnosisof pages 1-2)

2. Etiology

2.1 Disease causal factors

Primary cause: biallelic pathogenic variants in GCDH, encoding mitochondrial glutaryl‑CoA dehydrogenase (FAD‑dependent homotetramer), impairing conversion of glutaryl‑CoA to crotonyl‑CoA. (schuurmans2023exploringgenotype–phenotypecorrelations pages 2-2, barroso2023glutarylcoadehydrogenasemisfolding pages 1-2)

2.2 Risk factors

Genetic: autosomal recessive inheritance; population-specific founder variants reported (e.g., p.Ala421Val in Amish; IVS1+5G>T in Ojibwe; p.Arg402Trp relatively frequent in Europeans). (schuurmans2023exploringgenotype–phenotypecorrelations pages 2-3)
Physiologic/environmental triggers for neurologic crises: catabolic stressors including infectious illness, surgery, immunizations, fasting, and febrile illness, especially in early childhood. (kolker2011diagnosisandmanagement pages 1-2, kolker2011diagnosisandmanagement pages 2-4)

2.3 Protective factors

Early detection + combined metabolic management is protective against striatal injury, especially when initiated pre‑symptomatically. (kolker2011diagnosisandmanagement pages 1-2, kolker2011diagnosisandmanagement pages 4-5)

2.4 Gene–environment interaction (clinical concept)

GA1’s major neurologic injury is strongly triggered by catabolic states (environment/physiology) interacting with the underlying enzymatic block. (kolker2011diagnosisandmanagement pages 2-4, kolker2011diagnosisandmanagement pages 9-10)

3. Phenotypes

3.1 Core phenotype spectrum (current understanding)

Critical early-childhood neurologic vulnerability: Untreated GA1 typically causes neurologic disease during a finite early developmental window. The 2011 guideline summarizes that untreated GA‑I leads to neurologic disease in ~90% during 3–36 months, often after an encephalopathic crisis. (kolker2011diagnosisandmanagement pages 2-4)

Key phenotypes and suggested HPO terms (with evidence and typical timing): - Macrocephaly (HP:0000256): reported in ~75% of infants in guideline synthesis; can be early sign but non‑specific. (kolker2011diagnosisandmanagement pages 2-4) - Acute encephalopathic crisis / metabolic decompensation (e.g., HP:0002374 “Acute encephalopathy”): crises precipitated by infection/immunization/surgery; typical 3–36 months. (kolker2011diagnosisandmanagement pages 1-2, kolker2011diagnosisandmanagement pages 2-4) - Striatal/basal ganglia injury (radiologic/clinical correlate; e.g., HP:0002134 “Basal ganglia abnormality”): acute bilateral striatal injury following crises. (kolker2011diagnosisandmanagement pages 2-4) - Dystonia / complex movement disorder (HP:0001332): often severe, static, and disabling after striatal injury; dystonia on axial hypotonia is described as dominant. (kolker2011diagnosisandmanagement pages 2-4) - Developmental delay / motor delay (HP:0001263 / HP:0001270): transient early delay may occur; neuroregression can follow crises. (schuurmans2023exploringgenotype–phenotypecorrelations pages 2-2, kolker2011diagnosisandmanagement pages 2-4) - Seizures/status epilepticus (HP:0001250): may occur during decompensation; can contribute to mortality (case-based). (patil2024glutaricaciduriapresenting pages 1-2) - Characteristic neuroimaging: widened Sylvian fissures/frontotemporal atrophy are often noted; “macrocephaly and frontotemporal atrophy at birth” and widened Sylvian fissures are commonly cited. (barroso2023glutarylcoadehydrogenasemisfolding pages 1-2, patil2024glutaricaciduriapresenting pages 1-2)

3.2 Severity, progression, and frequency notes

High morbidity/mortality without treatment: “Untreated patients characteristically develop dystonia during infancy resulting in a high morbidity and mortality.” (Kölker et al., 2011 abstract) (kolker2011diagnosisandmanagement pages 1-2)
Insidious onset: guideline synthesis notes 10–20% may develop insidious/late onset without a documented crisis. (kolker2011diagnosisandmanagement pages 2-4)

3.3 Quality-of-life impact

Severe dystonia/complex movement disorder after striatal injury implies lifelong disability and dependence; direct standardized QoL instrument statistics were not retrieved in the current evidence set. (kolker2011diagnosisandmanagement pages 2-4)

4. Genetic / molecular information

4.1 Causal gene(s)

GCDH (chromosome 19p13.13/p13.2 reported across sources) encodes a 438 aa precursor with N‑terminal mitochondrial targeting sequence; mature enzyme is a FAD‑dependent homotetramer. (schuurmans2023exploringgenotype–phenotypecorrelations pages 2-2)

4.2 Pathogenic variant spectrum

Scale of known pathogenic variation (recent synthesis): - A 2023 comprehensive genotype–phenotype study reports 421 different GCDH pathogenic variants identified and analyzed across 532 patients, with four novel variants listed. (Schuurmans et al., 2023; DOI:10.1002/jimd.12608; https://doi.org/10.1002/jimd.12608; published 2023‑04) (schuurmans2023exploringgenotype–phenotypecorrelations pages 1-2)

Variant types: mostly missense, with also nonsense, intronic variants, and deletions described in databases. (schuurmans2023exploringgenotype–phenotypecorrelations pages 2-3)

4.3 Biochemical subtypes (HE vs LE) and relation to residual activity

Patients are frequently grouped by urinary GA excretion: LE <100 mmol/mol creatinine vs HE >100 mmol/mol creatinine. (schuurmans2023exploringgenotype–phenotypecorrelations pages 2-3)
Reported correlation: variants with 0–2% or <5% residual activity tend to be HE; variants with 3–30% residual activity tend to be LE/low‑GA excretion. (schuurmans2023exploringgenotype–phenotypecorrelations pages 2-3, barroso2023glutarylcoadehydrogenasemisfolding pages 1-2)
Importantly, the 2011 guideline notes LE patients have the same risk of striatal injury as HE (i.e., biochemical “mildness” does not ensure clinical safety). (kolker2011diagnosisandmanagement pages 1-2)

4.4 Population variation and founder effects (examples)

Founder variants: p.Ala421Val (Amish) and IVS1+5G>T (Ojibwe) are highlighted; p.Arg402Trp is relatively frequent in Europeans. (schuurmans2023exploringgenotype–phenotypecorrelations pages 2-3)
Example regional spectrum (Fujian, China): among 35 unrelated patients, three variants represented ~73% of alleles; c.1244‑2A>C was predominant. (zhou2023biochemicalandmolecular pages 1-2)

4.5 Modifier genes / epigenetics / chromosomal abnormalities

No specific modifier genes, epigenetic mechanisms, or chromosomal abnormalities were retrieved in the current evidence set.

5. Environmental information

GA1 is a Mendelian disorder; “environmental” contributions primarily manifest as catabolic triggers for crises: - Intercurrent infections, immunization, surgery, fasting/febrile illness precipitating encephalopathic crises during a vulnerable developmental period. (kolker2011diagnosisandmanagement pages 1-2, kolker2011diagnosisandmanagement pages 2-4)

No toxin/pollution/infectious etiologic agent was indicated.

6. Mechanism / pathophysiology

6.1 Causal chain (biochemical → cellular → clinical)

Upstream trigger: inherited GCDH deficiency (loss of mitochondrial glutaryl‑CoA dehydrogenase function) in lysine/hydroxylysine/tryptophan catabolism. (schuurmans2023exploringgenotype–phenotypecorrelations pages 2-2, kolker2011diagnosisandmanagement pages 1-2)
Metabolic block: impaired conversion of glutaryl‑CoA → crotonyl‑CoA, leading to accumulation of glutaryl‑CoA and derivatives including GA and 3‑OH‑GA; secondary carnitine depletion and increased C5DC reflect conjugation/detoxification. (schuurmans2023exploringgenotype–phenotypecorrelations pages 2-2, barroso2023glutarylcoadehydrogenasemisfolding pages 1-2)
Neurotoxicity/energy impairment: accumulated organic acids are described to interfere with cerebral energy metabolism and contribute to neurologic injury. (patil2024glutaricaciduriapresenting pages 1-2)
Tissue vulnerability: during early development, catabolic stress can trigger an encephalopathic crisis, leading to bilateral striatal injury and a severe dystonic movement disorder. (kolker2011diagnosisandmanagement pages 2-4, kolker2011diagnosisandmanagement pages 1-2)

6.2 Protein dysfunction and “misfolding disorder” concept (recent development)

A 2023 molecular study supports that many GA1 missense variants cause GCDH misfolding with altered oligomerization/tetramerization, reduced stability/solubility, increased aggregation, and loss of activity—supporting GA1 as a protein misfolding disorder and motivating pharmacological chaperone therapies. (Barroso et al., 2023; DOI:10.3390/ijms241713158; published 2023‑08; https://doi.org/10.3390/ijms241713158) (barroso2023glutarylcoadehydrogenasemisfolding pages 1-2)

6.3 Pathways and ontology suggestions

Pathway concept: lysine degradation / amino‑acid catabolism in mitochondria (supported by disease definitions and biomarkers). (schuurmans2023exploringgenotype–phenotypecorrelations pages 2-2, kolker2011diagnosisandmanagement pages 1-2)
Suggested GO Biological Process terms (examples): lysine catabolic process; tryptophan catabolic process; mitochondrial fatty acid beta‑oxidation (context: acyl‑CoA dehydrogenase family); response to starvation; cellular response to oxidative stress (the latter not directly retrieved here).
Suggested GO Cellular Component: mitochondrion; mitochondrial matrix.
Suggested CL cell types: striatal medium spiny neuron (target of striatal injury); astrocyte and microglia (gliosis is reported in mouse gene therapy study outcomes). (mateubosch2024systemicdeliveryof pages 1-2)

6.4 Molecular profiling / omics

No transcriptomics/proteomics/metabolomics multi‑omics datasets were retrieved in the current evidence set.

7. Anatomical structures affected

7.1 Organ level

Central nervous system is the principal affected system, with the key lesion being striatal/basal ganglia injury. (kolker2011diagnosisandmanagement pages 2-4)

7.2 Tissue/cell level

Striatum / basal ganglia circuits: bilateral striatal injury is the neuropathological correlate of the movement disorder. (kolker2011diagnosisandmanagement pages 1-2)

7.3 Subcellular level

Mitochondria: GCDH is a mitochondrial enzyme; dysfunction is mitochondrial metabolic. (schuurmans2023exploringgenotype–phenotypecorrelations pages 2-2)

7.4 Suggested UBERON terms

Striatum (UBERON:0002435)
Basal ganglion (UBERON:0002420)
Brain (UBERON:0000955)

8. Temporal development

8.1 Onset

Many infants are initially asymptomatic or show macrocephaly/transient delay early in life. (schuurmans2023exploringgenotype–phenotypecorrelations pages 2-2)

8.2 Critical period and progression

A major “window of vulnerability” is infancy to early childhood; encephalopathic crises and striatal injury are concentrated in 3–36 months in guideline synthesis, and encephalopathic crises are described as rare after ~6 years. (kolker2011diagnosisandmanagement pages 2-4, kolker2011diagnosisandmanagement pages 10-12)

9. Inheritance and population

9.1 Inheritance

Autosomal recessive. (kolker2011diagnosisandmanagement pages 1-2)

9.2 Epidemiology (recent data prioritized)

Fujian Province, China (2014–2022): incidence 1 in 63,948 based on 1,151,069 screened and 18 NBS diagnoses. (Zhou et al., 2023, Orphanet J Rare Dis, published 2023‑07; DOI:10.1186/s13023-023-02833-z; https://doi.org/10.1186/s13023-023-02833-z) (zhou2023biochemicalandmolecular pages 1-2)
Germany (Heidelberg NBS context): cited birth prevalence 1:135,000. (Zaunseder et al., 2024, Int J Neonatal Screen, published 2024‑12; DOI:10.3390/ijns10040083; https://doi.org/10.3390/ijns10040083) (zaunseder2024digitaltierstrategyimproves pages 1-2)
Broad synthesis: prevalence varies widely (~1:125,000 general to ~1:250 high‑risk groups). (schuurmans2023exploringgenotype–phenotypecorrelations pages 2-2)

9.3 Carrier frequency / penetrance / expressivity

Not quantified in the current evidence set; GA1 shows variable expressivity and incomplete genotype–phenotype correlation (see Section 4). (schuurmans2023exploringgenotype–phenotypecorrelations pages 1-2)

10. Diagnostics

10.1 Core biochemical markers

Screening marker (DBS, MS/MS): C5DC (glutarylcarnitine). (kolker2011diagnosisandmanagement pages 4-5, zhou2023biochemicalandmolecular pages 1-2)
Confirmatory urine organic acids (GC/MS): elevated GA and 3‑OH‑GA. (kolker2011diagnosisandmanagement pages 4-5, zhou2023biochemicalandmolecular pages 1-2)

10.2 Confirmatory genetic/enzyme testing

The 2011 guideline recommends diagnosis by: - Quantitative GA/3‑OH‑GA, plus GCDH mutation analysis (reported sensitivity 98–99%), and/or enzyme analysis; enzyme activity testing in fibroblasts/leukocytes is described as the “gold standard” for confirmation. (kolker2011diagnosisandmanagement pages 7-8)

10.3 Newborn screening implementation and performance (real‑world)

Heidelberg (Germany) program (2014–2021): reported sensitivity 100%, specificity 99.94%, false‑positive rate 0.06%, PPV 1.5%. (zaunseder2024digitaltierstrategyimproves pages 2-4)

False positives and follow‑up: In the Heidelberg suspected‑diagnosis set, urinary 3‑OH‑GA excluded GA1 in 90% of false positives; 7% had elevated 3‑OH‑GA prompting additional genetic/enzymatic work‑up. (zaunseder2024digitaltierstrategyimproves pages 5-7)

Recent development (2024): digital‑tier machine learning to reduce GA1 NBS false positives. The Heidelberg group reports that a digital‑tier strategy using logistic regression/ridge regression/SVM can reduce false positives by >90% while retaining case detection; e.g., reducing test‑set false positives from 235 → 16 (LR trained on full set) or 235 → 18 (LR trained on suspected set) with 100% sensitivity. (zaunseder2024digitaltierstrategyimproves pages 1-2, zaunseder2024digitaltierstrategyimproves pages 7-8, zaunseder2024digitaltierstrategyimproves media 0bbb340b)

10.4 False negatives and “low excretor” challenge

Low excretors can have normal C5DC in DBS and normal urine GA/3‑OH‑GA, causing false‑negative NBS, and may require diagnosis via clinical suspicion + MRI + molecular testing. (gragnaniello2025diagnosisofglutaric pages 1-2)
A delayed-diagnosis case-based review emphasizes that biochemical markers may be “within normal limits” and that exome sequencing can establish diagnosis when biomarkers/imaging are inconclusive. (larancuent2025delayeddiagnosisof pages 1-2)

10.5 Differential diagnosis

Not comprehensively retrieved from the current evidence set; in practice includes other organic acidurias and basal ganglia injury disorders.

11. Outcome / prognosis

11.1 Prognosis with vs without early treatment

Guideline-level evidence supports strong benefit of early diagnosis and combined therapy: - “It has been shown that in the majority of neonatally diagnosed patients striatal injury can be prevented by combined metabolic treatment.” (Kölker et al., 2011 abstract) (kolker2011diagnosisandmanagement pages 1-2) - The guideline also states: “initiation of treatment after the onset of symptoms is generally not effective in preventing permanent damage.” (same abstract) (kolker2011diagnosisandmanagement pages 1-2)

11.2 Residual risk despite early treatment

A 2023 review notes that, despite improved outcomes with NBS and therapy, 15–23% of early-treated patients may still experience encephalopathic crises. (barroso2023glutarylcoadehydrogenasemisfolding pages 1-2)

12. Treatment

12.1 Standard of care (authoritative guideline)

The 2011 revised recommendations emphasize: - Maintenance therapy: low‑lysine diet (often with lysine‑free/tryptophan‑reduced amino acid supplements) plus L‑carnitine supplementation; recommended especially during the 0–6 year vulnerability window. (kolker2011diagnosisandmanagement pages 8-9, kolker2011diagnosisandmanagement pages 7-8) - Emergency therapy: prompt, aggressive treatment during febrile illness/surgery/immunization; includes high‑energy carbohydrate intake, temporary natural protein reduction/omission for 24–48 h with staged reintroduction, and increased carnitine dosing with careful monitoring. (kolker2011diagnosisandmanagement pages 9-10, kolker2011diagnosisandmanagement pages 10-12)

Guideline quote supporting comparative importance: - “It showed for the first time that both basic metabolic treatment (low lysine diet, carnitine supplementation) and emergency treatment were clearly beneficial for patients diagnosed by newborn screening.” (kolker2011diagnosisandmanagement pages 4-5) - “The beneficial effect of emergency treatment was more pronounced than that of maintenance treatment.” (kolker2011diagnosisandmanagement pages 4-5)

12.2 Evidence of real-world implementations

NBS-linked metabolic care is implemented in multiple countries/centers; large NBS datasets show confirmatory workflows and follow-up testing (e.g., urine 3‑OH‑GA confirmation in Heidelberg). (zaunseder2024digitaltierstrategyimproves pages 5-7)

12.3 Emerging therapies (2023–2024 prioritized)

(A) Gene replacement therapy (preclinical)

A 2024 preclinical study reports systemic AAV9‑GCDH delivery in Gcdh−/− mice: - Neonatal systemic AAV‑GCDH restored hepatic and striatal GCDH activity and prevented high‑lysine‑diet induced lethality (~60% death in untreated KO vs complete survival with neonatal gene therapy), reduced brain metabolite accumulation, and protected against striatal injury on MRI and pathology. (Mateu‑Bosch et al., 2024‑09; DOI:10.1016/j.omtm.2024.101276; https://doi.org/10.1016/j.omtm.2024.101276) (mateubosch2024systemicdeliveryof pages 1-2)

(B) Pharmacological chaperones / allosteric stabilizers (structure-guided discovery)

A 2024 Journal of Medicinal Chemistry study applies a site‑directed enzyme enhancement therapy (SEE‑Tx) computational platform to identify allosteric pharmacological chaperones (structure‑targeted allosteric regulators) for GCDH: - Virtual screening of ~2.7 million compounds, experimental validation hit rate >20%, and multiple validated binders (one with Kd 3.4 μM) that increased stability and/or activity in biochemical assays—supporting feasibility of small-molecule rescue strategies for misfolding variants. (Barroso et al., 2024‑09; DOI:10.1021/acs.jmedchem.4c00292; https://doi.org/10.1021/acs.jmedchem.4c00292) (barroso2024useofthe pages 10-10, barroso2024useofthe pages 2-3)

12.4 MAXO suggestions (examples)

Dietary lysine restriction (MAXO: dietary modification)
Emergency metabolic decompensation management (MAXO: emergency treatment)
Levocarnitine supplementation (MAXO: supplementation)
Gene therapy (AAV-mediated gene transfer) (MAXO: gene therapy)

13. Prevention

Secondary prevention: NBS programs detect GA1 before symptoms; guideline-level evidence indicates early detection + treatment can prevent striatal injury in most neonatally diagnosed cases. (kolker2011diagnosisandmanagement pages 1-2)
Tertiary prevention: strict emergency protocols during illness/surgery/immunization reduce risk of acute striatal injury in vulnerable period. (kolker2011diagnosisandmanagement pages 9-10, kolker2011diagnosisandmanagement pages 10-12)

14. Other species / natural disease

No naturally occurring GA1 in non-human species was retrieved in the current evidence set.

15. Model organisms

15.1 Mouse model (genetic)

Gcdh knockout mouse challenged with high‑lysine diet is used to model provoked metabolic injury and test therapeutics; AAV9‑GCDH gene therapy demonstrates prevention of lethality and striatal pathology, supporting translational development. (mateubosch2024systemicdeliveryof pages 1-2, mateubosch2024systemicdeliveryof pages 6-7)

15.2 Suggested applications and limitations

Application: evaluate metabolite‑driven neurotoxicity and CNS-targeting gene replacement strategies.
Limitation (from gene therapy study): CNS transduction is much higher with neonatal dosing; adult dosing yields poor CNS expression, highlighting developmental constraints. (mateubosch2024systemicdeliveryof pages 6-7)

Key quantitative evidence table

The following table compiles major statistics (epidemiology, screening performance, variant frequencies, and emerging therapies) from the retrieved sources.

Topic	Metric/Result	Population/Study	Year	PMID or DOI	URL	Evidence type	Citation
Epidemiology	Worldwide frequency about 1 in 100,000 births	General/global estimate summarized in GA1 molecular review	2023	DOI: 10.3390/ijms241713158	https://doi.org/10.3390/ijms241713158	Review/mechanistic human disease summary	(barroso2023glutarylcoadehydrogenasemisfolding pages 1-2)
Epidemiology	Prevalence ranges from ~1:125,000 in general populations to ~1:250 in high-risk groups	Literature synthesis in genotype-phenotype study	2023	DOI: 10.1002/jimd.12608	https://doi.org/10.1002/jimd.12608	Human literature synthesis	(schuurmans2023exploringgenotype–phenotypecorrelations pages 2-2)
Epidemiology	Estimated birth prevalence in Germany 1:135,000	Heidelberg NBS program background	2024	DOI: 10.3390/ijns10040083	https://doi.org/10.3390/ijns10040083	NBS program	(zaunseder2024digitaltierstrategyimproves pages 1-2)
Epidemiology	Incidence 1 in 63,948 newborns	Fujian Province, China; 1,151,069 screened, 18 newborns diagnosed	2023	DOI: 10.1186/s13023-023-02833-z	https://doi.org/10.1186/s13023-023-02833-z	Human NBS cohort	(zhou2023biochemicalandmolecular pages 1-2)
Disease burden/outcomes	Despite early treatment, 15–23% of patients still experience encephalopathic crises	Review of treated early-diagnosed GA1	2023	DOI: 10.3390/ijms241713158	https://doi.org/10.3390/ijms241713158	Review/outcomes summary	(barroso2023glutarylcoadehydrogenasemisfolding pages 1-2)
Genetics	421 distinct pathogenic GCDH variants identified; phenotypes aggregated from 532 patients	Large genotype-phenotype analysis	2023	DOI: 10.1002/jimd.12608	https://doi.org/10.1002/jimd.12608	Human literature synthesis/genetics	(schuurmans2023exploringgenotype–phenotypecorrelations pages 1-2)
Genetics	Variant databases listed 240 pathogenic variants in LOVD and 232 in ClinVar	Database-informed genotype review	2023	DOI: 10.1002/jimd.12608	https://doi.org/10.1002/jimd.12608	Human genetics/database synthesis	(schuurmans2023exploringgenotype–phenotypecorrelations pages 2-3)
Biochemical phenotype	High excretors (HE): urinary GA >100 mmol/mol creatinine; Low excretors (LE): <100 mmol/mol creatinine	Standard GA1 biochemical classification	2023	DOI: 10.1002/jimd.12608	https://doi.org/10.1002/jimd.12608	Human biochemical genetics	(schuurmans2023exploringgenotype–phenotypecorrelations pages 2-3)
Residual enzyme activity	HE usually associated with residual activity 0–2% or <5%; LE with 3–30% residual activity	Genotype-biochemistry correlations across reports	2023	DOI: 10.1002/jimd.12608; DOI: 10.3390/ijms241713158	https://doi.org/10.1002/jimd.12608 ; https://doi.org/10.3390/ijms241713158	Human genetics/mechanistic review	(schuurmans2023exploringgenotype–phenotypecorrelations pages 2-3, barroso2023glutarylcoadehydrogenasemisfolding pages 1-2)
Fujian molecular spectrum	71 variants across 70 alleles; 19 pathogenic variants identified	35 unrelated GA1 patients from Fujian	2023	DOI: 10.1186/s13023-023-02833-z	https://doi.org/10.1186/s13023-023-02833-z	Human cohort/genetics	(zhou2023biochemicalandmolecular pages 1-2)
Common variant frequency	c.1244-2A>C accounted for 63.38% of alleles	Fujian cohort	2023	DOI: 10.1186/s13023-023-02833-z	https://doi.org/10.1186/s13023-023-02833-z	Human cohort/genetics	(zhou2023biochemicalandmolecular pages 1-2)
Common variant frequency	p.Ala421Thr (c.1261G>A) accounted for 5.63% of alleles	Fujian cohort	2023	DOI: 10.1186/s13023-023-02833-z	https://doi.org/10.1186/s13023-023-02833-z	Human cohort/genetics	(zhou2023biochemicalandmolecular pages 1-2)
Common variant frequency	p.Gly136Cys (c.406G>T) accounted for 4.22% of alleles	Fujian cohort	2023	DOI: 10.1186/s13023-023-02833-z	https://doi.org/10.1186/s13023-023-02833-z	Human cohort/genetics	(zhou2023biochemicalandmolecular pages 1-2)
Common genotype	Homozygous c.[1244-2A>C];[1244-2A>C] in 18/35 (52.43%) patients	Fujian cohort	2023	DOI: 10.1186/s13023-023-02833-z	https://doi.org/10.1186/s13023-023-02833-z	Human cohort/genetics	(zhou2023biochemicalandmolecular pages 1-2)
Excretor distribution	28 HE and 5 LE patients	Fujian cohort with urine GA classification	2023	DOI: 10.1186/s13023-023-02833-z	https://doi.org/10.1186/s13023-023-02833-z	Human cohort/biochemical	(zhou2023biochemicalandmolecular pages 1-2)
NBS program size	Initial extraction 1,055,885 profiles; analytic dataset 1,025,953 profiles; 494 suspected GA1 after cleaning	Heidelberg NBS study	2024	DOI: 10.3390/ijns10040083	https://doi.org/10.3390/ijns10040083	NBS program	(zaunseder2024digitaltierstrategyimproves pages 2-4)
NBS performance	Sensitivity 100%, specificity 99.94%, false-positive rate 0.06%, PPV 1.5%	Heidelberg GA1 NBS program (2014–2021)	2024	DOI: 10.3390/ijns10040083	https://doi.org/10.3390/ijns10040083	NBS program	(zaunseder2024digitaltierstrategyimproves pages 2-4)
Fujian NBS performance	265 screen-positive newborns; positivity 0.023%; PPV 6.42% (17/265)	Fujian NBS cohort	2023	DOI: 10.1186/s13023-023-02833-z	https://doi.org/10.1186/s13023-023-02833-z	Human NBS cohort	(zhou2023biochemicalandmolecular pages 1-2)
NBS sex effect	False positives: 326/485 (67%) male vs 159/485 (33%) female; confirmed GA1 4 male / 5 female	Heidelberg suspected-diagnosis set	2024	DOI: 10.3390/ijns10040083	https://doi.org/10.3390/ijns10040083	NBS program	(zaunseder2024digitaltierstrategyimproves pages 5-7, zaunseder2024digitaltierstrategyimproves pages 4-5)
Screening biomarker levels	Mean Glut: GA1 2.698 ± 1.548 µmol/L; suspected-not-confirmed 0.526 ± 0.106 µmol/L; normal 0.157 ± 0.057 µmol/L	Heidelberg NBS metabolite distributions	2024	DOI: 10.3390/ijns10040083	https://doi.org/10.3390/ijns10040083	NBS program/biomarker study	(zaunseder2024digitaltierstrategyimproves pages 5-7)
Excretor biomarker levels	Mean Glut in LE 1.9 ± 1.28 µmol/L (n=6) vs HE 4.3 ± 0.2 µmol/L (n=3)	Heidelberg confirmed GA1 cases	2024	DOI: 10.3390/ijns10040083	https://doi.org/10.3390/ijns10040083	NBS program/biomarker study	(zaunseder2024digitaltierstrategyimproves pages 5-7)
Confirmatory follow-up	Urinary 3-OH-GA excluded GA1 in 90% (435/485) false positives; 7% (34/485) had elevated urinary 3-OH-GA prompting more testing	Heidelberg follow-up after positive NBS	2024	DOI: 10.3390/ijns10040083	https://doi.org/10.3390/ijns10040083	NBS follow-up program	(zaunseder2024digitaltierstrategyimproves pages 5-7)
Digital-tier NBS improvement	False positives reduced from 235 to 16 on test set (93.19% reduction) with LR model trained on full dataset; 100% sensitivity maintained	Heidelberg independent test set	2024	DOI: 10.3390/ijns10040083	https://doi.org/10.3390/ijns10040083	NBS program/machine learning	(zaunseder2024newapproachesin pages 76-80, zaunseder2024digitaltierstrategyimproves pages 7-8, zaunseder2024digitaltierstrategyimproves media 0bbb340b)
Digital-tier NBS improvement	False positives reduced from 235 to 18 on test set (92.34% reduction) with LR model trained on suspected-diagnosis dataset; 100% sensitivity maintained	Heidelberg independent test set	2024	DOI: 10.3390/ijns10040083	https://doi.org/10.3390/ijns10040083	NBS program/machine learning	(zaunseder2024digitaltierstrategyimproves pages 8-10, zaunseder2024digitaltierstrategyimproves pages 7-8, zaunseder2024digitaltierstrategyimproves media 0bbb340b)
Traditional vs digital-tier specificity	Traditional test-set screening: 0 FN, 235 FP, sensitivity 100%, specificity 99.90%	Heidelberg test set	2024	DOI: 10.11588/heidok.00035789	https://doi.org/10.11588/heidok.00035789	NBS program/modeling thesis	(zaunseder2024newapproachesin pages 76-80)
False-negative risk	NBS sensitivity reported as 93.3% and specificity 99.42% in a delayed-diagnosis report discussing missed cases	Case-based review of diagnostic performance	2025	DOI: 10.7759/cureus.86380	https://doi.org/10.7759/cureus.86380	Case report/review	(larancuent2025delayeddiagnosisof pages 5-7)
Low-excretor frequency	LE phenotype estimated in 30–40% of GA1 patients	Diagnostic review/case report	2025	DOI: 10.7759/cureus.86380	https://doi.org/10.7759/cureus.86380	Case report/review	(larancuent2025delayeddiagnosisof pages 2-3)
AAV gene therapy	Untreated KO mice under HLD had ~60% death; neonatal AAV-GCDH yielded complete survival after HLD challenge	Gcdh knockout mouse model	2024	DOI: 10.1016/j.omtm.2024.101276	https://doi.org/10.1016/j.omtm.2024.101276	Mouse model/gene therapy	(mateubosch2024systemicdeliveryof pages 1-2)
AAV biodistribution/transduction	Neonatal delivery produced ~40-fold more striatal viral genomes at 1 month than later treatment	AAV9-GCDH in Gcdh knockout mice	2024	DOI: 10.1016/j.omtm.2024.101276	https://doi.org/10.1016/j.omtm.2024.101276	Mouse model/gene therapy	(mateubosch2024systemicdeliveryof pages 6-7)
AAV dosing	Systemic doses evaluated included about 7.5×10^12 vg/kg up to ~5×10^13 vg/kg	AAV9-GCDH preclinical optimization	2024	DOI: 10.1016/j.omtm.2024.101276	https://doi.org/10.1016/j.omtm.2024.101276	Mouse model/gene therapy	(mateubosch2024systemicdeliveryof pages 6-7)
Pharmacological chaperone discovery	Virtual screening of ~2.7 million compounds yielded ~2,200 candidates; 94 compounds purchased for follow-up	SEE-Tx GCDH allosteric screen	2024	DOI: 10.1021/acs.jmedchem.4c00292	https://doi.org/10.1021/acs.jmedchem.4c00292	In vitro/computational drug discovery	(barroso2024useofthe pages 10-10)
Pharmacological chaperone discovery	Hit rate >20% in experimental validation	SEE-Tx GCDH chaperone campaign	2024	DOI: 10.1021/acs.jmedchem.4c00292	https://doi.org/10.1021/acs.jmedchem.4c00292	In vitro/computational drug discovery	(barroso2024useofthe pages 10-10)
Pharmacological chaperone potency	One lead bound GCDH with Kd = 3.4 µM; additional validated binders 6.9–44.9 µM range reported for examples	SEE-Tx validated allosteric regulators	2024	DOI: 10.1021/acs.jmedchem.4c00292	https://doi.org/10.1021/acs.jmedchem.4c00292	In vitro/computational drug discovery	(barroso2024useofthe pages 9-10, barroso2024useofthe pages 2-3)

Table: This table compiles key quantitative findings for glutaric acidemia type 1, including epidemiology, newborn screening performance, variant frequencies, and emerging therapy results. It is designed as a quick-reference evidence summary for a disease knowledge base entry.

Visual evidence (newborn screening performance)

Table 2 from Zaunseder et al. (2024) provides the detailed sensitivity/specificity and false-positive reductions achieved by the digital-tier ML strategy (e.g., 235 → 16/18 false positives on the independent test set with maintained sensitivity), supporting the quantitative claims in Section 10. (zaunseder2024digitaltierstrategyimproves media 0bbb340b)

Notes on evidence gaps (from current tool retrieval)

MONDO/Orphanet/MeSH/ICD identifiers were not directly retrieved in the current evidence set and should be populated via dedicated ontology/database queries.
No high-quality, GA1-specific 2023–2024 human interventional clinical trials were retrieved here; emerging therapies are currently supported primarily by preclinical studies and structure-guided discovery.
QoL instrument data and formal differential diagnosis lists were not retrieved in the current evidence set.

References

(kolker2011diagnosisandmanagement pages 1-2): Stefan Kölker, Ernst Christensen, James V. Leonard, Cheryl R. Greenberg, Avihu Boneh, Alberto B. Burlina, Alessandro P. Burlina, Marjorie Dixon, Marinus Duran, Angels García Cazorla, Stephen I. Goodman, David M. Koeller, Mårten Kyllerman, Chris Mühlhausen, Edith Müller, Jürgen G. Okun, Bridget Wilcken, Georg F. Hoffmann, and Peter Burgard. Diagnosis and management of glutaric aciduria type i – revised recommendations. Journal of Inherited Metabolic Disease, 34:677-694, Mar 2011. URL: https://doi.org/10.1007/s10545-011-9289-5, doi:10.1007/s10545-011-9289-5. This article has 422 citations and is from a peer-reviewed journal.
(kolker2011diagnosisandmanagement pages 2-4): Stefan Kölker, Ernst Christensen, James V. Leonard, Cheryl R. Greenberg, Avihu Boneh, Alberto B. Burlina, Alessandro P. Burlina, Marjorie Dixon, Marinus Duran, Angels García Cazorla, Stephen I. Goodman, David M. Koeller, Mårten Kyllerman, Chris Mühlhausen, Edith Müller, Jürgen G. Okun, Bridget Wilcken, Georg F. Hoffmann, and Peter Burgard. Diagnosis and management of glutaric aciduria type i – revised recommendations. Journal of Inherited Metabolic Disease, 34:677-694, Mar 2011. URL: https://doi.org/10.1007/s10545-011-9289-5, doi:10.1007/s10545-011-9289-5. This article has 422 citations and is from a peer-reviewed journal.
(zhou2023biochemicalandmolecular pages 1-2): Jinfu Zhou, Guilin Li, Lin Deng, Peiran Zhao, Yinglin Zeng, Xiaolong Qiu, Jinying Luo, and Liangpu Xu. Biochemical and molecular features of chinese patients with glutaric acidemia type 1 from fujian province, southeastern china. Orphanet Journal of Rare Diseases, Jul 2023. URL: https://doi.org/10.1186/s13023-023-02833-z, doi:10.1186/s13023-023-02833-z. This article has 7 citations and is from a peer-reviewed journal.
(schuurmans2023exploringgenotype–phenotypecorrelations pages 2-2): Imke M. E. Schuurmans, Bianca Dimitrov, Julian Schröter, Antonia Ribes, Rubén Pérez de la Fuente, Berta Zamora, Clara D. M. van Karnebeek, Stefan Kölker, and Alejandro Garanto. Exploring genotype–phenotype correlations in glutaric aciduria type 1. Journal of Inherited Metabolic Disease, 46:371-390, Apr 2023. URL: https://doi.org/10.1002/jimd.12608, doi:10.1002/jimd.12608. This article has 26 citations and is from a peer-reviewed journal.
(schuurmans2023exploringgenotype–phenotypecorrelations pages 1-2): Imke M. E. Schuurmans, Bianca Dimitrov, Julian Schröter, Antonia Ribes, Rubén Pérez de la Fuente, Berta Zamora, Clara D. M. van Karnebeek, Stefan Kölker, and Alejandro Garanto. Exploring genotype–phenotype correlations in glutaric aciduria type 1. Journal of Inherited Metabolic Disease, 46:371-390, Apr 2023. URL: https://doi.org/10.1002/jimd.12608, doi:10.1002/jimd.12608. This article has 26 citations and is from a peer-reviewed journal.
(zaunseder2024digitaltierstrategyimproves pages 2-4): Elaine Zaunseder, Julian Teinert, Nikolas Boy, Sven F. Garbade, Saskia Haupt, Patrik Feyh, Georg F. Hoffmann, Stefan Kölker, Ulrike Mütze, and Vincent Heuveline. Digital-tier strategy improves newborn screening for glutaric aciduria type 1. International Journal of Neonatal Screening, 10:83, Dec 2024. URL: https://doi.org/10.3390/ijns10040083, doi:10.3390/ijns10040083. This article has 1 citations.
(barroso2023glutarylcoadehydrogenasemisfolding pages 1-2): Madalena Barroso, Marcus Gertzen, Alexandra F. Puchwein-Schwepcke, Heike Preisler, Andreas Sturm, Dunja D. Reiss, Marta K. Danecka, Ania C. Muntau, and Søren W. Gersting. Glutaryl-coa dehydrogenase misfolding in glutaric acidemia type 1. International Journal of Molecular Sciences, 24:13158, Aug 2023. URL: https://doi.org/10.3390/ijms241713158, doi:10.3390/ijms241713158. This article has 5 citations.
(mateubosch2024systemicdeliveryof pages 1-2): Anna Mateu-Bosch, Eulàlia Segur-Bailach, Emma Muñoz-Moreno, María José Barallobre, Maria Lourdes Arbonés, Sabrina Gea-Sorlí, Frederic Tort, Antonia Ribes, Judit García-Villoria, and Cristina Fillat. Systemic delivery of aav-gcdh ameliorates hld-induced phenotype in a glutaric aciduria type i mouse model. Molecular Therapy - Methods & Clinical Development, 32:101276, Sep 2024. URL: https://doi.org/10.1016/j.omtm.2024.101276, doi:10.1016/j.omtm.2024.101276. This article has 10 citations.
(barroso2024useofthe pages 2-3): Madalena Barroso, Alexandra Puchwein-Schwepcke, Lars Buettner, Ingrid Goebel, Katrin Küchler, Ania C. Muntau, Aida Delgado, Ana M. Garcia-Collazo, Marc Martinell, Xavier Barril, Elena Cubero, and Søren W. Gersting. Use of the novel site-directed enzyme enhancement therapy (see-tx) drug discovery platform to identify pharmacological chaperones for glutaric acidemia type 1. Journal of Medicinal Chemistry, 67:17087-17100, Sep 2024. URL: https://doi.org/10.1021/acs.jmedchem.4c00292, doi:10.1021/acs.jmedchem.4c00292. This article has 4 citations and is from a highest quality peer-reviewed journal.
(gragnaniello2025diagnosisofglutaric pages 1-2): Vincenza Gragnaniello, Andrea Puma, Daniela Gueraldi, Ignazio D’Errico, Chiara Cazzorla, Christian Loro, Elena Porcù, Leonardo Salviati, and Alberto B. Burlina. Diagnosis of glutaric aciduria type i based on neuroradiological findings: when neonatal screening fails. Italian Journal of Pediatrics, May 2025. URL: https://doi.org/10.1186/s13052-025-01975-z, doi:10.1186/s13052-025-01975-z. This article has 0 citations and is from a peer-reviewed journal.
(larancuent2025delayeddiagnosisof pages 1-2): Cesar E. Larancuent, Tracey Weiler, and Sajel L. Kana. Delayed diagnosis of glutaric aciduria type 1: a case report. Cureus, Jun 2025. URL: https://doi.org/10.7759/cureus.86380, doi:10.7759/cureus.86380. This article has 0 citations.
(schuurmans2023exploringgenotype–phenotypecorrelations pages 2-3): Imke M. E. Schuurmans, Bianca Dimitrov, Julian Schröter, Antonia Ribes, Rubén Pérez de la Fuente, Berta Zamora, Clara D. M. van Karnebeek, Stefan Kölker, and Alejandro Garanto. Exploring genotype–phenotype correlations in glutaric aciduria type 1. Journal of Inherited Metabolic Disease, 46:371-390, Apr 2023. URL: https://doi.org/10.1002/jimd.12608, doi:10.1002/jimd.12608. This article has 26 citations and is from a peer-reviewed journal.
(kolker2011diagnosisandmanagement pages 4-5): Stefan Kölker, Ernst Christensen, James V. Leonard, Cheryl R. Greenberg, Avihu Boneh, Alberto B. Burlina, Alessandro P. Burlina, Marjorie Dixon, Marinus Duran, Angels García Cazorla, Stephen I. Goodman, David M. Koeller, Mårten Kyllerman, Chris Mühlhausen, Edith Müller, Jürgen G. Okun, Bridget Wilcken, Georg F. Hoffmann, and Peter Burgard. Diagnosis and management of glutaric aciduria type i – revised recommendations. Journal of Inherited Metabolic Disease, 34:677-694, Mar 2011. URL: https://doi.org/10.1007/s10545-011-9289-5, doi:10.1007/s10545-011-9289-5. This article has 422 citations and is from a peer-reviewed journal.
(kolker2011diagnosisandmanagement pages 9-10): Stefan Kölker, Ernst Christensen, James V. Leonard, Cheryl R. Greenberg, Avihu Boneh, Alberto B. Burlina, Alessandro P. Burlina, Marjorie Dixon, Marinus Duran, Angels García Cazorla, Stephen I. Goodman, David M. Koeller, Mårten Kyllerman, Chris Mühlhausen, Edith Müller, Jürgen G. Okun, Bridget Wilcken, Georg F. Hoffmann, and Peter Burgard. Diagnosis and management of glutaric aciduria type i – revised recommendations. Journal of Inherited Metabolic Disease, 34:677-694, Mar 2011. URL: https://doi.org/10.1007/s10545-011-9289-5, doi:10.1007/s10545-011-9289-5. This article has 422 citations and is from a peer-reviewed journal.
(patil2024glutaricaciduriapresenting pages 1-2): Manojkumar G Patil, Neha Tyagi, Om Prasanth Reddy Avuthu, and Shradha Salunkhe. Glutaric aciduria presenting with an acute encephalitic crisis: a case report. Cureus, Jul 2024. URL: https://doi.org/10.7759/cureus.65722, doi:10.7759/cureus.65722. This article has 1 citations.
(kolker2011diagnosisandmanagement pages 10-12): Stefan Kölker, Ernst Christensen, James V. Leonard, Cheryl R. Greenberg, Avihu Boneh, Alberto B. Burlina, Alessandro P. Burlina, Marjorie Dixon, Marinus Duran, Angels García Cazorla, Stephen I. Goodman, David M. Koeller, Mårten Kyllerman, Chris Mühlhausen, Edith Müller, Jürgen G. Okun, Bridget Wilcken, Georg F. Hoffmann, and Peter Burgard. Diagnosis and management of glutaric aciduria type i – revised recommendations. Journal of Inherited Metabolic Disease, 34:677-694, Mar 2011. URL: https://doi.org/10.1007/s10545-011-9289-5, doi:10.1007/s10545-011-9289-5. This article has 422 citations and is from a peer-reviewed journal.
(zaunseder2024digitaltierstrategyimproves pages 1-2): Elaine Zaunseder, Julian Teinert, Nikolas Boy, Sven F. Garbade, Saskia Haupt, Patrik Feyh, Georg F. Hoffmann, Stefan Kölker, Ulrike Mütze, and Vincent Heuveline. Digital-tier strategy improves newborn screening for glutaric aciduria type 1. International Journal of Neonatal Screening, 10:83, Dec 2024. URL: https://doi.org/10.3390/ijns10040083, doi:10.3390/ijns10040083. This article has 1 citations.
(kolker2011diagnosisandmanagement pages 7-8): Stefan Kölker, Ernst Christensen, James V. Leonard, Cheryl R. Greenberg, Avihu Boneh, Alberto B. Burlina, Alessandro P. Burlina, Marjorie Dixon, Marinus Duran, Angels García Cazorla, Stephen I. Goodman, David M. Koeller, Mårten Kyllerman, Chris Mühlhausen, Edith Müller, Jürgen G. Okun, Bridget Wilcken, Georg F. Hoffmann, and Peter Burgard. Diagnosis and management of glutaric aciduria type i – revised recommendations. Journal of Inherited Metabolic Disease, 34:677-694, Mar 2011. URL: https://doi.org/10.1007/s10545-011-9289-5, doi:10.1007/s10545-011-9289-5. This article has 422 citations and is from a peer-reviewed journal.
(zaunseder2024digitaltierstrategyimproves pages 5-7): Elaine Zaunseder, Julian Teinert, Nikolas Boy, Sven F. Garbade, Saskia Haupt, Patrik Feyh, Georg F. Hoffmann, Stefan Kölker, Ulrike Mütze, and Vincent Heuveline. Digital-tier strategy improves newborn screening for glutaric aciduria type 1. International Journal of Neonatal Screening, 10:83, Dec 2024. URL: https://doi.org/10.3390/ijns10040083, doi:10.3390/ijns10040083. This article has 1 citations.
(zaunseder2024digitaltierstrategyimproves pages 7-8): Elaine Zaunseder, Julian Teinert, Nikolas Boy, Sven F. Garbade, Saskia Haupt, Patrik Feyh, Georg F. Hoffmann, Stefan Kölker, Ulrike Mütze, and Vincent Heuveline. Digital-tier strategy improves newborn screening for glutaric aciduria type 1. International Journal of Neonatal Screening, 10:83, Dec 2024. URL: https://doi.org/10.3390/ijns10040083, doi:10.3390/ijns10040083. This article has 1 citations.
(zaunseder2024digitaltierstrategyimproves media 0bbb340b): Elaine Zaunseder, Julian Teinert, Nikolas Boy, Sven F. Garbade, Saskia Haupt, Patrik Feyh, Georg F. Hoffmann, Stefan Kölker, Ulrike Mütze, and Vincent Heuveline. Digital-tier strategy improves newborn screening for glutaric aciduria type 1. International Journal of Neonatal Screening, 10:83, Dec 2024. URL: https://doi.org/10.3390/ijns10040083, doi:10.3390/ijns10040083. This article has 1 citations.
(kolker2011diagnosisandmanagement pages 8-9): Stefan Kölker, Ernst Christensen, James V. Leonard, Cheryl R. Greenberg, Avihu Boneh, Alberto B. Burlina, Alessandro P. Burlina, Marjorie Dixon, Marinus Duran, Angels García Cazorla, Stephen I. Goodman, David M. Koeller, Mårten Kyllerman, Chris Mühlhausen, Edith Müller, Jürgen G. Okun, Bridget Wilcken, Georg F. Hoffmann, and Peter Burgard. Diagnosis and management of glutaric aciduria type i – revised recommendations. Journal of Inherited Metabolic Disease, 34:677-694, Mar 2011. URL: https://doi.org/10.1007/s10545-011-9289-5, doi:10.1007/s10545-011-9289-5. This article has 422 citations and is from a peer-reviewed journal.
(barroso2024useofthe pages 10-10): Madalena Barroso, Alexandra Puchwein-Schwepcke, Lars Buettner, Ingrid Goebel, Katrin Küchler, Ania C. Muntau, Aida Delgado, Ana M. Garcia-Collazo, Marc Martinell, Xavier Barril, Elena Cubero, and Søren W. Gersting. Use of the novel site-directed enzyme enhancement therapy (see-tx) drug discovery platform to identify pharmacological chaperones for glutaric acidemia type 1. Journal of Medicinal Chemistry, 67:17087-17100, Sep 2024. URL: https://doi.org/10.1021/acs.jmedchem.4c00292, doi:10.1021/acs.jmedchem.4c00292. This article has 4 citations and is from a highest quality peer-reviewed journal.
(mateubosch2024systemicdeliveryof pages 6-7): Anna Mateu-Bosch, Eulàlia Segur-Bailach, Emma Muñoz-Moreno, María José Barallobre, Maria Lourdes Arbonés, Sabrina Gea-Sorlí, Frederic Tort, Antonia Ribes, Judit García-Villoria, and Cristina Fillat. Systemic delivery of aav-gcdh ameliorates hld-induced phenotype in a glutaric aciduria type i mouse model. Molecular Therapy - Methods & Clinical Development, 32:101276, Sep 2024. URL: https://doi.org/10.1016/j.omtm.2024.101276, doi:10.1016/j.omtm.2024.101276. This article has 10 citations.
(zaunseder2024digitaltierstrategyimproves pages 4-5): Elaine Zaunseder, Julian Teinert, Nikolas Boy, Sven F. Garbade, Saskia Haupt, Patrik Feyh, Georg F. Hoffmann, Stefan Kölker, Ulrike Mütze, and Vincent Heuveline. Digital-tier strategy improves newborn screening for glutaric aciduria type 1. International Journal of Neonatal Screening, 10:83, Dec 2024. URL: https://doi.org/10.3390/ijns10040083, doi:10.3390/ijns10040083. This article has 1 citations.
(zaunseder2024newapproachesin pages 76-80): Elaine Serena Zaunseder. New approaches in mathematical and data-based modeling for newborn screening. Text, Jan 2024. URL: https://doi.org/10.11588/heidok.00035789, doi:10.11588/heidok.00035789. This article has 0 citations and is from a peer-reviewed journal.
(zaunseder2024digitaltierstrategyimproves pages 8-10): Elaine Zaunseder, Julian Teinert, Nikolas Boy, Sven F. Garbade, Saskia Haupt, Patrik Feyh, Georg F. Hoffmann, Stefan Kölker, Ulrike Mütze, and Vincent Heuveline. Digital-tier strategy improves newborn screening for glutaric aciduria type 1. International Journal of Neonatal Screening, 10:83, Dec 2024. URL: https://doi.org/10.3390/ijns10040083, doi:10.3390/ijns10040083. This article has 1 citations.
(larancuent2025delayeddiagnosisof pages 5-7): Cesar E. Larancuent, Tracey Weiler, and Sajel L. Kana. Delayed diagnosis of glutaric aciduria type 1: a case report. Cureus, Jun 2025. URL: https://doi.org/10.7759/cureus.86380, doi:10.7759/cureus.86380. This article has 0 citations.
(larancuent2025delayeddiagnosisof pages 2-3): Cesar E. Larancuent, Tracey Weiler, and Sajel L. Kana. Delayed diagnosis of glutaric aciduria type 1: a case report. Cureus, Jun 2025. URL: https://doi.org/10.7759/cureus.86380, doi:10.7759/cureus.86380. This article has 0 citations.
(barroso2024useofthe pages 9-10): Madalena Barroso, Alexandra Puchwein-Schwepcke, Lars Buettner, Ingrid Goebel, Katrin Küchler, Ania C. Muntau, Aida Delgado, Ana M. Garcia-Collazo, Marc Martinell, Xavier Barril, Elena Cubero, and Søren W. Gersting. Use of the novel site-directed enzyme enhancement therapy (see-tx) drug discovery platform to identify pharmacological chaperones for glutaric acidemia type 1. Journal of Medicinal Chemistry, 67:17087-17100, Sep 2024. URL: https://doi.org/10.1021/acs.jmedchem.4c00292, doi:10.1021/acs.jmedchem.4c00292. This article has 4 citations and is from a highest quality peer-reviewed journal.

Ask OpenScientist

OpenScientist Report

Inheritance

Subtypes

Mechanistic Hypotheses

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Environmental Factors

Biochemical Markers

Diagnosis

Prevalence

Clinical Trials

Experimental Models

Animal Models

Source YAML

References & Deep Research

References

Deep Research

Disease Characteristics Research Template

Target Disease

Research Objectives

1. Disease Information

2. Etiology

3. Phenotypes

4. Genetic/Molecular Information

5. Environmental Information

6. Mechanism / Pathophysiology

7. Anatomical Structures Affected

8. Temporal Development

9. Inheritance and Population

10. Diagnostics

11. Outcome/Prognosis

12. Treatment

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

Citation Requirements

Output Format

Comprehensive Disease Characteristics Report: Glutaryl‑CoA Dehydrogenase Deficiency (Glutaric Aciduria Type 1, GA1)

Executive summary

Abbreviations

1. Disease information

1.1 What is the disease?

1.2 Key identifiers (retrieved from current evidence)

1.3 Synonyms and alternative names

1.4 Evidence provenance (patient vs aggregated)

2. Etiology

2.1 Disease causal factors

2.2 Risk factors

2.3 Protective factors

2.4 Gene–environment interaction (clinical concept)

3. Phenotypes

3.1 Core phenotype spectrum (current understanding)

3.2 Severity, progression, and frequency notes

3.3 Quality-of-life impact

4. Genetic / molecular information

4.1 Causal gene(s)

4.2 Pathogenic variant spectrum

4.3 Biochemical subtypes (HE vs LE) and relation to residual activity

4.4 Population variation and founder effects (examples)

4.5 Modifier genes / epigenetics / chromosomal abnormalities

5. Environmental information

6. Mechanism / pathophysiology

6.1 Causal chain (biochemical → cellular → clinical)

6.2 Protein dysfunction and “misfolding disorder” concept (recent development)

6.3 Pathways and ontology suggestions

6.4 Molecular profiling / omics

7. Anatomical structures affected

7.1 Organ level

7.2 Tissue/cell level

7.3 Subcellular level

7.4 Suggested UBERON terms

8. Temporal development

8.1 Onset

8.2 Critical period and progression

9. Inheritance and population